

















Review

Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries

Brian Godman ^{1,2,3,*} , Abiodun Egwuenu ⁴ , Mainul Haque ⁵ , Oliver Ombeva Malande ^{6,7}, Natalie Schellack ⁸, Santosh Kumar ⁹ , Zikria Saleem ¹⁰ , Jacqueline Sneddon ¹¹, Iris Hoxha ¹², Salequl Islam ¹³, Julius Mwita ¹⁴, Renata Cristina Rezende Macedo do Nascimento ¹⁵ , Isabella Piassi Dias Godói ^{16,17} , Loveline Lum Niba ^{18,19} , Adefolarin A. Amu ²⁰, Joseph Acolatse ²¹ , Robert Incoom ²¹, Israel Abebrese Sefah ^{22,23} , Sylvia Opanga ²⁴, Amanj Kurdi ^{1,25} , Ibrahim Chikowe ²⁶ , Felix Khuluza ²⁶, Dan Kibuule ²⁷ , Olayinka O. Ogunleye ^{28,29}, Adesola Olalekan ^{30,31} , Vanda Markovic-Pekovic ³², Johanna C. Meyer ², Abubakr Alfadl ^{33,34}, Thuy Nguyen Thi Phuong ³⁵, Aubrey C. Kalungia ³⁶, Stephen Campbell ^{37,38}, Alice Pisana ³⁹, Janney Wale ⁴⁰ and R. Andrew Seaton ^{11,41,42}



Citation: Godman, B.; Egwuenu, A.; Haque, M.; Malande, O.O.; Schellack, N.; Kumar, S.; Saleem, Z.; Sneddon, J.; Hoxha, I.; Islam, S.; et al. Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. *Life* **2021**, *11*, 528. <https://doi.org/10.3390/life11060528>

Academic Editors: Caterina Aurilio, Antonella Paladini, Pasquale Sansone and Vincenzo Pota

Received: 24 March 2021

Accepted: 2 June 2021

Published: 7 June 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

- 1 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK; amanj.baker@strath.ac.uk
- 2 Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria 0204, South Africa; hannelie.meyer@smu.com
- 3 School of Pharmaceutical Sciences, Universiti Sains Malaysia (USM), Penang 11800, Malaysia
- 4 AMR Programme Manager, Nigeria Centre for Disease Control (NCDC), Ebitu Ukiwe Street, Jabi, Abuja, Nigeria; abiodun.egwuenu@ncdc.gov.ng
- 5 Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia; runurono@gmail.com
- 6 Department of Child Health and Paediatrics, Egerton University, Nakuru, Kenya; ombevaom@gmail.com
- 7 East Africa Centre for Vaccines and Immunization (ECAVI), Namela House, Naguru, Kampala, Uganda
- 8 Faculty of Health Sciences, Basic Medical Sciences Building, University of Pretoria, Prinshof 349-Jr, Pretoria 0084, South Africa; natalie.schellack@up.ac.za
- 9 Department of Periodontology and Implantology, Karnavati University, Gandhinagar 382422, India; drsantoshkumar2004@gmail.com
- 10 Department of Pharmacy Practice, Faculty of Pharmacy, The University of Lahore, Lahore 54000, Pakistan; xikria@gmail.com
- 11 Healthcare Improvement Scotland, Delta House, 50 West Nile Street, Glasgow G1 2NP, UK; jacqueline.sneddon@nhs.scot (J.S.); Andrew.Seaton@ggc.scot.nhs.uk (R.A.S.)
- 12 Department of Pharmacy, Faculty of Medicine, University of Medicine Tirana, Tirana, Albania; iris.hoxha@umed.edu.al
- 13 Department of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh; salequl@juniv.edu
- 14 Department of Internal Medicine, Faculty of Medicine, University of Botswana, Gaborone, Botswana; mwitajc@ub.ac.bw
- 15 Department of Pharmacy, Postgraduate Program in Pharmaceutical Sciences (CiPharma), School of Pharmacy, Federal University of Ouro Preto, Ouro Preto 35400-000, Minas Gerais, Brazil; renata.nascimento@ufop.edu.br
- 16 Institute of Health and Biological Studies, Universidade Federal do Sul e Sudeste do Pará, Avenida dos Ipês, s/n, Cidade Universitária, Cidade Jardim, Marabá 68500-00, Pará, Brazil; isabellapiassi@gmail.com
- 17 Researcher of the Center for Research in Management, Society and Epidemiology in Nursing and in the Network of Health Care—Universidade do Estado de Minas Gerais; Av. Paraná, 3001 Jardim Belvedere, Divinópolis CEP 35501-170, Minas Gerais, Brazil
- 18 Effective Basic Services (eBASE) Africa, Ndamukong Street, Bamenda, Cameroon; lumnyanga@gmail.com
- 19 Department of Public Health, University of Bamenda, P.O. Box 39, Bambili, Cameroon
- 20 Pharmacy Department, Eswatini Medical Christian University, P.O. Box A624, Swazi Plaza, Mbabane H101, Kingdom of Eswatini; folarinamu@gmail.com
- 21 Pharmacy Directorate, Cape Coast Teaching Hospital (CCTH), Cape Coast—CC-071-9967, Ghana; joezy_35@yahoo.com (J.A.); robertincoom30@yahoo.com (R.I.)
- 22 Pharmacy Department, Keta Municipal Hospital, Ghana Health Service, Keta-Dzelukope, Ghana; isefah1980@gmail.com
- 23 Pharmacy Practice Department of Pharmacy Practice, School of Pharmacy, University of Health and Allied Sciences, Ho, Volta Region, Ghana
- 24 Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy, University of Nairobi, Nairobi, Kenya; sopanga@uonbi.ac.ke
- 25 Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq

- ²⁶ Pharmacy Department, College of Medicine, Blantyre, Malawi; ichikowe@medcol.mw (I.C.); fkhuluza@medcol.mw (F.K.)
- ²⁷ Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia; dkibuule@unam.na
- ²⁸ Department of Pharmacology, Therapeutics and Toxicology, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria; yinkabode@yahoo.com
- ²⁹ Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria
- ³⁰ Department of Medical Laboratory Science, University of Lagos, Idiara, Lagos, Nigeria; olayinka.ogunleye@lasucom.edu.ng
- ³¹ Centre for Genomics of Non-Communicable Diseases and Personalized Healthcare (CGNPH), University of Lagos, Akoka, Lagos, Nigeria
- ³² Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina; vanda.markovic-pekovic@med.unibl.org
- ³³ National Medicines and Poisons Board, Federal Ministry of Health, Khartoum, Sudan; abubakr13@yahoo.com
- ³⁴ Department of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, Unaizah 56264, Qassim, Saudi Arabia
- ³⁵ Pharmaceutical Administration & PharmacoEconomics, Hanoi University of Pharmacy, Hanoi, Vietnam; thuy_ntp@hup.edu.vn
- ³⁶ Department of Pharmacy, School of Health Sciences, University of Zambia, Lusaka, Zambia; chichokalungia@gmail.com
- ³⁷ Centre for Primary Care and Health Services Research, School of Health Sciences, University of Manchester, Manchester M13 9PL, UK; stephen.campbell@manchester.ac.uk
- ³⁸ NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester M13 9PL, UK
- ³⁹ Department of Global Public Health, Karolinska Institutet, 17177 Stockholm, Sweden; alice.pisana@stud.ki.se
- ⁴⁰ Independent Researcher, 11a Lydia Street, Brunswick, VIC 3056, Australia; socrates111@bigpond.com
- ⁴¹ Infectious Disease Department, Queen Elizabeth University Hospital, Govan Road, Glasgow G51 4TF, UK
- ⁴² Department of Medicine, University of Glasgow, Glasgow G12 8QQ, UK
- * Correspondence: brian.godman@strath.ac.uk; Tel.: +44-0141-548-3825; Fax: +44-0141-552-2562

Abstract: Antimicrobial resistance (AMR) is a high priority across countries as it increases morbidity, mortality and costs. Concerns with AMR have resulted in multiple initiatives internationally, nationally and regionally to enhance appropriate antibiotic utilization across sectors to reduce AMR, with the overuse of antibiotics exacerbated by the COVID-19 pandemic. Effectively tackling AMR is crucial for all countries. Principally a narrative review of ongoing activities across sectors was undertaken to improve antimicrobial use and address issues with vaccines including COVID-19. Point prevalence surveys have been successful in hospitals to identify areas for quality improvement programs, principally centering on antimicrobial stewardship programs. These include reducing prolonged antibiotic use to prevent surgical site infections. Multiple activities centering on education have been successful in reducing inappropriate prescribing and dispensing of antimicrobials in ambulatory care for essentially viral infections such as acute respiratory infections. It is imperative to develop new quality indicators for ambulatory care given current concerns, and instigate programs with clear public health messaging to reduce misinformation, essential for pandemics. Regular access to effective treatments is needed to reduce resistance to treatments for HIV, malaria and tuberculosis. Key stakeholder groups can instigate multiple initiatives to reduce AMR. These need to be followed up.

Keywords: antimicrobials; antimicrobial stewardship programs; antimicrobial resistance; healthcare-associated infections; COVID-19; lower- and middle-income countries; misinformation; patient initiatives; surgical site infections; vaccines

1. Introduction

Antimicrobial resistance (AMR) is a high-priority area across all countries, increasing morbidity, mortality and costs [1–7], with several studies documenting the clinical and economic impact of AMR [2,3,8–15]. There is considerable resistance to commonly prescribed antibiotics among low- and middle-income countries (LMICs) including Bangladesh, with

resistance rates continuing to rise across countries [16–18]. Rising AMR rates need to be urgently addressed, with the World Bank (2017) believing that even in a low-AMR scenario, the loss on world output due to AMR could exceed US\$1 trillion annually after 2030, and potentially up to US\$3.4 trillion annually, unless addressed, equivalent to 3.8% of annual Gross Domestic Product (GDP) [19]—with the costs of AMR appreciably exceeding those of the antibiotics prescribed [13].

Rising AMR rates are due to a number of factors including rising antimicrobial utilization especially in LMICs [20,21], with the overuse of antimicrobials linked with increasing AMR [19,22,23]. Alongside this, the availability of substandard, spurious or falsified antibiotics, high rates of self-medication especially in LMICs often for self-limiting diseases, the extensive use of antimicrobials to prevent and treat diseases in animals considering that their manure is often used in food production and for aquaculture, water pollution, lack of hand hygiene and proper sanitation as well as travelling between countries enhances AMR rates [11,19,21,23–34]. In their recent paper, Van Boeckel et al. (2019) found nearly a 3-fold increase in bacteria showing resistance above 50% to antimicrobials in chickens and pigs in LMICs between 2000 and 2018 [35], with resistance rates expected to rise unless addressed.

Low vaccination rates against disease have also enhanced antimicrobial use and AMR, with current concerns that vaccination rates are being further compromised by the COVID-19 pandemic, with its resultant impact on patient movement and available facilities as a result of lockdown and on other measures [11,21,36–42], exacerbated by vaccine hesitancy generally alongside misinformation [43,44]. We are though seeing approaches to combat this including mobile vaccination clinics [45].

The general overuse of antimicrobials has been worsened by the COVID-19 pandemic [3,46–48], with concerns with differential diagnosis between infections such as tuberculosis (TB) and bacterial upper respiratory tract infections (URTIs) from influenza, coughs, fever and COVID-19 [49,50]. Published studies suggest that over 70% of patients with COVID-19 received antibiotics, including broad-spectrum antibiotics, even when not clinically indicated [41,51,52]. Typically, less than 10% of COVID-19 patients appear to have bacterial or fungal infections [53], with some studies suggesting that only 3.2% of COVID-19 infections are co-infections warranting antibiotics [21,54]. In their recent meta-analysis, Langford et al. (2021) found that overall three-quarters of patients with COVID-19 were prescribed antibiotics, which is significantly higher than the estimated prevalence of bacterial co-infections [21,55]. Consequently, the authors concluded that unnecessary antibiotic use is high in patients with COVID-19 [55], which will enhance AMR rates.

Concerns with rising AMR rates and the consequences have resulted in international, regional, national, and local strategies to try and reduce the rises [12,56–68]. National initiatives include National Action Plans (NAPs) under the direction of the WHO, building on its Global Action Plan [59,60,69–74]. We are already seeing countries assess their progress of NAPs against agreed targets, and this will continue [63,75,76].

Alongside this, there are concerns with multi-resistant microorganisms and the implications for patients with TB, human immunodeficiency virus (HIV), malaria, and typhoid, as well as those with co-infections [77]. Early treatment for patients with co-infections with HIV and drug-resistant TB is essential to reduce the significant risk of death [77,78]. There is also ongoing research to better predict patients with MDR-TB and improve future care [79]. Treatment centers, especially in rural areas, are important to monitor treatment progress and provide access to medicines, to enhance successful management and reduce future cases [80].

Overall, we are aware that coordinated activities among all key stakeholders can address over-utilization of antibiotics. Multiple demand-side measures including education of all key stakeholders, prescribing restrictions, and follow-up in pharmacies stabilized or reduced the utilization of antibiotics in former Soviet Union republics including Azerbaijan, the Republic of Srpska, Bosnia and Herzegovina, and Slovenia versus Poland that failed to instigate such measures [61,62,81,82]. In Poland, there was a small but statistically

significant average annual increase in total antibiotic consumption between 2007 and 2016 [82].

We are also aware that there are concerns with high prevalence rates of hospital-associated infections (HAIs) in a number of LMICs, with major challenges surrounding the appropriate use of antibiotics to reduce surgical site infections (SSIs) [83–85]. The instigation of ASPs in hospitals, including undertaking point prevalence surveys (PPS) to identify areas for quality improvement programs, can improve future antibiotic use and reduce AMR [3,86–96]. There are though manpower and resource challenges with implementing ASPs in hospitals in LMICs [97]. Having said this, successful ASPs have been introduced in hospitals in LMICs to improve antimicrobial prescribing providing guidance to others [3,76,87,98]. Successful programs have also been introduced in ambulatory care in LMICs to improve prescribing and dispensing of antibiotics for essentially viral infections such as acute respiratory infections (ARIs) and including URTIs [64,99,100]. We are also seeing new technologies being developed, including Apps, to provide prescribing advice and other information to physicians and patients to reduce inappropriate use of antibiotics [101]. However, there are concerns with variable adherence to guidelines, possibly exacerbated by guidelines not always considering local resistance patterns, as well as other activities such as community engagement to improve patient care in practice [64,102,103].

We would like to build on these issues and challenges to discuss potential ways to decrease future AMR rates among LMICs. We have chosen LMICs as they currently have the greatest increase in antimicrobial use, the highest rate of self-purchasing of antibiotics, as well as the highest rate of antimicrobial use in hospitals [20,64,104,105]. In addition, mortality rates from AMR are likely to be highest among LMICs, including those in Africa and Asia, by 2050 unless addressed [11,25]. Effectively tackling AMR is crucial for the future of all countries, exacerbated by few new antibiotics currently being developed; however, this is counterbalanced to some extent by developments in vaccine technology [10,19,32,106]. We hope our review paper will consolidate current knowledge in key areas to provide guidance on potential ways forward among all key stakeholders across LMICs to reduce AMR rates, especially where there are continued concerns.

2. Materials and Methods

We undertook a narrative review of published papers to document potential ways to enhance appropriate prescribing and dispensing of antimicrobials. We purposely did not undertake a systematic review as an appreciable number of these have already been conducted on different aspects to improve future prescribing and dispensing of antimicrobials [85,86,92,100,104,105,107–134]. In addition, we did not document the number of publications by country and sector as we are aware that some countries are more prolific in their publications than others, and such analyses may bias the actual situation. We did though divide initiatives up into those directed at hospitals compared with those in ambulatory care. We are aware that issues such as self-purchasing of antibiotics are especially important in LMICs as up to 100% of pharmacies in these countries dispense antibiotics without a prescription despite legislation which can account for up to 93% to 100% of all dispensed antibiotics [123,124,129,135,136]. This because our principal aim was to provide possible future guidance to all key stakeholder groups within LMICs for potential debate based on the considerable experiences of the co-authors from multiple LMICs. We have successfully used this approach before to stimulate debate in other priority healthcare areas to provide future guidance [64,85,137–147].

The World Bank classification was used to break countries down into LMICs or upper income countries where applicable [148]. Similar to previous studies conducted by the co-authors, upper-income countries will only be commented upon where pertinent [64,84,146]. This is because we are aware that there are different practices and beliefs, as well as a greater availability of healthcare professionals and resources, in higher- versus middle- and low-income countries. In addition, in LMICs, the costs of medicines can account for up

to 60% or more of total healthcare expenditure, much of which will be out of pocket, with potentially catastrophic consequences for families when members become ill [149–154].

There can also be long waiting times for patients to see physicians in primary health-care centers (PHCs) in LMICs, long distances to travel to PHCs, and pharmacists are typically open later in the day, resulting in patients often seeking their advice as alternatives to physicians [155–160]. This is helped by the fact that community pharmacists are typically trusted by patients and less expensive than physicians, with patients not having to pay physician fees when the need arises [99,135,157,161]. However, we are aware that there can be concerns with the knowledge of pharmacists and their assistants regarding antibiotics and AMR [159,162–164].

When documenting interventions that have been undertaken to enhance appropriate prescribing and dispensing of antimicrobials, we will break these down into the 4Es to enhance understanding and comparisons, namely Education, Engineering, Economics and Enforcement [165,166]. Education includes developing guidelines or formularies, with adherence to well-constructed guidelines increasingly seen as demonstrating good quality care [147,167–172]. This also includes educational and monitoring activities surrounding the WHO AWaRe list of antibiotics [173–175]. Instigating Drug and Therapeutic Committees (DTCs) and ASPs in hospitals to provide educational activities to enhance the rational use of medicines including antimicrobials [97,176–179] is also classified as education. Engineering includes organizational or managerial interventions which incorporate prescribing and quality targets. These include the percentage of antibiotics prescribed according to agreed guidance and the WHO AWaRe list, the percentage of patients not prescribed prolonged antibiotics to prevent SSIs as well as the percentage of patients reaching agreed target blood pressure levels [147,166,169,175,180,181]. Economics includes financial incentives to physicians, pharmacists, patients or hospitals, for instance providing financial incentives to hospitals to improve their patient safety records and/or reduce payments where there are concerns, incentivizing physicians for attaining agreed prescribing targets including adherence to guidelines, or fining pharmacists for illegally dispensing an antibiotic without a prescription [9,147,166,182,183]. Enforcement includes regulations by law such as banning the dispensing of antibiotics in pharmacies without a prescription, compulsory generic substitution as well as national policies outlining the need for DTCs in hospitals and how their activities should be monitored [100,166,177].

No ethical approval was required for this review as we were not dealing with patients. This is in line with previous similar papers published by the co-authors [64,84,105,138,146,147,184,185].

3. Results

There are a number of key issues that need to be addressed to enhance appropriate antimicrobial use in patients and reduce AMR. We will break our findings down into key areas within hospitals and subsequently ambulatory care before concluding with guidance on potential activities that can be undertaken among all key stakeholder groups to reduce AMR.

Activities that can be undertaken in hospitals include PPS studies to gain baseline data of current utilization patterns to guide future quality improvement programs as part of ASPs and other activities. Initiatives in ambulatory care center around activities to improve prescribing and dispensing of antimicrobials especially for self-limiting infections such as viral URTIs. These are especially important since, as mentioned, we are aware that up to 100% of pharmacies in LMICs dispense antibiotics without a prescription despite legislation, and this can account for up to 93% to 100% of all dispensed antibiotics [123,124,129,135,136]. Having said this, HAIs are considered as the most adverse event in healthcare delivery [104,186].

3.1. Antimicrobial Use in Hospitals

The first consideration within hospitals is to ensure that activities to improve antimicrobial prescribing are given a high priority if this is not already the case. This includes

initiatives such as instigating active infection, prevention and control committees (IPC committees) [187–192], which can be part of antimicrobial stewardship groups [76,86]. The latter can be part of IPC committees or attached to Drug and Therapeutic Committees (DTCs). In addition, PPS studies can be undertaken and ASPs indicated to improve future antimicrobial use in hospitals (Table 1).

Table 1. Hospital activities to improve antimicrobial use.

Activity	Role with Improving Antimicrobial Prescribing
IPC committees	<ul style="list-style-type: none"> • Can be a core component of enhancing antimicrobial use within hospitals through instigating pertinent quality improvement programs [189], with minimum requirements for IPCs established by the WHO and others [190,191] • Studies have shown that IPCs can reduce AMR in key hospital wards [191] • However, there can be issues with lack of resources and identity as well as negative staff attitudes [187]
PPS studies	<ul style="list-style-type: none"> • PPs studies are important to gain an understanding of current antimicrobial use in hospitals and potential programs for quality improvement initiatives [105,168,193,194] • PPS studies help determine the extent of HAIs within LMICs [104], with typically a higher rate of HAIs among LMICs at 5.7–19.1% of patients versus 5.7–7.5% in high-income countries [104,195,196]—although rates up to 28% to 45.8% have been recorded among hospitals in sub-Saharan African countries [104,197,198] • This is a key issues as HAIs are associated with appreciable morbidity, mortality and costs [104,131,199,200], with higher prevalence rates of HAIs in LMICs due to a number of factors including poorly enforced ward environmental sanitation practices, lack of monitoring of adherence to IPC guidelines and concerns with facilities [104,201] • Key concerns with PPS studies include the extent of documentation of the rationale for the choice of antimicrobial(s), whether the rationale is in line with local/national recommendations, whether culture and sensitivity testing (CST) is being routinely undertaken, the extent of switching from intravenous (IV) to oral use, the timing and duration of administration of antibiotics to prevent SSIs and adherence to local or national guidance—increasingly seen as a key quality indicator [88,168,169,171,202] • Specific data collection forms have been designed for Africa recognizing the additional burden of HIV, TB, malaria and malnutrition [88,203], with APPs developed to accelerate data collection and analysis [204,205]
ASPs	<ul style="list-style-type: none"> • Seen as a core element especially within hospitals to improve future antibiotic prescribing (Section 3.1.1) • Publications including from the Commonwealth Partnership for Antimicrobial Stewardship and practical toolkits from the WHO and others can assist with implementation [171,206–211] • However, ASPs can take time to implement in LMICs in view of ongoing cultures and resources [97]: <ul style="list-style-type: none"> ○ In Tanzania, one year after the instigation of the NAP, 35.9% of respondents had instigated some form of ASP in their hospital; however, hospital antibiotic policy documents were only available in 15.4% of facilities [76]. Encouragingly, IPC committees were now present in the majority of hospitals surveyed ○ In Vietnam, by the end of 2018, ASPs had been initiated in 47% of its hospitals, but actual implementation has been slow [212,213]

However, there can be issues with the instigation of IPC committees and their effectiveness in hospitals (Table 1), concerns about the knowledge of ASPs among clinicians in LMICs, concerns with resource issues with establishing active ASPs including manpower, as well as a lack of institutional policies in LMICs [97,188,214–216]. These issues can be exacerbated by a lack of clear commitment nationally despite the instigation of NAPs, which needs to be addressed to improve future antimicrobial use [213,216].

Figure 1 incorporates the core elements of any ASP, with Kakkar et al. (2020) discussing the potential composition of personnel within antimicrobial stewardship groups in LMICs including physicians, pharmacists, microbiologists, infection control personnel as well as hospital administrators [213]. Ideally, there should be a single focal point, with leaders of ASPs typically being either physicians or pharmacists, with pharmacists increasingly helping to drive forward ASPs in LMICs [87,98,171,211,217]. ASPs can also be part of DTC activities if needed in some hospitals [211].




Figure 1. Core elements of any antimicrobial stewardship program.

Box 1 contains a number of indicators that have been used to assess the quality of antimicrobial prescribing within hospitals.

Box 1. Possible indicators that have been used in LMICs to assess the quality of antimicrobial prescribing (adapted from [88,170,171,193,211,218–220]).

- Availability, ready access and subsequent compliance to local or regional treatment guidelines for key infections. This includes the availability of antibiograms within hospitals to guide empiric use whilst waiting for culture and sensitivity test (CST) findings as well as a potential list of restricted antibiotics depending on physician experience
- Whether antibiotics prescribed are included in the hospital formulary/national essential medicine lists
- Rationale (indication) for antimicrobial use documented in the patient's notes
- Whether therapy was empiric or targeted based on CST findings
- Documentation of the dose in the patient's notes
- Documentation of a stop/review date for given antibiotics in the patient's notes. This can include the rate of de-escalation to a narrower-spectrum antibiotic where appropriate
- Documentation of any missed doses of antibiotics
- Extent of IV to oral switching (based on the stability of the gastrointestinal tract)
- Duration of surgical prophylaxis
- Changes in antibiotic use over time in terms of Defined Daily Doses/100(0) bed days and/or days of therapy/patient-days
- Whether active antimicrobial stewardship groups and/or drug and therapeutic committees/Infection Prevention and Control groups in the hospital

Multiple activities to reduce HAIs include encouraging greater hand hygiene, regular reviews surrounding the use and care of catheters, instigating appropriate strategies to reduce ventilator-associated pneumonia including subgluteal space suctioning before each position change, chlorhexidine gluconate bathing as well as active monitoring of agreed guidelines to reduce HAIs [132,221,222]. A number of initiatives have been undertaken to improve hand hygiene in LMICs including those orchestrated by the WHO and others providing direction [223,224].

Multiple activities can also be undertaken to improve antibiotic utilization to reduce SSIs among LMICs [84]. Recent publications have documented that the number of patients receiving their first dose of antibiotics within 60 min of the first incision, with a second dose administered for longer procedures, can be as low as 6.7% of surgical patients in LMICs [84,108,225,226]. This is a concern as studies have shown the risks of SSIs are almost five times higher when antibiotics are administered more than two hours prior to the first incision and almost doubled when administered after the first incision [84,227]. There are

also concerns that extending prophylaxis beyond one day, which is frequent among LMICs with for instance a mean up to 8.7 days post-operatively in Nigeria, does not appear to improve outcomes whilst concurrently increasing the potential for acute kidney injury, *Clostridium difficile* infections, and AMR as well as increasing costs [84,228–233]. Vicentini et al. (2019) in their published study found that adequate antibiotic choices and length of administration were associated with significantly reduced risks of SSIs [234], with a number of approaches successfully undertaken in LMICs to improve antibiotic use surrounding the prevention of SSIs [84].

3.1.1. Antimicrobial Stewardship Programs (ASPs) and Other Activities to Improve Antimicrobial Utilization in Hospitals

ASPs as well as other interventions can improve overall utilization of antimicrobials in hospitals as well as reduce costs alongwith improved hand hygiene and other activities to reduce HAIs and SSIs (Table 1) [223,235–237]. There are a number of areas that can be initial targets for ASP programs to gain their acceptance among key stakeholder groups in hospitals to address barriers [211–213]. These include developing guidelines for specific indications and monitoring subsequent usage against these guidelines, as well as developing prompts for physicians to regularly review antibiotic prescriptions.

Table 2 summarizes some of the activities that have been undertaken in LMICs to improve antimicrobial utilization in hospitals, which build on reviews in predominantly high-income countries including the use of computerized decision support systems [236,238]. This includes (Table 2) activities surrounding SSIs and their impact to provide future guidance. Activities principally centre on educational initiatives [93], with educational initiatives known to enhance understanding of ASPs in LMICs given concerns about knowledge and activities among students and physicians in a number of LMICs [214,215,239,240].

Table 2. Summary of published studies across LMICs documenting the impact of ASP interventions including those surrounding SSIs.

Author, Country and Year	Brief Details of the Intervention	Impact of the Intervention
Bozkurt et al., Turkey, 2014 [241]	<p>Principally educational interventions to improve appropriate antibiotic use for SSIs. These included:</p> <ul style="list-style-type: none"> • Series of meetings with physicians from each clinic organized by the Infection Control Committee • Daily visits from the Infection Control Nurse and twice weekly visits from the Infectious Diseases Control Specialist—more if compliance with agreed guidelines was low • Observations regularly shared with the group 	<ul style="list-style-type: none"> • Use of appropriate antibiotics increased from 51% to 63.4% of cases • Duration of antibiotic use improved from 10.3% to 59.4% of cases • Total cost of antibiotics in the medical units, surgical units and ICUs decreased by 32.5%, 38.6% and 11.1%, respectively, over the time of the study
Hou et al., China, 2014 [242]	<p>A number of interventions were undertaken to improve antibiotic utilization in ICUs as part of ASPs. These included:</p> <ul style="list-style-type: none"> • Education—all healthcare professionals trained on antimicrobial-stewardship relevant knowledge as well as developing a new antibiotic formulary • Engineering—Physicians had strict regulations surrounding antibiotic prescribing including restrictions surrounding quinolones. Target of 40 DDDs/100 patient-days for the hospital and 120 for the ICU, with regular feedback to the Director of the Unit 	<ul style="list-style-type: none"> • Total antibiotic consumption in the hospital decreased from 69.69 DDDs/100 patient-days to 50.76 DDDs between April and August 2011; and in the ICU decreased from 197.65 to 143.41 DDDs/100 patient-days • Significant improvements in resistance to amikacin, ceftazidime, ciprofloxacin, ceftriaxone, gentamicin, ofloxacin and piperacillin in <i>Enterobacteriaceae</i> and resistance to ceftazidime, imipenem, and meropenem in non-fermenting Gram-negative rods • Rates of no prescribing of antibiotics initially or just a single antibiotic prescription significantly increased ($p < 0.001$)
Amdany et al., Kenya, 2014 [243]	<p>Principally an educational initiative to enhance the use of oral vs. IV metronidazole including education, audit and feedback</p>	<ul style="list-style-type: none"> • Post-implementation audit showed an increase of more than 40% compliance in all the four criteria utilized to assess an increase in oral use • As a result, reduced costs, patient discomfort and possible iatrogenic infections

Table 2. Cont.

Author, Country and Year	Brief Details of the Intervention	Impact of the Intervention
Yang et al., China, 2014 [244]	Education and Engineering interventions to improve antibiotic use for SSIs. These included the Introduction of a Drug Rational Usage Guideline System (DRUGS) vs. paper-based guidelines to enhance adherence to surgical prophylaxis guidelines	<ul style="list-style-type: none"> • Timing of the initial dose improved from 32.9% of patients with antibiotics instigated within 30 min to 2 h pre incision to 85.8% post-intervention (statistically significant) • Average length of stay decreased from 7.00 days with paper-based guidelines to 2.55 days with DRUGS • Average cost of antibiotics prescribed decreased from ¥3481 with paper-based guidelines to ¥1693 with DRUGS
Okumura et al., Brazil, 2015/2016 [245,246]	<p>Primarily Education comparing the outcomes from two different ASP approaches among patients in the general ward and ICU:</p> <ul style="list-style-type: none"> • Bundled ASP including clinical pharmacist chart review, discussions with microbiologists/infectious disease physicians, education of physicians and continuous follow-up of pertinent physicians until clinical resolution/discharge • Conventional ASP involving a clinical pharmacist chart review and discussions with infectious disease physician 	<ul style="list-style-type: none"> • DDDs/1000 patient-days decreased from 557.2 to 417 ($p < 0.05$) in the bundled ASP group • Mortality decreased in the bundled ASP group ($p < 0.01$) and the risk difference was 10.8% (95% CI: 2.41–19.14) • The bundled strategy though was overall more expensive at US\$2119.70/patient; however, more cost-effective
Saied et al., Egypt, 2015 [247]	<p>Primarily Education and Engineering to improve antibiotic use of SSIs. These included</p> <ul style="list-style-type: none"> • 2 day training curriculum course for pertinent surgeons • On-the-job training provided to junior surgeons and residents • Wall-mounted poster developed to remind prescribers of the optimal timing and duration of antibiotic administration for SAP • Regular audit and feedback meetings orchestrated by the senior surgeon in the hospital (3 of 5 participating hospitals) 	<ul style="list-style-type: none"> • The optimal timing of the first dose improved significantly in the 3 hospitals subject to the intervention—increasing from 6.7% of pertinent patients to 38.7% ($p < 0.01$) • All hospitals involved showed a significant rise in the optimal duration of surgical prophylaxis—overall increase of 3–28% across the hospitals ($p < 0.01$)
Ntumba et al., Kenya, 2015 [248]	<p>Primarily Education and Engineering to improve the use of antibiotics in relation to SSIs. These included:</p> <ul style="list-style-type: none"> • Local adaptation of guidelines • Creation and tools for advocacy, training, and leadership around appropriate SAP 	<ul style="list-style-type: none"> • Patients receiving antibiotics post-operatively decreased from 50% to 26% • Crude SSI rates significantly decreased from 9.3% to 5% of patients
Apisarntharak et al., Thailand, 2015 [249]	<p>This ASP principally involved Education with a 12 h training course run by infectious diseases clinical pharmacists (IDCPs) with physicians looking after patients in medical wards coupled with an option for infectious diseases consultations (IDCs), daily rounds with IDCPs, or both if wished, with a control (Usual Standard of Care) group</p>	<p>For patients with input from the IDCP group or the IDCP plus IDC group vs. controls, they were:</p> <ul style="list-style-type: none"> • Less likely to be prescribed inappropriate antibiotics ($p < 0.001$) • Have greater de-escalation of antibiotics ($p < 0.001$) • Received antibiotics <7 days ($p < 0.001$) • Have shorter lengths of stay ($p < 0.001$)
Boyles et al., South Africa, 2017 [250]	<ul style="list-style-type: none"> • Principally Education over a sustained period for this ASP • Intervention comprising online education materials, a dedicated antibiotic prescription chart and weekly dedicated ward rounds 	<ul style="list-style-type: none"> • Total antibiotic consumption fell from 1046 DDDs/1000 patient-days in 2011 (control period) to 868 by 2013 and remained at this level for the next 2 years—driven by a reduction in IV antibiotic use, particularly ceftriaxone • Inflation-adjusted cost savings on antibiotics were SA Rand of 3.2 million over 4 years

Table 2. Cont.

Author, Country and Year	Brief Details of the Intervention	Impact of the Intervention
Brink et al., South Africa, 2017) [251]	<p>Education and Engineering. Key activities driven by hospital pharmacists included:</p> <ul style="list-style-type: none"> Recording current SSI rates and developing a SAP ‘toolkit’ Testing and revising the SAP guidelines and toolkits at pilot sites prior to their launch at regional training and institutional workshops Obtaining consensus and endorsement from key professionals in the hospital through adapting and modifying guidelines where appropriate Choosing at least one or more surgical procedures to audit including recording pre-intervention SAP practices and trends for the chosen surgeries Subsequently measure compliance to agreed four process measures over a 4-week period and feedback 	<ul style="list-style-type: none"> Timely administration of antibiotics increased to 56.4% of surgical patients ($p < 0.0001$) Antibiotic choice consistent with the guidelines increased to 95.9% of patients and the duration of prophylaxis was now appropriate among 93.9% of patients
Allegranzi et al., Kenya, Uganda, Zambia, and Zimbabwe, 2018 [252]	<p>Primarily Education and Engineering to improve antibiotic prescribing for SSIs. This included:</p> <ul style="list-style-type: none"> 5 planned visits to each hospital in the four African countries during the study period supported by a range of educational tools Local teams identified key areas of concern with preventing SSIs to concentrate on through monitoring an agreed range of SAP indicators (six pre-identified ones including skin preparation and optimal timing of prophylaxis) Subsequent launch activities of pertinent tools and indicators alongside monitoring/feedback to improve prescribing 	<ul style="list-style-type: none"> Appropriate use of SAP improved from 12.8% (baseline) to 39.1% of patients ($p < 0.0001$) among the studied hospitals Cumulative SSI incidence decreased from a baseline of 8.0% to 3.8% post-intervention ($p < 0.0001$)
Khdour et al., Palestine, 2018 [253]	<ul style="list-style-type: none"> Primarily education—the ASP team drew up new antibiotic guidelines for the empiric treatment of common infections within the ICU Clinical pharmacists subsequently performed the initial review of subsequent treatment and made therapeutic recommendations if needed which were reviewed by the ASP team on the 2nd, 4th and 7th days, allowing for CST findings. Subsequent interventions were recommended by the ASP team if needed Four months of pre-ASP data were compared with 4 months of post-ASP data to assess the impact 	<ul style="list-style-type: none"> High acceptance of ASP team recommendations (78.4%)—most accepted were dose optimization (87.0%) and de-escalation (84.4%) ASP interventions significantly reduces antimicrobial use—from 87.3 DDDs/100 beds vs. 66.1 DDDs/100 beds $p < 0.001$) Median length of stay was significantly reduced post-ASP—down from 11 (3–21) to 7 (4–19) days ($p < 0.01$)
Abubakar et al., Nigeria, 2019 [254]	<p>Primarily Education and Engineering to improve antibiotic prescribing for the prevention of SAP. This included:</p> <ul style="list-style-type: none"> Development and dissemination of an agreed departmental protocol for SAP, presented and agreed before its adoption to enhance subsequent adoption rates Educational meetings with key clinicians to enhance uptake of agreed protocols combined with wall mounted posters Regular audit and feedback meetings using baseline data 	<ul style="list-style-type: none"> Patients in the postintervention period were 5.6 times more likely to receive SAP within 60 min before the incision vs. pre-intervention ($p < 0.001$) The rate of redundant antibiotic prescriptions was reduced by 19.1%
Karaali et al., Turkey, 2019 [255]	<p>Multiple activities to improve antibiotic prescribing for SSIs including Education, and Engineering. These incorporated:</p> <ul style="list-style-type: none"> Local guidelines updated by two members of the infection control committee One general surgery team leader appointed to be responsible for improving SAP as part of ASPs in their group Periodic training sessions to supervise and regulate SAP by surgical team leaders Instigation of a new protocol, whereby clean and clean-contaminated cases would not be given SAP for longer than 24 h and that discharge prescriptions would not include antibiotics. However, no verbal or written sanctions were imposed for abuse 	<ul style="list-style-type: none"> Compliance with SAP guidance significantly increasing from 55.6% to 64.5% of patients ($p < 0.05$)—although differences between surgical types Significant reduction in the extent of prolonged prophylaxis (beyond 24 h) from 60.2% of patients pre intervention to 7.5% post-intervention ($p < 0.05$) Extent of antibiotic prescribing after discharge reduced to 9.4% of patients down from 80.6% of patients pre-intervention ($p < 0.05$) However, limited impact on the timing of first antibiotic dose—increasing from 81.9% of patients to 83.7%

Table 2. Cont.

Author, Country and Year	Brief Details of the Intervention	Impact of the Intervention
Mahmoudi et al., Iran, 2019 [256]	<p>Principally Education and Engineering to improve SAP:</p> <ul style="list-style-type: none"> Revising SAP guidelines following meetings between a clinical pharmacist and the surgical department with senior clinical pharmacists delivering lectures about SAP to key members of the surgical departments Clinical pharmacists participating in ward rounds, attending recovery rooms and communicating with surgeons when guidelines not followed Clinical pharmacists providing educational materials Rationality of SAP continually evaluated during the perioperative period in accordance with agreed guidelines with clinical pharmacists communicated any concerns directly with relevant physicians 	<ul style="list-style-type: none"> Rate of antibiotic prescribing beyond 48 h appreciably improved to just 5.7% of patients—down from 92.1% of patients pre-intervention Appropriateness of antibiotic use increased to 91.4% of patients from 30.1% pre-intervention Mean cost of antibiotics decreased more than 11-fold and length of stay decreased from an average of 5.14 days pre-intervention to 4.33 days ($p < 0.001$) post-intervention
Xiao et al., China, 2020 [257]	<p>Multiple activities include Education, Engineering, Economics and Enforcement over a 6-year campaign:</p> <ul style="list-style-type: none"> Hospitals were encouraged to establish ASTs with healthcare authorities promoting education and training programs for medical staff Health authorities also supervised hospitals and issued penalties including personal warnings and dismissals, as well as downgraded hospitals Prescription rights were withdrawn where serious protocol violations observed 	<p>Over the six years—2016 vs. 2010:</p> <ul style="list-style-type: none"> Proportion of outpatients and surgical patients who received antibiotics decreased from 19.5% to 8.5% and from 97.9% to 38.3% respectively Overall antibiotic use decreased from 85.3 ± 29.8 DDDs/100 patient days to 48.5 ± 8.0 Antibiotic procurement expenditure declined from 22.3% of total drug procurement costs to 12.1% Incidence of methicillin-resistant <i>Staphylococcus aureus</i> isolates decreased from 54.4% to 34.4% in 2016); similarly, for carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from 30.8% to 22.3%
Mardani et al., Iran, 2020 [258]	<p>Principally education for this ASP comprising:</p> <ul style="list-style-type: none"> Continuous educational programs for nurses and physicians employed in different wards of the hospital An inter-disciplinary ASP team performed a weekly scrutiny of treatment for patients based on their electronic medical records and provided feedback include reduction in multiple antibiotic use and dosage changes 	<ul style="list-style-type: none"> Reduction in MDR cases in the year post-intervention from 145 and 75 ($p = 0.011$) Significant reduction in all positive blood cultures ($p = 0.001$) Significant reduction in meropenem use ($p = 0.043$) as well as a significant reduction generally in antibiotic consumption, multidrug-resistant organisms and CDIs
van den Bergh et al., South Africa, 2020 [259]	<p>Principally education to improve compliance to agreed guidelines:</p> <ul style="list-style-type: none"> A Community Acquired Pneumonia (CAP) bundle was developed including seven process measures (including admission criteria, drug choice, dose and length) and three outcome measures (including length of stay and mortality) that pharmacists used to audit compliance to the bundle and provide feedback Training sessions were conducted on the CAP and implementing ASPs within hospitals. After each learning session, a checklist of essential activities and deadlines was provided to each pharmacist Baseline data were collected to identify areas for improvement. In a four-week period after the learning sessions, pharmacists applied the learnt ideas to improve compliance to the CAP guidelines and ways to give feedback to address identified gaps to improve future compliance with multi-disciplinary team members and hospital leadership 	<ul style="list-style-type: none"> 2464 patients from 39 hospitals were included with the ASP showing positive results: CAP bundle compliance improved to 53.6% from 47.8% to 53.6% ($p < 0.0001$) Diagnostic stewardship compliance improved to 54.6% from 49.1% of patients ($p < 0.0001$) Improved compliance with process measures was significant for five of the seven components. These include choice and dose of antibiotics prescribed as well as IV to oral switch However, there was no significant difference in mortality or median length of stay pre- and post-intervention The study represents the first collaboration between public and private sector hospitals in ASPs in South Africa

We are aware that ASPs have been successfully instigated in Accident and Emergency Departments in hospitals. However, this typically applies to higher-income countries [134,260,261].

3.1.2. Dealing with Antimicrobial Shortages in Hospitals

Other strategies that antimicrobial stewardship groups and DTCs can undertake in hospitals is to develop effective approaches to address antimicrobial shortages, with medicine shortages being an increasing concern across countries [145,262–264]. Shortages of antimicrobials can lead to administering less effective, more toxic, and costlier antimicrobials as well as potentially increasing AMR rates [264–266]. One way to address this is for key personnel in hospitals, including those who are part of ASTs, to agree in advance therapeutic interchange strategies [264]. This can include consultations between prescribers and hospital pharmacists before alternative antibiotics are administered [264].

Emergency procurement procedures should also be in place in hospitals alongside regular reviews of stock levels in wards, exacerbated by the current COVID-19 pandemic [263,267]. Available resources and funding is also essential to reduce the possibility of antimicrobial shortages in hospitals. The Bamako Initiative in sub-Saharan Africa is one such initiative adopted by Ministers of Health to increase access to medicines including antimicrobials through revolving drug funds [268,269]. However, sustaining earlier gains with this initiative remains a challenge, and alternative drug financing schemes are essential to ensure physicians and patients can access appropriate antimicrobials in hospital to improve outcomes and reduce length of stay [270].

3.2. Antimicrobial Use in Ambulatory Care

We will principally concentrate on ARIs as these are the most common infections seen in ambulatory care in LMICs and where the highest rate of inappropriate prescribing and dispensing takes place [64,102,271–273]. Suboptimal management of ARIs in LMICs is exacerbated by a number of issues including social-cultural issues, diagnostic uncertainty, clinician competency and misconceptions as well as from commercial, patient and time pressures [64,114,129,133,274–276].

Consequently, there are a number of strategies that can be undertaken in ambulatory care across LMICs to address current issues to improve future antimicrobial utilization. These can principally be divided into those impacting on the prescribing of antimicrobials by physicians for what are essentially viral infections, those strategies that can reduce inappropriate dispensing of antibiotics without a prescription as well as those that can address concerns with multi-resistant organisms for infections such as malaria and TB. In addition, there are a number of strategies that can be implemented to improve vaccination rates including during pandemics.

Improving antimicrobial utilization in ambulatory care for ARIs is especially important in the current pandemic, with, as mentioned, published studies suggesting that over 70% of patients with COVID-19 are receiving antibiotics, including broad-spectrum antibiotics, even when not clinically indicated [51,52], with perhaps as low as 3.2% of infections in ambulatory care warranting antibiotics [21,54].

3.2.1. Initiatives among Physicians to Improve Antibiotic Prescribing

A number of initiatives have been undertaken across LMICs to improve physician prescribing of antibiotics for ARIs. Table 3 summarizes examples of the many multiple activities that have been undertaken in LMICs to improve antimicrobial prescribing especially for ARIs, principally in education, and their impact.

Table 3. Initiatives to improve antibiotic utilization among physicians in ambulatory care in LMICs especially for ARIs.

Author, Country, Year	Intervention and Impact	Impact
Teng et al., Malaysia, 2006 [277]	Education—Academic detailing from the resident family medicine specialist accompanied by an information leaflet	<ul style="list-style-type: none"> Reduction in general antibiotic prescribing rates from 14.3% pre-intervention to 11.0% post-intervention (RR 0.77, 95% CI 0.72 to 0.83) Reduction in URTI-specific antibiotic prescribing rates from 27.7% and 16.6% post-intervention (RR 0.60, 95% CI 0.54 to 0.66).
Shrestha et al., Nepal, 2006 [278]	Principally Education—7 health posts and 33 subhealth posts were stratified by type with health workers. The intervention was based on 5 days of training on the adapted Practical Approach to Lung Health (PAL) guidelines and their use	<ul style="list-style-type: none"> Appropriate prescribing of antibiotics and adherence to guidelines improved However, this was not statistically significant unlike other areas such as polypharmacy and generic prescribing rates
Awad et al., Sudan, 2006 [279]	<ul style="list-style-type: none"> Twenty health centers in Khartoum State were randomly assigned to receive either (a) no intervention; (b) audit and feedback; (c) audit and feedback + seminar; or (d) audit and feedback + academic detailing The targeted interventions involving audit and feedback combined with academic detailing 	<ul style="list-style-type: none"> Significant reduction in the mean number of physician encounters with an antibiotic prescribed by 6.3 and 7.7 ($p < 0.001$) at 1 and 3 months post-intervention respectively The mean number of encounters where antibiotics were inappropriately prescribed were also significantly reduced post-intervention ($p < 0.001$) However, reducing the number of interventions reduced their overall impact
Kafle et al., Nepal, 2009 [280]	<ul style="list-style-type: none"> Principally Education—Supervision/monitoring involving periodic visits by district supervisors to 41 primary healthcare (PHC) facilities The intervention included small-group training among prescribers followed by peer-group discussions alongside self-assessment of the data presented 	<ul style="list-style-type: none"> In children under five, there was a significant improvement in use of antimicrobials in diarrhea There was also a significant improvement in the prescribing of antibiotics for URTIs without pneumonia
Yip et al., China, 2014 [281]	Principally Economics: In Ningxia Province, a randomized study was undertaken to evaluate the effects of capitation with pay-for-performance on antibiotic prescribing practices, health spending, outpatient visit volumes, and patient satisfaction	<ul style="list-style-type: none"> Approximately 15% reduction in antibiotic prescriptions Small reduction in total spending per visit
Boonyasiri et al., Thailand, 2014 [282]	Principally Education including: <ul style="list-style-type: none"> Training HCPs on the rational use of antibiotics Introduction of clinical practice guidelines Potential for throat swabs (stool cultures for acute diarrhea) Printed brochures for patients/relatives in waiting rooms containing likely etiology as well necessity and harm of antibiotics for URIs and acute diarrhea 	The multifaceted program resulted in: <ul style="list-style-type: none"> Limited prescribing of antibiotics for URIs (13.0%) and for acute diarrhea (19.1%) Clinical responses on day 3 after receiving care revealed more than 97% of the patients who received antibiotics/those who did not receive antibiotics were cured or improved

Table 3. Cont.

Author, Country, Year	Intervention and Impact	Impact
Wei et al., China, 2019 [273]	<ul style="list-style-type: none"> • Principally Education • The multiple interventions comprised: clinical guidelines, monthly prescribing review meetings, doctor–patient communication skills training, and education materials for caregivers 	<p>This multifaceted approach appreciably reduced prescribing rates for antibiotics (ABR) in children with URIs:</p> <ul style="list-style-type: none"> • A 49% reduction in ABR after 6 months in the intervention arm having adjusted for patient and prescribing doctor covariates • The reductions persisted after 18 months but at a lower rate (−36%) • Factors sustaining the reduction included physicians' improved knowledge and communication skills combined with focused prescription review meetings
Tay et al., Malaysia, 2019 [283]	<p>Principally Education—Educational toolkits included a training module for HCPs on URI and acute diarrhoea involving:</p> <ul style="list-style-type: none"> • One-hour educational sessions covering diagnostic criteria and treatment decision pathways • Educational posters in Malay and English in the waiting area and consultation rooms as well as multimedia educational videos in the waiting areas • Physician reminders 	<p>Appreciable reduction in antibiotic prescribing:</p> <ul style="list-style-type: none"> • URIs down from 29.1% to 13.7% • Acute diarrhea down from 11.2% to 6.7%

Among LMICs, there is an absolute imperative to develop actionable quality and patient safety indicators that better represent current prescribing compared with the traditional WHO/INRUD criteria [284]. This reflects the rise in the number of patients in LMICs, especially sub-Saharan Africa, with both infectious and non-infectious communicable diseases (NCDs) as well as combinations of infectious diseases such as HIV and TB and combinations of infectious diseases and NCDs [285–289]. Consequently, there is a need to develop more specific quality and patient safety indicators for LMICs to improve future antimicrobial prescribing. This can be achieved using agreed and common coding of data to enable coordinated and transferable learning between countries including patients attending ambulatory care clinics in sub-Saharan Africa. This will be the subject of future research activities among the group.

These activities build on recent studies, including those undertaken in sub-Saharan Africa, suggesting that adherence to guidelines is a better indicator of the quality of prescribing in ambulatory care in LMICs compared with the current WHO/INRUD criteria [167,169,181,290]. Having said that, it is important that there is only one national reference guideline since contradictions can arise when there are multiple guidelines within a country [291]. It is also essential that any guidelines produced must be readily available in multiple media formats including online and downloadable, as well as in print. National guidelines also need to be combined with educational inputs and auditing of prescribing practices to further improve future prescribing [114,172,181,290,292,293].

Regular updates of any guidelines, especially online, are also essential to improve adherence rates, and any updates need to be rapidly disseminated. This is being achieved among a number of sub-Saharan African countries through mobile technologies [101,293], providing guidance to other LMICs.

We are aware though that over prescribing of antibiotics can be appreciably more common in telemedicine consultations than in face-to-face visits [294,295]. Consequently, these consultations also need to be part of any future quality initiatives.

3.2.2. Initiatives to Reduce Inappropriate Dispensing of Antimicrobials among Pharmacists in the Community

There are concerns with the extent of inappropriate dispensing of antimicrobials in community pharmacies and drugs stores across LMICs, especially with, as mentioned, such utilization accounting for up to 93% to 100% of all dispensed antibiotics [123,124,129,135,136].

These concerns can be exacerbated by variable knowledge regarding antibiotics and AMR among community pharmacists [162,296–298]. Having said this, there are key issues in rural settings in LMICs that need to be considered by Governments and others when reviewing strategies to reduce inappropriate dispensing of antimicrobials. These include the fact that pharmacists maybe the only healthcare professional available and they are trusted [49,135,156,299]. There can also be major issues with affordability among patients in LMICs. Meeting both physician fees and the cost of medicines can have catastrophic consequences for individuals and families in LMICs [151,152,300]. Trained pharmacists, assisted by guidelines, can reduce inappropriate self-purchasing of antibiotics in LMICs as well as be leaders of ambulatory care ASPs in their countries to improve future antibiotic utilization especially for infections that are essentially viral [99,157,301].

Strategies to successfully reduce inappropriate self-purchasing of antimicrobials range from having well-educated pharmacists offering advice (Education) to patients as seen in Kenya, regulations by law restricting the purchasing of antimicrobials without a prescription coupled with fines (Economics and Enforcement), or a combination of these as seen in the Republic of Srpska (Education, Economics and Enforcement) [99,100,157,183].

The extent of ‘enforcement’ including the potential for fines or closure of pharmacies is vital as this impacts on the outcome of this intervention (Table 4). For instance, in Venezuela, the Government implemented policies to limit self-purchasing of antibiotics of three antibiotic groups. However, there were no public awareness campaigns and ‘Enforcement’ was only via government publications with no follow up. As a result, there was no decrease in antibiotic utilization levels but, in fact, the opposite with an increase [302]. Similarly, in Colombia, whilst initial enforcement of the law in 2005 had a modest impact on overall sales in the first three years (−1.00 DDDs/1000 inhabitants per day), a follow-up study five years after implementation found that 80.3% of pharmacies were still not complying with the law due to lax monitoring, prompting calls for greater enforcement [302,303]. This contrasts with an appreciable reduction in antibiotics dispensed without a prescription in a number of countries following multiple interventions, e.g., Saudi Arabia (Table 4).

We see similar examples in other disease areas where the intensity of follow-up of prescribing restrictions (enforcement) appreciably impacts on their effectiveness and outcome in practice [304–306].

Table 4. Examples of initiatives to reduce self-purchasing of antibiotics in pharmacies predominantly in LMICs (adapted from [64,100,183]).

Country and Year	Activity
Brazil and Mexico, 2013—private pharmacies [307]	<p>Enforcement—assessing the impact of legislation to ban self-purchasing of antibiotics on dispensing patterns between 2007 and 2012 in private pharmacies in Brazil and Mexico (has always been the case among public pharmacies in Brazil [137,308]) Variable results seen</p> <ul style="list-style-type: none"> • Total antibiotic usage increased in Brazil (from 5.7 to 8.5 DDD/TID) but decreased in Mexico (10.5 to 7.5 DDD/TID) • A change in the level of dispensing of −1.35 DDD/TID ($p < 0.01$) for Brazil and −1.17 DDD/TID ($p < 0.00$) for Mexico • In Brazil, there was a decrease in the level of consumption of the penicillins, sulfonamides and macrolides by 0.64 DDD/TID ($p = 0.02$), 0.41 DDD/TID ($p = 0.02$) and 0.47 DDD/TID ($p = 0.01$) respectively <p>The authors concluded that whilst the effect of the restrictions was similar across the countries; in Brazil, the trend of increased dispensing of antibiotics without a prescription was tempered after the restrictions were introduced whilst in Mexico the trend of decreasing dispensing accelerated</p>

Table 4. Cont.

Country and Year	Activity
Brazil—Both private and public pharmacies—2015 to 2017	<p>Enforcement:</p> <ul style="list-style-type: none"> • Moura et al. (2015) [308] showed a decrease in antibiotic use of 1.87 DDD/TID ($p < 0.001$) immediately after restrictions banning the sales of antibiotics without a prescription among private pharmacies (2008 to 2012), with a greater decrease in the more developed regions as well as in the State Capitals • Not surprisingly, Moura et al. (2015) [308] found no difference in sales among public pharmacies where there had always been restrictions and it is generally impossible to sell antibiotics without a prescription ($p = 0.643$) • Lopes-Junior et al. (2015) [309] found that sales of amoxicillin (commonly sold antibiotic) in private pharmacies fell by approximately 30% post-legislation despite a general growth in the pharmaceutical market, with falls in sales of other popular antibiotics including tetracyclines (30.5% decrease), sulfonamides (28.5% decrease), and macrolides (25% decrease) • Mattos et al. (2017) [310] documented an increase in antibiotic sales among private pharmacies from 2008 to 2011 including the cephalosporins, quinolones, and aminopenicillins. Following changes in the law with restrictions in private pharmacies, there was a decrease in dispensing in 2012 for the cephalosporins (−19.4%), quinolones (−12.7%) and aminopenicillins (−11.1%) <p>The differences in the findings in Brazil between the different studies may well reflect differences in datasets and methodologies</p>
Thailand, 2015 [311]	<ul style="list-style-type: none"> • Principally Education involving a multidisciplinary intervention among grocery stores in a rural province in Thailand using trained community leaders • Grocery stores in the intervention group had 87% fewer antibiotics available postintervention compared with preintervention • Grocery stores in the control group saw only an 8% reduction in antibiotic availability between the 2 time periods
Republic of Srpska, 2017 [157,312]	<ul style="list-style-type: none"> • Education and Enforcement including guidelines for pharmacists and greater enforcement of the regulations resulted in self-purchasing of antibiotics for self-diagnosed URTIs significantly decreasing from 58% of requests to 18.5% • Encouragingly, the most common reason for not dispensing an antibiotic was that antibiotics cannot be dispensed without a prescription
Kenya—2018 [99] and 2021 [313]	<ul style="list-style-type: none"> • Monitoring of antibiotics dispensed among pharmacies linked to the University of Nairobi showed a low level of dispensing of antibiotics without a prescription, with 94.1% of antibiotics dispensed with a valid prescription (Education) • No antibiotics were dispensed for patients with ARIs including influenza or a common cold, with over-the-counter (OTC) medicines such as cough and cold syrups and lozenges typically dispensed • A more recent study conducted during the COVID-19 pandemic showed no dispensing of either antimalarials or antibiotics without a prescription
Saudi Arabia, 2020 [183]	<ul style="list-style-type: none"> • Principally Economics and Enforcement • In May 2018, the law and regulations surrounding self-purchasing without a prescription were enforced alongside fines • Before enforcement, 70.7% of pharmacies reported self-purchasing was common, with 96.6% and 87.7% of participating pharmacies dispensed antibiotics without a prescription for pharyngitis and urinary tract infections (UTIs) respectively • Following law enforcement and fines, only 12.9% reported self-purchasing still common, with only 12.1% and 5.2% dispensing antibiotics without prescriptions for pharyngitis and UTIs respectively • When antibiotics were dispensed without a prescription, typically this only happened following considerable pressure from patients
India, Malaysia and Vietnam, 2021 [153,299]	<ul style="list-style-type: none"> • There have been ongoing educational and other initiatives in recent years in India, Malaysia and Vietnam to try and reduce unnecessary self-purchasing of antimicrobials • These initiatives seem to be working with no change or a decrease in the dispensing of antimicrobials among 83.3% to 100% of pharmacies surveyed in Malaysia and Vietnam in the initial months following the start of the COVID-19 pandemic despite the hype and concerns generally with increasing use of antibiotics • In India—no change in up to 57.7% of pharmacists surveyed

However, it can be difficult in practice in a number of LMICs to enforce regulations banning self-purchasing of antibiotics due to manpower issues as well as shortages of antimicrobials within public healthcare facilities. Such activities may also be counter-productive in rural areas in LMICs and we have seen that trained pharmacists can help reduce inappropriate dispensing of antibiotics.

Monitoring pharmacy dispensing activities through mobile technologies as well as potentially implementing information technology (IT) surveillance systems to track antibiotics through the supply chain are also potential strategies to reduce inappropriate dispensing [99,135].

Adoption of such tactics may mean re-looking at pharmacists' knowledge regarding AMR and its causes, with the potential for increased training if needed starting in pharmacy school and continuing post-qualification [159,162,314,315]. In addition, potentially ensuring through regulation and other mechanisms that any antibiotic dispensed for ARIs and other common conditions are principally from the Access group of antibiotics and not from the WHO 'Watch' or 'Reserve' list [173,174].

3.2.3. Initiatives to Reduce Inappropriate Dispensing of Antimicrobials among Patients and the Public

The impact of programs to reduce inappropriate prescribing and dispensing of antimicrobials for essentially viral infections such as ARIs can be enhanced by concurrently targeting patients and the public. This is because multiple studies have shown that some people can put considerable pressure on healthcare professionals to prescribe and dispense antibiotics for ARIs [314,316–318]. Knowledge about antibiotics and AMR can vary though among patients and the public, and they can have strong beliefs about the effectiveness of antibiotics for them even for viral infections, which adds to the pressure to prescribe or dispense antimicrobials for ARIs [318–324].

Similar to the situation with physicians and pharmacists, multifaceted approaches are needed to change attitudes and behaviors among patients and caregivers [325,326]. However, such programs have had variable degrees of success for countries including both high-income countries and LMICs [318,327–329]. Published studies, particularly among high-income countries, suggest that a number of factors can enhance the success of any antibiotic awareness campaign. These include (i) the use of carefully designed simple key messages; (ii) targeting a wide audience including patients and their families; (iii) designing key messages for all key stakeholder groups for completeness; (iv) using mass media including social media to raise awareness; and (v) repeating key messages especially for new parents and others [318,328,330–332].

Two systematic reviews have suggested that campaigns among patients can significantly reduce antibiotic utilization. McDonagh et al. (2018) found that parent education reduced antibiotic prescribing for ARIs by 21% [116]. Cross et al. (2017), mainly including studies from high-income countries, also found that the majority of studies reported reductions in antibiotic utilization. The reduction was greater than 14% in the prescribing of antibiotics for RTIs, up to a maximum reduction of 30% [318].

However, the impact of patient education initiatives in LMICs have not yet been fully elucidated, nor their costs and cost-effectiveness [115]. Consequently, caution is still needed before fully embarking on such campaigns in LMICs unless these are part of research programs.

3.2.4. Initiatives to Address MDR Organisms for HIV, Malaria and TB

There are concerns that patients with TB living in rural areas, and without regular supply of medicines, will have poorer treatment outcomes [80,333]. Potential reasons for this include insufficient funds for transport to treatment centers despite the medicines often being provided free of charge alongwith missing out on regular reviews of medicine use addressing concerns including compliance with prescribed medicines, similar to the situation with NCDs [80,158,334]. Poorer outcomes and lack of adherence to treatments will enhance resistance rates [80,335].

The overall burden of TB has been declining at an annual average of 2%; however, the number of patients with drug-resistant TB (DR-TB) is increasing. Aminoglycosides, such as kanamycin, and some polypeptides, such as capreomycin, are used to treat DR-TB. However, whilst aminoglycosides are inhibitors of prokaryotic protein synthesis at commonly accepted therapeutic concentrations, they can affect the protein synthesis of cells at larger concentrations, leading to toxicity such as ototoxicity, vestibulotoxicity, and nephrotoxicity [336]. Hearing loss though can now be monitored using an ototoxicity grading system within a mobile app to assist health professionals in assessing patients for ototoxicity. Subsequently, monitoring progression of hearing loss to improve planning for any changes in care [337]. Such developments are likely to continue to improve the future use of aminoglycosides.

There are also concerns with rising resistance rates to antimicrobials used to treat malaria since for instance when resistance of *P. falciparum* to sulfadoxine-pyrimethamine was greater than 10%, the risk ratio for malaria infections was 5.9 times higher compared to a period of time with low resistance rates, and the risk of death from malaria 10.8 times higher [6,338].

Developing resistance to treatments for HIV also increases mortality with studies from sub-Saharan Africa indicating that when pre-treatment drug-resistance levels are evident but below 10%, AMR will be responsible for an estimated 710,000 AIDS deaths and 380,000 new infections by 2030. This increases to an estimated 890,000 AIDS deaths and 450,000 new infections by 2030 attributable to HIV when resistance rates are above 10% [6,339].

Strategies to address concerns with resistance to treatments for HIV, malaria and TB include initiatives to ensure regular access to treatment facilities, including expanding these in rural areas given concerns with travel costs and time off work, as well as regular access to treatments ideally provided free of charge. Alongside this, regular monitoring of adherence rates knowing adherence can be a major issue in some patients [80,340–342]. Strategies to improve adherence rates include patient and staff education addressing pertinent issues of anxiety and depression with their condition, encouraging clinic visits, addressing socioeconomic factors where possible as well as increasing the use of digital technologies including mobile phones and video-observed therapy [341–348].

Concurrent with this, we are aware of groups in South Africa undertaking research on HIV reservoirs and using locally discovered potent, broadly neutralizing antibodies to neutralize HIV in the reservoir to render patients non-infectious as a cure strategy [349]. Recent promising data from primates indicate the potential value of this approach and clinical trials are being planned.

We are also aware of ongoing research that provides an expansive dataset of compounds that could be redirected for antimalarial development and also point towards proteins that can be targeted in multiple parasite life cycle stages to improve the management of patients with malaria resistant to current treatments [350]. We will be monitoring these developments and their implications.

3.2.5. Programs to Address Concerns with Vaccine Uptake Including Misinformation as Well as Other Situations Adversely Affecting Antimicrobial Use

Reduced vaccine uptake including vaccine hesitancy fueled by misinformation is a concern in view of the impact on AMR, morbidity and mortality (Table 5) [10,37].

Table 5. Positive impact of vaccine uptake and concerns with vaccine hesitancy.

Disease Area	Impact
Hib conjugate vaccine and pneumococcal polysaccharide vaccine	<ul style="list-style-type: none"> • The introduction of the Hib conjugate vaccine resulted in an appreciable reduction in cases as well as a significant decrease in beta-lactamase-positive strains [10,351,352] • A similar situation was seen following the introduction of the pneumococcal polysaccharide vaccine across countries [10,32,353–355]
<i>S. pneumoniae</i> and rotavirus	<ul style="list-style-type: none"> • A pooled analysis illustrated the benefits of vaccination against <i>S. pneumoniae</i> and rotavirus in reducing antibiotic consumption, providing 19.7% and 11.4% protection against the use of antibiotics to treat acute respiratory infection and diarrhea respectively [356] • Overall, it was estimated that these vaccines prevented 23.8 million antibiotic-treated ARI episodes annually among children aged 24–59 months, while the rotavirus vaccines prevented an estimated 13.6 million episodes of antibiotic-treated diarrhea amongst children 0–23 months [356].
COVID-19	<ul style="list-style-type: none"> • Abbas et al. (2020) calculated that for every one excess death in Africa due to COVID-19, carrying on with routine vaccination could have prevented 84 deaths in children due to diphtheria, pertussis, hepatitis B, <i>Haemophilus influenzae</i> type b, measles, meningitis, <i>Streptococcus pneumoniae</i>, rotavirus, tetanus, rubella, and yellow fever [37] • The unintended consequences of lockdown and other activities including reduced vaccine uptake must be factored into future decision making regarding potential strategies to address pandemics • This includes a greater role for community pharmacists with vaccination programs during pandemics [36,357]

This increasing recognition of the role of vaccines in reducing antimicrobial use and AMR is reflected in the recent WHO Action Framework to enhance current vaccination rates, encourage greater knowledge and dissemination on the role of vaccines to reduce AMR as well as encourage the development of new vaccines to further reduce AMR [358,359].

Addressing mis- and dis-information surrounding vaccines is critical to reduce future morbidity and mortality arising from pandemics [360,361]. We are already seeing social media companies such as Facebook and Twitter tightening up on accounts that repeatedly publish misinformation about COVID-19, building on activities among some African countries to fine companies for spreading misinformation [36,362], and such activities are likely to continue. This builds on activities by the WHO to join forces with Governments to address the level of misinformation surrounding COVID-19 as an example [363] as well as Governments funding projects to specifically address misinformation surrounding vaccines for COVID-19 to enhance their uptake [364,365]. Inclusivity is essential to engage with community groups and patient organizations [366], and ensure that clear public health messaging is delivered that is sensitive to age, culture, socioeconomic context and education, and to build population resilience against AMR behaviors [367].

Potential ways forward, building on the activities of the WHO and Governments, especially with proposed medicines for COVID-19 including hydroxychloroquine, lopinavir/ritonavir and remdesivir that failed to live up to their preceived promise [368–373], include instigating a culture of evidence-based medicine among all key stakeholder groups starting in universities and continuing post-qualification [36,166,374]. Such activities would have helped reduce shortages and price rises of hydroxychloroquine and antibiotics arising from the initial studies as well as help reduce inappropriate prescribing of antibiotics [41,49,153,166].

Governments and others working with pertinent patient organizations within countries also need to proactively address misinformation [366], especially if, as mentioned, this increases future morbidity, mortality and costs, as seen with misinformation regarding hydroxychloroquine and unwarranted fears about vaccines. Transparent communication and

appropriate public health messaging, in collaboration with patient groups and community leaders, are key for increasing the trust of the community and improving vaccination rates where concerns.

3.3. Suggested Activities among All Key Stakeholder Groups to Improve Future Antibiotic Utilization

Suggested strategies to improve the utilization of antimicrobials among LMICs and thereby reduce AMR have been divided into short- and long-term initiatives to provide future guidance (Table 6). These build on the potential for expanding the use of electronic health records and electronic prescribing as well as digital technologies, including clinical decision support systems (CDSS), to improve appropriate use of antibiotics across countries and sectors in LMICs [101,238,375,376]. Such developments should be welcomed given the increasing complexity of medical decision making and, as mentioned, the high percentage of patients especially in sub-Saharan Africa with co-morbidities including HIV, malaria and TB, as well as co-morbidities with both infectious and non-infectious diseases.

Effectively addressing inappropriate antibiotic prescribing is particularly challenging since the majority of antibiotic prescribing in LMICs is undertaken by general clinicians and their assistants who are not experts in infection management and with often influence from pharmaceutical companies in the absence of continual professional development [155,172,377–379]. This is compounded across Africa due to high workloads as well as limited consultation times and available resources, driven mainly by a shortage of healthcare professionals and the high prevalence of infectious diseases [380]. Recent evidence is promising though about the feasibility and effectiveness of digital tools to improve future antibiotic prescribing and dispensing [101,204,205,381].

Table 6. Suggested strategies for LMICs to improve appropriate utilization of antimicrobials across sectors.

Time Scale	Potential Strategies
	<i>Health authority/Government—the following (if not already done so):</i>
Short term	<ul style="list-style-type: none"> • Governments and health authorities must be committed to reducing inappropriate use of antibiotics across sectors, building on current NAPs and other activities. This will necessarily involve resources (financial, technical and personnel) being made available for implementation and monitoring activities surrounding NAPs. This includes regulations to enhance ASP activities in hospitals and the community incorporating PPS surveys and other activities. In addition, recognizing that any ASPs may need to be culture and country specific, and sustainable in the long term, as well as multidisciplinary given concerns with their introduction in some LMICs [213,382] • Ensure functional supply chains to meet the needs of prescribers including proactively addressing issues of shortage and building on activities across countries [262,383,384] • Ascertain through PPS and other studies current rates of prescribing and dispensing of antimicrobials across sectors including ARIs in the community. This can include instigating PPS studies in hospitals to identify key areas for quality improvement. Similarly (if needed) assess current vaccination rates for critical vaccines • In ambulatory care—ascertain current knowledge among key stakeholder groups including physicians, pharmacists, nurses and patients regarding AMR and the appropriateness of antibiotics especially for ARIs/COVID-19—using both quantitative and qualitative approaches. Subsequently instigate pertinent educational activities starting in universities as well as through patient organizations. This includes current training regarding antibiotics, AMR and ASPs in universities • Assess the potential for introducing point-of-care testing and other clinical support systems especially following the current pandemic, including issues of affordability, as well as developing/supporting the implementation of a national integrated AMR surveillance system building on current activities monitoring rates of COVID-19 infections [49,153,299,385] • Develop/update/disseminate robust guidelines surrounding the management of key infectious diseases across sectors, recognizing that active communication and dissemination of guidelines, as well as trust in the guidelines from all key stakeholder groups and ease of use, are key to enhancing adherence rates [170,386–389]. Consequently, these must be evidence based and with awareness of the WHO AWaRE list [173,390]. Subsequently, monitor prescribing against current guidelines and NAPs, enhanced by auditing, academic detailing and implementing electronic prescribing systems [386,389]

Table 6. Cont.

Time Scale	Potential Strategies
	<ul style="list-style-type: none"> • This includes developing/refining pertinent quality indicators for use across sectors building on those already used in hospitals (Box 1) and developing new ones for ambulatory care in LMICs. In addition, evaluating potential approaches to improve adherence to any developed quality indicators including benchmarking, helped again by electronic prescribing systems [386,389], being part of CPD programs and possibly including financial incentives (small in relation to physician income) • Work with key stakeholder groups including patient organizations to enhance adherence to treatments for conditions including HIV, malaria and TB given concerns with adherence to prescribed treatments and the subsequent impact on resistance rates. This could involve re-looking at issues such as increasing the number of clinics in rural areas as well as helping with transportation costs • Work with patient organizations and others to also reduce misinformation regarding pandemics and their treatment as well as generally regarding vaccines given current concerns. As part of this, instigate country-wide vaccination programs including those for COVID-19, pneumococcal and influenza vaccines, with vaccines provided free of charge and available across sectors, which may require donor help initially • Work with national/international pharmacy organizations to develop a range of additional activities that could be introduced where pertinent to reduce inappropriate self-purchasing of antimicrobials (building on Table 4). This could include introducing remuneration schemes for pharmacists if reducing dispensing of antibiotics appreciably impacts on their profit levels as well as IT and other systems to monitor the supply chain <p><i>Physicians and nurse practitioners</i></p> <ul style="list-style-type: none"> • Ascertain current knowledge and beliefs about antibiotics, ASPs and AMR across sectors especially where there are concerns with the current situation and gaps in knowledge • Work with key Governments and other organizations to develop (where pertinent) and make sure current national guidelines are evidence based and regularly updated as well as readily accessible through decision support systems and other mechanisms, as well as easy to use (as this is not always the case—[292]). In addition, encourage physicians through auditing and other practices to regularly consult national guidelines about optimal treatment approaches for their patients where there are concerns as this is also not always the case [181] • Help with developing and instigating additional educational activities where pertinent [391]. This can include skills for communication with patients to help address current concerns • Encourage physicians and nurse practitioners to become actively involved in ASPs as part of NAPs and wider programs • Ascertain attitudes to the instigation of proven and cost-effective point-of-care testing and vaccination programs and subsequently address concerns to improve their roll out and uptake across countries • Work with other healthcare professionals and patient organizations to address concerns with adherence to medicines for infectious diseases such as HIV and TB including instigating appropriate interventions and monitoring their impact <p><i>Pharmacists (hospital)</i></p> <ul style="list-style-type: none"> • Become actively involved with progressing ASPs in the hospital, building on activities in countries such as South Africa [217] • This can include addressing concerns with a lack of understanding regarding ASPs/AMR within hospitals [214,215] and providing educational support regarding appropriate antimicrobials to prescribe—especially if the main educational input in hospitals is via pharmaceutical companies [378,379] • Become involved with undertaking PPS studies in hospitals including potential targets for key areas such as antimicrobial use to prevent SSIs (Tables 1 and 2). The development of an App and other approaches may help here [204]. As part of this, regularly feedback concerns with antimicrobial usage patterns in hospitals to key stakeholder groups and work with them on potential ways forward • Help with programs to enhance adherence to treatments for HIV, malaria and TB and subsequently monitor their impact • Actively work with others in the hospital to proactively address possible shortages including agreeing in advance potential therapeutic interchange recommendations [264] <p><i>Pharmacists (Community)</i></p> <ul style="list-style-type: none"> • Universities and others to work with community pharmacists to ascertain current knowledge and beliefs about antibiotics and AMR, especially for patients with ARIs, as well as the need to develop specific guidelines for ARIs and other self-limiting conditions (Table 3)

Table 6. Cont.

Time Scale	Potential Strategies
	<ul style="list-style-type: none"> • Work with patients to address misinformation regarding antibiotics, AMR and the current pandemic, as well as enhance the role of pharmacists to administer vaccines/provide point-of-care testing, especially if they are a trusted source. As such, build on their role in the pandemic as a source of information generally regarding social distancing activities and possible symptomatic relief [36,49,153] • Instigate additional educational activities among pharmacy students regarding antibiotics and AMR, as well as instigate/enhance CPD activities among community pharmacies with the help of relevant pharmaceutical societies and the Government to address concerns with lack of knowledge • Encourage pharmacists, rather than technicians, through CPD and other measures to be the principal personnel within community pharmacies reviewing antimicrobial prescriptions and evaluating patients regarding their need for antimicrobials, especially for ARIs/COVID-19 • Pharmacists to work with health authorities to computerize and track medicine use, i.e., via computerized IT systems, as well as work with health authorities and others to help transition away from focusing on business interests, especially in urban areas, to professional healthcare provision—again building on their role in the pandemic • Advocate the introduction and benchmarking of national standards and guidelines for Good Pharmacy Practice (GPP) in community pharmacy settings as part of CPD, where this does not exist • Help with programs to enhance adherence to treatments for HIV, malaria and TB, and subsequently monitor their impact
	<p data-bbox="331 904 576 934"><i>Patients and the public</i></p> <ul style="list-style-type: none"> • Patient organizations helping with health education and public health messaging programs in schools/and more widely regarding the appropriate use of antibiotics and AMR, as well as key issues surrounding COVID-19 including vaccines (as well as other vaccines to reduce AMR). This includes helping to address mis- and dis-information especially where this can impact on future morbidity, mortality and personal finances • Improve education and the extent of culturally sensitive information regarding antibiotics, AMR, and COVID-19 including vaccines through advocacy programs, patient information leaflets, social media, public health messaging and other community-based activities. As part of this, work with Governments and health authorities to ascertain the cost-effectiveness of campaigns directed at reducing inappropriate utilization of antibiotics for self-limiting conditions such as viral ARIs, as well as campaigns that can help reduce the level of misinformation especially surrounding prevention and treatments during pandemics • Ascertain the rationale for any self-purchasing of antimicrobials, and use the findings to develop potential future strategies to reduce inappropriate requests for antibiotics including dispensing without a prescription. Public health messaging needs to be clear and via optimal channels depending on the country and circumstance • Use educational initiatives to encourage parents/caregivers of young children to seek professional help for their ARIs/suspected COVID-19 including community pharmacists • Work with key Government and other groups to enhance adherence to treatments for HIV, malaria and TB where challenges remain
Longer-term potential strategies	<p data-bbox="331 1509 1485 1599">The findings from the situational analyses and ongoing educational activities can be used together with other research findings within each LMIC to develop pertinent long-term strategies for all key stakeholder groups. These include:</p> <ul style="list-style-type: none"> • Health authorities/Governments <ul style="list-style-type: none"> ○ Regularly monitoring antimicrobial utilization across sectors as part of any agreed NAP. This includes instigating electronic prescribing and tracking systems and addressing issues with telemedicine/vaccination programs where and when concerns are raised ○ Instigation of additional multiple strategies, where pertinent, to improve antibiotic utilization across sectors, including the provision of necessary resources required for implementing ASPs/IPC committees in hospitals, testing, clinical decision support systems, and regular updating of guidelines. This also includes developing quality indicators especially in ambulatory care given concerns with current WHO/International Network for Rational Use of Drugs (INRUD) criteria [167] ○ Regularly reviewing strategies to reduce inappropriate dispensing of antimicrobials in community pharmacies ○ Instigate additional programs and support to enhance adherence to treatments for HIV, malaria and TB and monitor their impact

Table 6. Cont.

Time Scale	Potential Strategies
	<ul style="list-style-type: none"> ○ Regularly review vaccination programs and update if necessary—this may mean the need for additional donor help ○ Increasing investment in research for new and existing antimicrobials, diagnostic tools, and vaccines ● Physicians and nurse practitioners <ul style="list-style-type: none"> ○ Regular reviews of current educational activities in medical/nursing schools regarding students' knowledge of antibiotics, AMR, ASPs, COVID-19 and adapt/update where necessary ○ Regular monitoring of prescribing activities across sectors especially with regard to quality improvement programs in hospitals and ambulatory care. This can include increased accountability of prescribers with a requirement to justify their treatment approach alongside building on restrictions for certain antibiotics, building on the WHO Access, Watch, Reserve (AwaRe) antibiotic groupings [61,81,392,393] as well as on agreed quality indicators ○ Keep working with key stakeholders to enhance adherence to treatments such as those for HIV and TB ● Hospital Pharmacists <ul style="list-style-type: none"> ○ Work with key groups in hospitals to improve antimicrobial utilization through continued involvement in ASPs, IPCs and PPS studies—and monitoring of utilization patterns against agreed quality indicators ○ Concurrent with this, regularly review therapeutic interchange policies for possible antimicrobial shortages ○ Input into regular reviews of country NAPs and potential next steps ○ Work with pharmacy schools regarding possible additional educational activities to improve future utilization ● Community pharmacists <ul style="list-style-type: none"> ○ Regular reviews of current educational activities in pharmacy schools regarding student knowledge of antibiotics, AMR, ASPs, vaccines and COVID-19, and update where necessary ○ Act to ensure educational activities fully equip pharmacists for their extended roles as custodians of antimicrobials in ambulatory care. This can include instigating prescribing licenses for pharmacists to dispense agreed antimicrobials under guidance [123,124,394] ○ Help with additional activities including updating guidelines where relevant, especially when pandemics occur, as well as review initiatives including additional education and incentives to enhance appropriate dispensing of antimicrobials in the community ○ Development of pharmacist-led vaccination programs within the community, building on current concerns/issues with the COVID-19 pandemic ○ Work with key groups to strengthen the enforcement of pharmacy regulations and laws to curb irrational dispensing of antibiotics. Medicine tracking systems and mobile technologies can be effectively utilized to reduce inappropriate dispensing especially in rural areas where enforcement is problematic and maybe counter-productive ● Patients and the public <ul style="list-style-type: none"> ○ Regularly review the influence of any educational activities for their effectiveness, cost and value in all media and at all sites—especially important to reduce AMR and any misinformation surrounding COVID-19 ○ Continue to refine and update educational activities, including the work of patient organizations, and with all key stakeholder groups including Governments and healthcare professionals

4. Discussion

AMR continues to be a high priority across countries in view of its impact on morbidity, mortality and costs [11,15,19], driven by the overuse of antimicrobials across all sectors including in animals and for the treatment of infectious diseases in patients. The overuse of antimicrobials in humans has been exacerbated by the recent COVID-19 pandemic, where, as mentioned, typically less than 10% of COVID-19 patients have bacterial or fungal infections [53], with as low as 3.2% of COVID-19 infections warranting antibiotics [21,54]. There are similar concerns with current low vaccination rates in a number of countries

including current vaccine hesitancy surrounding the COVID-19 vaccine along with misinformation surrounding treatments for COVID-19, all of which negatively impact on costs and outcomes [36,43,49,153,161,166,360].

Despite issues of resources including personnel, a number of activities can be undertaken in LMICs to improve future prescribing of antibiotics. These center around the instigation of ASPs in hospitals including PPS studies to identify areas for quality improvement, with a number of quality indicators now developed to monitor the appropriateness of future prescribing (Box 1). Strategies to improve future antibiotic prescribing in hospitals include those to reduce inappropriate timing and duration of antibiotic prescribing to prevent SSIs. Tables 1 and 2 document a number of examples of initiatives that have been successfully instigated in hospitals in LMICs to improve future antibiotic prescribing, thereby providing exemplars to others.

Successful strategies have also been implemented among physicians in LMIC to reduce inappropriate prescribing of antibiotics for essentially viral infections (Table 3), with patients playing a key role. Patients and pharmacists are also important to reduce inappropriate dispensing of antibiotics without a prescription (Table 4). However, recognizing that in rural LMICs, especially where there are high patient co-payment levels, community pharmacists maybe the only healthcare professional accessible and available. Community pharmacists are often more accessible than ambulatory care physicians in LMICs, and there is no need for physician co-pays, which combined with the cost of treatments can be catastrophic for some families [151,152,300].

Healthcare professionals, including community pharmacists, along with patient organizations have a key role to play to encourage evidence-based approaches to healthcare, thereby reducing the impact of misinformation. Misinformation has been a real concern during the current COVID-19 pandemic resulting in for instance reduced uptake of the vaccines and the implications for this and other vaccines (Table 5), with a number of strategies identified to address this (Section 3.2.5).

A number of strategies and initiatives have also been identified to reduce levels of multi-drug resistance organisms to HIV, malaria, and TB, given the resultant impact on morbidity and mortality. Key areas include the provision of treatments free of charge, ready access to healthcare facilities as well as initiatives to enhance adherence to prescribed treatments.

Potential strategies for all key stakeholders were subsequently consolidated into short-, medium- and long-term activities to provide future direction (Table 6). The key is Government commitment through NAPs and other activities to drive forward future initiatives. We will be monitoring the situation given continued concerns with AMR and its resultant impact on mortality as well as GDP.

We are aware of a number of limitations with this review paper. These include the fact that we did not undertake a systematic review for the reasons discussed. We also did not break the number of examples down by country or care setting as our objective was to provide pertinent examples to guide others. In addition, we are aware that some developing countries are more pro-active with their research than others, potentially biasing the findings. Despite these limitations, we believe that our findings and suggestions are robust, providing future direction.

5. Conclusions

In conclusion, reducing AMR should be a high priority across countries given its clinical and economic impact. Reducing AMR rates requires multiple coordinated activities across sectors driven by Governments and others. This is essential given limited new antimicrobials being developed, although compensated to some extent by developments in vaccine technologies. This will also require strategies to address high rates of vaccine hesitance that exist in a number of countries as seen in the recent COVID-19 pandemic. A coordinated approach including all key stakeholder groups is also essential to minimize misinformation and maximize the impact of future interventions to reduce AMR rates.

Author Contributions: Conceptualization, B.G., M.H., J.S. and R.A.S.; methodology, B.G., M.H. and A.K.; data curation, B.G., A.E., M.H., O.O.M., N.S., S.K., Z.S., J.S., I.H., S.I., J.W., R.C.R.M.d.N., I.P.D.G., L.L.N., A.A.A., J.A., R.I., I.A.S., S.O., A.K., I.C., F.K., D.K., O.O.O., A.O., V.M.-P., J.C.M., T.N.T.P., A.C.K., S.C. and J.W.; writing—original, B.G.; writing—review and editing, all authors. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: No ethical approval was needed for this review paper as this study did not involve humans or animals.

Informed Consent Statement: Not applicable for this review paper.

Data Availability Statement: All sources of information have been referenced.

Conflicts of Interest: The authors declare they have no conflict of interest although some do work for health authorities or are advisers to them.

Abbreviations

ABR	prescribing rates for antibiotics
AMR	Antimicrobial resistance
ARIs	acute respiratory infections
ASPs	antimicrobial stewardship programs
AST	Antimicrobial stewardship team
CDC	Centers for Disease Control and Prevention, US
CDDEP	Center for Disease Dynamics, Economics and Policy
CPD	Continuous professional development
CST	culture and sensitivity testing
DTCs	Drug and Therapeutic Committees
ECDC	European Centre for Disease Prevention and Control
4Es	Education, Engineering, Economics and Enforcement
GDP	Gross Domestic Product
GPP	Good Pharmacy Practice
HAIs	hospital-associated infections
HCPs	healthcare professionals
Hib	Haemophilus influenzae type b
HIV	human immunodeficiency virus
ICU	intensive care unit
IDCPs	infectious diseases clinical pharmacists
IDCs	infectious diseases consultations
INRUD	International Network for Rational Use of Drugs
IPCs	Infection, Prevention and Control committees
IV	intravenous
LMICs	low- and middle-income countries
MDR	multidrug resistant
MDR-TB	multidrug-resistant TB
NAP	National Action Plans
NCDs	non-infectious communicable diseases
OECD	Organization for Economic Co-operation and Development
OTC	over the counter
PHCs	primary healthcare centres
PPSs	point prevalence surveys
SA	South Africa
SAP	surgical antimicrobial prophylaxis
SSIs	surgical site infections
TB	tuberculosis
UK	United Kingdom

URIs	upper respiratory infections
URTIs	upper respiratory tract infections
US	United States of America
UTIs	urinary tract infections
WHO	World Health Organization
XDR-TB	extensive drug-resistant TB

References

- Cassini, A.; Högberg, L.D.; Plachouras, D.; Quattrocchi, A.; Hoxha, A.; Simonsen, G.S.; Colomb-Cotinat, M.; Kretzschmar, M.E.; Devleeschauwer, B.; Cecchini, M.; et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. *Lancet Infect. Dis.* **2019**, *19*, 56–66. [CrossRef]
- Hofer, U. The cost of antimicrobial resistance. *Nat. Rev. Genet.* **2019**, *17*, 3. [CrossRef]
- Majumder, M.A.; Rahman, S.; Cohall, D.; Bharatha, A.; Singh, K.; Haque, M.; Gittens-St Hilaire, M. Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health. *Infect. Drug Resist.* **2020**, *13*, 4713–4738. [CrossRef]
- Founou, R.C.; Founou, L.L.; Essack, S.Y. Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis. *PLoS ONE* **2017**, *12*, e0189621. [CrossRef]
- Ndir, A.; Diop, A.; Ka, R.; Faye, P.M.; Dia-Badiane, N.M.; Ndoye, B.; Astagneau, P. Infections caused by extended-spectrum beta-lactamases producing Enterobacteriaceae: Clinical and economic impact in patients hospitalized in 2 teaching hospitals in Dakar, Senegal. *Antimicrob. Resist. Infect. Control* **2016**, *5*, 13. [CrossRef] [PubMed]
- Jiang, T.; Chen, X.S. Outcome Impacts due to Pathogen-Specific Antimicrobial Resistance: A Narrative Review of Published Literature. *Int. J. Environ. Res. Public Health* **2020**, *17*, 1395. [CrossRef] [PubMed]
- Graham, W.J.; Morrison, E.; Dancer, S.; Afsana, K.; Aulakh, A.; Campbell, O.M.; Cross, S.; Ellis, R.; Enkubahiri, S.; Fekad, B.; et al. What are the threats from antimicrobial resistance for maternity units in low- and middle-income countries? *Glob. Health Action* **2016**, *9*, 33381. [CrossRef]
- KPMG. The Global Economic Impact of Anti-Microbial Resistance. Available online: <https://home.kpmg/content/dam/kpmg/pdf/2014/12/amr-report-final.pdf> (accessed on 10 May 2021).
- Yusuf, M.A. Antimicrobial Stewardship: Bangladesh Perspective. *Bangladesh J. Infect. Dis.* **2018**, *5*, 1–2. [CrossRef]
- Jansen, K.U.; Anderson, A.S. The role of vaccines in fighting antimicrobial resistance (AMR). *Hum. Vaccines Immunother.* **2018**, *14*, 2142–2149. [CrossRef]
- O'Neill. Tackling Drug-resistant Infections Globally: Final Report and Recommendations. Available online: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf (accessed on 8 May 2021).
- OECD Health Policy Studies, Stemming the Superbug Tide. Available online: <https://www.oecd-ilibrary.org/sites/9789264307599-en/index.html?itemId=/content/publication/9789264307599-en&mimeType=text/html> (accessed on 8 May 2021).
- Shrestha, P.; Cooper, B.S.; Coast, J.; Oppong, R.; Thuy, N.D.T.; Phodha, T.; Celhay, O.; Guerin, P.J.; Wertheim, H.; Lubell, Y. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. *Antimicrob. Resist. Infect. Control* **2018**, *7*, 98. [CrossRef] [PubMed]
- Haque, M.; Godman, B. Potential Strategies to Improve Antimicrobial Utilisation in Hospitals in Bangladesh Building on Experiences Across Developing Countries. *Bangladesh J. Med. Sci.* **2021**, *19*, 355–357. [CrossRef]
- IACG. No Time to Wait: Securing the Future from Drug-Resistant Infections. Report to the Sec-Retary-General of the United Nations. April. Available online: https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_report_EN.pdf (accessed on 10 May 2021).
- Urmi, U.L.; Nahar, S.; Rana, M.; Sultana, F.; Jahan, N.; Hossain, B.; Alam, M.S.; Mosaddek, A.S.; McKimm, J.; Rahman, N.A.; et al. Genotypic to Phenotypic Resistance Discrepancies Identified Involving β -Lactamase Genes, blaKPC, blaIMP, blaNDM-1, and blaVIM in Uropathogenic Klebsiella pneumoniae. *Infect. Drug Resist.* **2020**, *13*, 2863–2875. [CrossRef]
- Ara, B.; Urmi, U.L.; Haque, T.A.; Nahar, S.; Rumnaz, A.; Ali, T.; Alam, M.S.; Mosaddek, A.S.M.; A Rahman, N.A.; Haque, M.; et al. Detection of mobile colistin-resistance gene variants (mcr-1 and mcr-2) in urinary tract pathogens in Bangladesh: The last resort of infectious disease management colistin efficacy is under threat. *Expert Rev. Clin. Pharm.* **2021**, *14*, 513–522. [CrossRef] [PubMed]
- Ahmed, I.; Rabbi, B.; Sultana, S. Antibiotic resistance in Bangladesh: A systematic review. *Int. J. Infect. Dis.* **2019**, *80*, 54–61. [CrossRef] [PubMed]
- The World Bank. Final Report—Drug-Resistant Infections. A Threat to Our Economic Future. Available online: <http://document.s1.worldbank.org/curated/en/323311493396993758/pdf/final-report.pdf> (accessed on 8 May 2021).
- Klein, E.Y.; Van Boeckel, T.P.; Martinez, E.M.; Pant, S.; Gandra, S.; Levin, S.A.; Goossens, H.; Laxminarayan, R. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. *Proc. Natl. Acad. Sci.* **2018**, *115*, E3463–E3470. [CrossRef]
- Sriram, A.; Kalanxhi, E.; Kapoor, G.; Craig, J.; Balasubramanian, R.; Brar, S.; Criscuolo, N.; Hamilton, A.; Klein, E.; Tseng, K.; et al. State of the World's Antibiotics 2021: A Global Analysis of Antimicrobial Resistance and Its Drivers. Center for Disease Dynamics, Economics & Policy: Washington, DC. Available online: <https://cddep.org/wp-content/uploads/2021/02/The-State-of-the-Worlds-Antibiotics-in-2021.pdf> (accessed on 10 May 2021).

22. Llor, C.; Bjerrum, L. Antimicrobial resistance: Risk associated with antibiotic overuse and initiatives to reduce the problem. *Adv. Drug Saf.* **2014**, *5*, 229–241. [[CrossRef](#)]
23. Morel, C.M.; Alm, R.A.; Årdal, C.; Bandera, A.; Bruno, G.M.; Carrara, E.; Colombo, G.L.; de Kraker, M.E.; Essack, S.; Frost, I.; et al. A one health framework to estimate the cost of anti-microbial resistance. *Antimicrob. Resist. Infect. Control* **2020**, *9*, 187. [[CrossRef](#)]
24. Ayukekbong, J.A.; Ntemgwa, M.; Atabe, A.N. The threat of antimicrobial resistance in developing countries: Causes and control strategies. *Antimicrob. Resist. Infect. Control* **2017**, *6*, 47. [[CrossRef](#)]
25. Dadgostar, P. Antimicrobial Resistance: Implications and Costs. *Infect. Drug Resist.* **2019**, *12*, 3903–3910. [[CrossRef](#)] [[PubMed](#)]
26. Khan, J.Z.; Hassan, Z.; Tajik, M.I. Antibiotic Resistance: Recommendations for Procurement Agencies of Public Sector Hospitals in Pakistan. *J. Coll. Physicians Surg. Pak.* **2020**, *30*, 340–341. [[CrossRef](#)] [[PubMed](#)]
27. Mohsin, M.; Van Boeckel, T.P.; Saleemi, M.K.; Umair, M.; Naseem, M.N.; He, C.; Khan, A.; Laxminarayan, R. Excessive use of medically important antimicrobials in food animals in Pakistan: A five-year surveillance survey. *Glob. Health Action* **2019**, *12* (Suppl. 1), 1697541. [[CrossRef](#)]
28. Ali, M.; Irtiqa, A.; Mahrukh, F.; Tooba, A. Factors leading to acquired bacterial resistance due to antibiotics in Pakistan. *Curr. Trends Biotechnol. Microbiol.* **2018**, *1*, 1–7. [[CrossRef](#)]
29. Bokhary, H.; Pangesti, K.; Rashid, H.; El Ghany, M.A.; Hill-Cawthorne, G. Travel-Related Antimicrobial Resistance: A Systematic Review. *Trop. Med. Infect. Dis.* **2021**, *6*, 11. [[CrossRef](#)] [[PubMed](#)]
30. Hoque, R.; Ahmed, S.M.; Naher, N.; Islam, M.A.; Rousham, E.K.; Islam, B.Z.; Hassan, S. Tackling antimicrobial resistance in Bangladesh: A scoping review of policy and practice in human, animal and environment sectors. *PLoS ONE* **2020**, *15*, e0227947. [[CrossRef](#)]
31. Islam, M.A.; Islam, M.; Hasan, R.; Hossain, M.I.; Nabi, A.; Rahman, M.; Goessens, W.H.; Endtz, H.P.; Boehm, A.B.; Faruque, S.M. Environmental Spread of New Delhi Metal-lo- β -Lactamase-1-Producing Multidrug-Resistant Bacteria in Dhaka, Bangladesh. *Appl. Environ. Microbiol.* **2017**, *83*, e00793-17. [[CrossRef](#)]
32. Buchy, P.; Ascioğlu, S.; Buisson, Y.; Datta, S.; Nissen, M.; Tambyah, P.A.; Vong, S. Impact of vaccines on antimicrobial resistance. *Int. J. Infect. Dis.* **2020**, *90*, 188–196. [[CrossRef](#)]
33. Thornber, K.; Verner-Jeffreys, D.; Hinchliffe, S.; Rahman, M.M.; Bass, D.; Tyler, C.R. Evaluating antimicrobial resistance in the global shrimp industry. *Rev. Aquac.* **2020**, *12*, 966–986. [[CrossRef](#)]
34. Aworh, M.K.; Kwaga, J.; Okolocha, E.; Harden, L.; Hull, D.; Hendriksen, R.S.; Thakur, S. Extended-spectrum β -lactamase-producing *Escherichia coli* among humans, chickens and poultry environments in Abuja, Nigeria. *One Health Outlook* **2020**, *2*, 8. [[CrossRef](#)] [[PubMed](#)]
35. Van Boeckel, T.P.; Pires, J.; Silvester, R.; Zhao, C.; Song, J.; Criscuolo, N.G.; Gilbert, M.; Bonhoeffer, S.; Laxminarayan, R. Global trends in antimicrobial resistance in animals in low- and middle-income countries. *Science* **2019**, *365*, 1251. [[CrossRef](#)] [[PubMed](#)]
36. Ogunleye, O.O.; Basu, D.; Mueller, D.; Sneddon, J.; Seaton, R.A.; Yinka-Ogunleye, A.F.; Wamboga, J.; Miljković, N.; Mwita, J.C.; Rweggerera, G.M.; et al. Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. *Front. Pharm.* **2020**, *11*. [[CrossRef](#)] [[PubMed](#)]
37. Abbas, K.; Procter, S.R.; van Zandvoort, K.; Clark, A.; Funk, S.; Mengistu, T.; Hogan, D.; Dansereau, E.; Jit, M.; Flasche, S. Routine childhood immunisation during the COVID-19 pandemic in Africa: A benefit-risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. *Lancet Glob. Health.* **2020**, *8*, e1264–e1272. [[CrossRef](#)]
38. Olorunsaiye, C.Z.; Yusuf, K.K.; Reinhart, K.; Salihu, H.M. COVID-19 and Child Vaccination: A Systematic Approach to Closing the Immunization Gap. *Int. J. Matern. Child Health AIDS* **2020**, *9*, 381–385. [[CrossRef](#)]
39. WHO. At Least 80 Million Children under One at Risk of Diseases such as Diphtheria, Measles and Polio as COVID-19 Disrupts Routine Vaccination Efforts, Warn Gavi, WHO and UNICEF. Available online: <https://www.who.int/news/item/22-05-2020-at-least-80-million-children-under-one-at-risk-of-diseases-such-as-diphtheria-measles-and-polio-as-covid-19-disrupts-routine-vaccination-efforts-warn-gavi-who-and-unicef> (accessed on 8 May 2021).
40. Atkins, K.E.; Flasche, S. Vaccination to reduce antimicrobial resistance. *Lancet Glob. Health* **2018**, *6*, e252. [[CrossRef](#)]
41. Rodríguez-Álvarez, M.; López-Vidal, Y.; Soto-Hernández, J.L.; Miranda-Novales, M.G.; Flores-Moreno, K.; de León-Rosales, S.P. COVID-19: Clouds Over the Antimicrobial Resistance Landscape. *Arch. Med. Res.* **2021**, *52*, 123–126. [[CrossRef](#)]
42. Troisi, M.; Andreano, E.; Sala, C.; Kabanova, A.; Rappuoli, R. Vaccines as remedy for antimicrobial resistance and emerging infections. *Curr. Opin. Immunol.* **2020**, *65*, 102–106. [[CrossRef](#)]
43. Wilson, S.L.; Wiysonge, C. Social media and vaccine hesitancy. *BMJ Glob. Health* **2020**, *5*, e004206. [[CrossRef](#)]
44. Piedrahita-Valdés, H.; Piedrahita-Castillo, D.; Bermejo-Higuera, J.; Guillem-Saiz, P.; Bermejo-Higuera, J.R.; Guillem-Saiz, J.; Sicilia-Montalvo, J.A.; Machío-Regidor, F. Vaccine Hesitancy on Social Media: Sentiment Analysis from June 2011 to April 2019. *Vaccines* **2021**, *9*, 28. [[CrossRef](#)] [[PubMed](#)]
45. Jarchow-MacDonald, A.A.; Burns, R.; Miller, J.; Kerr, L.; Willocks, L.J. Keeping childhood immunisation rates stable during the COVID-19 pandemic. *Lancet Infect. Dis.* **2021**, *21*, 459–460. [[CrossRef](#)]
46. UNA-SUS. FIOCRUZ IN THE AIR: Covid-19 and Antibiotic Self-Medication: A Dangerous Combination. Available online: <https://www.unasus.gov.br/noticia/fiocruz-no-ar-covid-19-e-a-automedicacao-de-antibioticos-uma-combinacao-perigosa> (accessed on 8 May 2021).
47. Schueler, P. Antibiotic Resistance and COVID-19. Available online: <https://www.bio.fiocruz.br/index.php/br/noticias/1823-modernidade-e-sustentabilidade-no-centro-tecnologico-de-plataformas-vegetais> (accessed on 7 May 2021).

48. Iwu, C.J.; Jordan, P.; Jaja, I.F.; Iwu, C.D.; Wiysonge, C.S. Treatment of COVID-19: Implications for antimicrobial resistance in Africa. *Pan Afr. Med. J.* **2020**, *35*. [[CrossRef](#)]
49. Sefah, I.A.; Ogunleye, O.O.; Essah, D.O.; Opanga, S.A.; Butt, N.; Wamaitha, A.; Guantai, A.N.; Chikowe, I.; Khuluza, F.; Kibuule, D.; et al. Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 across Developing Countries with a Particular Focus on Africa and the Implications. *Front. Pharm.* **2021**, *11*, 588106. [[CrossRef](#)] [[PubMed](#)]
50. Ongole, J.J.; Rossouw, T.M.; Fourie, P.B.; Stoltz, A.C.; Hugo, J.; Marcus, T.S. Sustaining essential healthcare in Africa during the COVID-19 pandemic. *Int. J. Tuberc. Lung Dis.* **2020**, *24*, 643–645. [[CrossRef](#)] [[PubMed](#)]
51. Strathdee, S.A.; Davies, S.C.; Marcelin, J.R. Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election. *Lancet* **2020**, *396*, 1050–1053. [[CrossRef](#)]
52. Rawson, T.M.; Moore, L.S.P.; Zhu, N.; Ranganathan, N.; Skolimowska, K.; Gilchrist, M.; Satta, G.; Cooke, G.; Holmes, A. Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing. *Clin. Infect. Dis.* **2020**, *71*, 2459–2468. [[CrossRef](#)] [[PubMed](#)]
53. Hsu, J. How covid-19 is accelerating the threat of antimicrobial resistance. *BMJ* **2020**, *369*, m1983. [[CrossRef](#)]
54. Nori, P.; Cowman, K.; Chen, V.; Bartash, R.; Szymczak, W.; Madaline, T.; Katiyar, C.P.; Jain, R.; Aldrich, M.; Weston, G.; et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. *Infect. Control Hosp. Epidemiol.* **2021**, *42*, 84–88. [[CrossRef](#)]
55. Langford, B.J.; So, M.; Raybardhan, S.; Leung, V.; Soucy, J.-P.R.; Westwood, D.; Daneman, N.; MacFadden, D.R. Antibiotic prescribing in patients with COVID-19: Rapid review and meta-analysis. *Clin. Microbiol. Infect.* **2021**, *27*, 520–531. [[CrossRef](#)]
56. Interagency Coordination Group on Antimicrobial Resistance. No Time to Wait: Securing the Future from Drug-Resistant Infections-Report to the Secretary-General of the United Nations. April 2019. Available online: https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_report_EN.pdf?ua=1 (accessed on 8 May 2021).
57. World Health Organisation. Antimicrobial Resistance. 2018. Available online: <http://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance> (accessed on 8 May 2021).
58. WHO. The Role of Pharmacist in Encouraging Prudent Use of Antibiotics and Averting Antimicrobial Resistance: A Review of Policy and Experience. 2014. Available online: http://www.euro.who.int/__data/assets/pdf_file/0006/262815/The-role-of-pharmacist-in-encouraging-prudent-use-of-antibiotics-and-averting-antimicrobial-resistance-a-review-of-policy-and-experience-Eng.pdf?ua=1 (accessed on 7 May 2021).
59. Federal Ministries of Agriculture, Rural Development, Environment and Health, Abuja, Nigeria. National Action Plan for Antimicrobial Resistance, 2017–2022. Available online: https://ncdc.gov.ng/themes/common/docs/protocols/77_1511368219.pdf (accessed on 8 May 2021).
60. Saleem, Z.; Hassali, M.A.; Hashmi, F.K. Pakistan’s national action plan for antimicrobial resistance: Translating ideas into reality. *Lancet Infect. Dis.* **2018**, *18*, 1066–1067. [[CrossRef](#)]
61. Fürst, J.; Čizman, M.; Mrak, J.; Kos, D.; Campbell, S.; Coenen, S.; Gustafsson, L.L.; Fürst, L.; Godman, B. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: Findings and implications. *Expert Rev. Anti-Infect. Ther.* **2014**, *13*, 279–289. [[CrossRef](#)]
62. Abilova, V.; Kurdi, A.; Godman, B. Ongoing initiatives in Azerbaijan to improve the use of antibiotics; findings and implications. *Expert Rev. Anti-Infect. Ther.* **2018**, *16*, 77–84. [[CrossRef](#)]
63. Engler, D.; Meyer, J.C.; Schellack, N.; Kurdi, A.; Godman, B. Compliance with South Africa’s Antimicrobial Resistance National Strategy Framework: Are we there yet? *J. Chemother.* **2021**, *33*, 21–31. [[CrossRef](#)] [[PubMed](#)]
64. Godman, B.; Haque, M.; McKimm, J.; Abu Bakar, M.; Sneddon, J.; Wale, J.; Campbell, S.; Martin, A.; Hoxha, I.; Abilova, V.; et al. Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: Findings and implications for the future. *Curr. Med. Res. Opin.* **2019**, *36*, 301–327. [[CrossRef](#)]
65. Government of India. National Action Plan Antimicrobial Resistance (NAP-AMR) 2017–2021. Available online: https://rr-asia.oie.int/wp-content/uploads/2020/03/india_national-action-plan-on-amr-india.pdf (accessed on 7 May 2021).
66. Bao, L.; Peng, R.; Wang, Y.; Ma, R.; Ren, X.; Meng, W.; Sun, F.; Fang, J.; Chen, P.; Wang, Y.; et al. Significant Reduction of Antibiotic Consumption and Patients’ Costs after an Action Plan in China, 2010–2014. *PLoS ONE* **2015**, *10*, e0118868. [[CrossRef](#)] [[PubMed](#)]
67. Versporten, A.; Bolokhovets, G.; Ghazaryan, L.; Abilova, V.; Pyshnik, G.; Spasojevic, T.; Korinteli, I.; Raka, L.; Kamaralieva, B.; Cizmovic, L.; et al. Antibiotic use in eastern Europe: A cross-national database study in coordination with the WHO Regional Office for Europe. *Lancet Infect. Dis.* **2014**, *14*, 381–387. [[CrossRef](#)]
68. Brazilian Health Regulatory Agency. National Program for the Prevention and Control of Healthcare Associated Infections (2016–2020). Available online: <https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/servicosdesaude/publicacoes/national-program-for-the-prevention-and-control-of-healthcare-associated-infections-2016-2020> (accessed on 8 May 2021).
69. WHO. Global Action Plan on Antimicrobial Resistance. 2015. Available online: https://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1 (accessed on 7 May 2021).

70. Ghana Ministry of Health, Ministry of Food and Agriculture, Ministry of Environment, Science, Technology and Innovation, Ministry of Fisheries and Aquaculture Development. Ghana National Action Plan for Antimicrobial Use and Resistance. 2017–2021. Available online: http://www.moh.gov.gh/wp-content/uploads/2018/04/NAP_FINAL_PDF_A4_19.03.2018-SIGNED-1.pdf (accessed on 7 May 2021).
71. Mendelson, M.; Matsoso, M.P. The South African Antimicrobial Resistance Strategy Framework. *AMR Control*. **2015**, 54–61.
72. Republic of Kenya. National Action Plan on Prevention and Containment of Antimicrobial Resistance, 2017–2022. Available online: <https://www.afro.who.int/publications/national-action-plan-prevention-and-containment-antimicrobial-resistance-2017-2022> (accessed on 10 May 2021).
73. Ministry of Health and Family Welfare (MoHFW), Government of Bangladesh. National Action Plan: Antimicrobial Resistance Containment in Bangladesh 2017–'22. Available online: <https://www.flemingfund.org/wp-content/uploads/d3379eafad36f597500cb07c21771ae3.pdf> (accessed on 7 May 2021).
74. Munkholm, L.; Rubin, O. The global governance of antimicrobial resistance: A cross-country study of alignment between the global action plan and national action plans. *Glob. Health* **2020**, *16*, 109. [[CrossRef](#)]
75. Zaney, G.D. Ghana's National Action Plan on AMR Implementation on Course—But It Requires Support from All. Available online: <https://allafrica.com/stories/201908270183.html> (accessed on 8 May 2021).
76. Sangeda, R.Z.; Kibona, J.; Munishi, C.; Arabi, F.; Manyanga, V.P.; Mwambete, K.D.; Horumpende, P.G. Assessment of Implementation of Antimicrobial Resistance Surveillance and Antimicrobial Stewardship Programs in Tanzanian Health Facilities a Year after Launch of the National Action Plan. *Front. Public Health* **2020**, *8*, 454. [[CrossRef](#)]
77. Bajehson, M.; Musa, B.M.; Gidado, M.; Nsa, B.; Sani, U.; Habibu, A.T.; Aliyu, I.; Hussaini, T.; Yusuf, A.; Gida, Y. Determinants of mortality among patients with drug-resistant tuberculosis in northern Nigeria. *PLoS ONE* **2019**, *14*, e0225165. [[CrossRef](#)]
78. Akram, J.; Khan, A.S.; Khan, H.A.; Gilani, S.A.; Akram, S.J.; Ahmad, F.J.; Mehboob, R. Extensively Drug-Resistant (XDR) Typhoid: Evolution, Prevention, and Its Management. *BioMed Res. Int.* **2020**, *2020*, 6432580. [[CrossRef](#)] [[PubMed](#)]
79. Kurbatova, E.V.; Taylor, A.; Gammino, V.M.; Bayona, J.; Becerra, M.; Danilovitz, M.; Falzon, D.; Gelmanova, I.; Keshavjee, S.; Leimane, V.; et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. *Tuberculosis* **2012**, *92*, 397–403. [[CrossRef](#)]
80. Ali, M.H.; Alrasheedy, A.A.; Kibuule, D.; Godman, B.; Hassali, M.A.; Ali, H.M.H. Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications. *Expert Rev. Anti-Infect. Ther.* **2019**, *17*, 927–937. [[CrossRef](#)] [[PubMed](#)]
81. Bojanić, L.; Markovic-Pekovic, V.; Skrbic, R.; Stojakovic, N.; Đermanović, M.; Bojanić, J.; Fürst, J.; Kurdi, A.B.; Godman, B. Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications. *Front. Pharm.* **2018**, *9*. [[CrossRef](#)] [[PubMed](#)]
82. Wojkowska-Mach, J.; Godman, B.; Glassman, A.; Kurdi, A.; Pilc, A.; Rozanska, A.; Skoczyński, S.; Wałaszek, M.; Bochenek, T. Antibiotic consumption and antimicrobial resistance in Poland; findings and implications. *Antimicrob. Resist. Infect. Control* **2018**, *7*, 136. [[CrossRef](#)] [[PubMed](#)]
83. Saleem, Z.; Hassali, M.A.; Godman, B.; Hashmi, F.K.; Saleem, F. A multicenter point prevalence survey of healthcare-associated infections in Pakistan: Findings and implications. *Am. J. Infect. Control* **2019**, *47*, 421–424. [[CrossRef](#)]
84. Mwita, J.C.; Ogunleye, O.O.; Olalekan, A.; Kalungia, A.C.; Kurdi, A.; Saleem, Z.; Sneddon, J.; Godman, B. Key Issues Surrounding Appropriate Antibiotic Use for Prevention of Surgical Site Infections in Low- and Middle-Income Countries: A Narrative Review and the Implications. *Int. J. Gen. Med.* **2021**, *14*, 515–530. [[CrossRef](#)] [[PubMed](#)]
85. Haque, M.; McKimm, J.; Godman, B.; Abu Bakar, M.; Sartelli, M. Initiatives to reduce postoperative surgical site infections of the head and neck cancer surgery with a special emphasis on developing countries. *Expert Rev. Anticancer. Ther.* **2018**, *19*, 81–92. [[CrossRef](#)]
86. Nathwani, D.; Varghese, D.; Stephens, J.; Ansari, W.; Martin, S.; Charbonneau, C. Value of hospital antimicrobial stewardship programs [ASPs]: A systematic review. *Antimicrob. Resist. Infect. Control* **2019**, *8*, 35. [[CrossRef](#)]
87. Akpan, M.R.; Isemin, N.U.; Udoh, A.E.; Ashiru-Oredope, D. Implementation of antimicrobial stewardship programmes in African countries: A systematic literature review. *J. Glob. Antimicrob. Resist.* **2020**, *22*, 317–324. [[CrossRef](#)]
88. Anand Paramadhas, B.D.; Tiroyakgosi, C.; Mpinda-Joseph, P.; Morokotso, M.; Matome, M.; Sinkala, F.; Gaolebe, M.; Malone, B.; Molosiwa, E.; Shanmugam, M.G.; et al. Point prevalence study of antimicrobial use among hospitals across Botswana; findings and implications. *Expert Rev. Anti-Infect. Ther.* **2019**, *17*, 535–546. [[CrossRef](#)]
89. Cai, Y.; Shek, P.Y.; Teo, I.; Tang, S.S.; Lee, W.; Liew, Y.X.; Chlebicki, P.; Kwa, A.L. A multidisciplinary antimicrobial stewardship programme safely decreases the duration of broad-spectrum antibiotic prescription in Singaporean adult renal patients. *Int. J. Antimicrob. Agents* **2016**, *47*, 91–96. [[CrossRef](#)]
90. Tang, S.J.; Gupta, R.; Lee, J.I.; Majid, A.M.; Patel, P.; Efirid, L.; Loo, A.; Mazur, S.; Calfee, D.P.; Archambault, A.; et al. Impact of Hospitalist-Led Interdisciplinary Antimicrobial Stewardship Interventions at an Academic Medical Center. *Jt. Comm. J. Qual. Patient Saf.* **2019**, *45*, 207–216. [[CrossRef](#)]
91. Schuts, E.C.; Hulscher, M.; Mouton, J.W.; Verduin, C.M.; Stuart, J.; Overdiek, H.; van der Linden, P.D.; Natsch, S.; Hertogh, C.M.P.M.; Wolfs, T.F.W.; et al. Current evidence on hospital antimicrobial stewardship objectives: A systematic review and meta-analysis. *Lancet Infect. Dis.* **2016**, *16*, 847–856. [[CrossRef](#)]

92. Shirazi, O.U.; Ab Rahman, N.S.; Zin, C.S. A Narrative Review of Antimicrobial Stewardship Interventions within In-Patient Settings and Resultant Patient Outcomes. *J. Pharm. Bioallied. Sci.* **2020**, *12*, 369–380.
93. Satterfield, J.; Miesner, A.R.; Percival, K.M. The role of education in antimicrobial stewardship. *J. Hosp. Infect.* **2020**, *105*, 130–141. [[CrossRef](#)]
94. Seni, J.; Mapunjo, S.G.; Wittenauer, R.; Valimba, R.; Stergachis, A.; Werth, B.J.; Saitoti, S.; Mhadu, N.H.; Lusaya, E.; Konduri, N. Antimicrobial use across six referral hospitals in Tanzania: A point prevalence survey. *BMJ Open* **2020**, *10*, e042819. [[CrossRef](#)]
95. Álvarez-Marín, R.; López-Cerero, L.; Guerrero-Sánchez, F.; Palop-Borras, B.; Rojo-Martín, M.D.; Ruiz-Sancho, A.; Herrero-Rodríguez, C.; García, M.V.; Lazo-Torres, A.M.; López, I.; et al. Do specific antimicrobial stewardship interventions have an impact on carbapenem resistance in Gram-negative bacilli? A multicentre quasi-experimental ecological study: Time-trend analysis and characterization of carbapenemases. *J. Antimicrob. Chemother.* **2021**. [[CrossRef](#)]
96. López-Viñau, T.; Peñalva, G.; García-Martínez, L.; Castón, J.J.; Muñoz-Rosa, M.; Cano, Á.; Recio, M.; Cisneros, J.M.; Pérez-Nadales, E.; Rumbao Aguirre, J.; et al. Impact of an Antimicrobial Stewardship Program on the Incidence of Carbapenem Resistant Gram-Negative Bacilli: An Interrupted Time-Series Analysis. *Antibiotics* **2021**, *10*, 586. [[CrossRef](#)]
97. Cox, J.A.; Vlieghe, E.; Mendelson, M.; Wertheim, H.; Ndegwa, L.; Villegas, M.V.; Gould, I.; Hara, G.L. Antibiotic stewardship in low- and middle-income countries: The same but different? *Clin. Microbiol. Infect.* **2017**, *23*, 812–818. [[CrossRef](#)] [[PubMed](#)]
98. Brink, A.J.; Messina, A.P.; Feldman, C.; Richards, G.A.; Becker, P.J.; Goff, D.A.; Bauer, K.A.; Nathwani, D.; Bergh, D.V.D. Antimicrobial stewardship across 47 South African hospitals: An implementation study. *Lancet Infect. Dis.* **2016**, *16*, 1017–1025. [[CrossRef](#)]
99. Mukokinya, M.M.A.; Opanga, S.; Oluka, M.; Godman, B. Dispensing of antimicrobials in Kenya: A cross-sectional pilot study and its implications. *J. Res. Pharm. Pract.* **2018**, *7*, 77. [[CrossRef](#)] [[PubMed](#)]
100. Jacobs, T.G.; Robertson, J.; van den Ham, H.A.; Iwamoto, K.; Pedersen, H.B.; Mantel-Teeuwisse, A.K. Assessing the impact of law enforcement to reduce over-the-counter (OTC) sales of antibiotics in low- and middle-income countries; a systematic literature review. *BMC Health Serv. Res.* **2019**, *19*, 536. [[CrossRef](#)] [[PubMed](#)]
101. Olaoye, O.; Tuck, C.; Khor, W.P.; McMenamin, R.; Hudson, L.; Northall, M.; Panford-Quainoo, E.; Asima, D.M.; Ashiru-Oredope, D. Improving Access to Antimicrobial Prescribing Guidelines in 4 African Countries: Development and Pilot Implementation of an App and Cross-Sectional Assessment of Attitudes and Behaviour Survey of Healthcare Workers and Patients. *Antibiotics* **2020**, *9*, 555. [[CrossRef](#)]
102. Gasson, J.; Blockman, M.; Willems, B. Antibiotic prescribing practice and adherence to guidelines in primary care in the Cape Town Metro District, South Africa. *S. Afr. Med. J.* **2018**, *108*, 304–310. [[CrossRef](#)] [[PubMed](#)]
103. Elias, C.; Moja, L.; Mertz, D.; Loeb, M.; Forte, G.; Magrini, N. Guideline recommendations and antimicrobial resistance: The need for a change. *BMJ Open* **2017**, *7*, e016264. [[CrossRef](#)]
104. Saleem, Z.; Godman, B.; Hassali, M.A.; Hashmi, F.K.; Azhar, F.; Rehman, I.U. Point prevalence surveys of health-care-associated infections: A systematic review. *Pathog. Glob. Health* **2019**, *113*, 191–205. [[CrossRef](#)] [[PubMed](#)]
105. Saleem, Z.; Hassali, M.A.; Godman, B.; Versporten, A.; Hashmi, F.K.; Saeed, H.; Saleem, F.; Salman, M.; Rehman, I.U.; Khan, T.M. Point prevalence surveys of antimicrobial use: A systematic review and the implications. *Expert Rev. Anti-Infect. Ther.* **2020**, *18*, 897–910. [[CrossRef](#)]
106. Rappuoli, R.; De Gregorio, E.; Del Giudice, G.; Phogat, S.; Pecetta, S.; Pizza, M.; Hanon, E. Vaccinology in the post-COVID-19 era. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2020368118. [[CrossRef](#)] [[PubMed](#)]
107. Batura, N.; Cuevas, C.; Khan, M.; Wiseman, V. How effective and cost-effective are behaviour change interventions in improving the prescription and use of antibiotics in low-income and middle-income countries? A protocol for a systematic review. *BMJ Open* **2018**, *8*, e021517. [[CrossRef](#)]
108. Cooper, L.; Sneddon, J.; Afriyie, D.K.; Sefah, I.A.; Kurdi, A.; Godman, B.; Seaton, R.A. Supporting global antimicrobial stewardship: Antibiotic prophylaxis for the prevention of surgical site infection in low- and middle-income countries (LMICs): A scoping review and meta-analysis. *JAC-Antimicrob. Resist.* **2020**, *2*. [[CrossRef](#)]
109. Ocan, M.; Obuku, E.A.; Bwanga, F.; Akena, D.; Richard, S.; Ogwal-Okeng, J.; Obua, C. Household antimicrobial self-medication: A systematic review and meta-analysis of the burden, risk factors and outcomes in developing countries. *BMC Public Health* **2015**, *15*, 742. [[CrossRef](#)]
110. da Silva, A.A.; de Almeida Dias, D.A.; Marques, A.F.; di Biase, C.B.; Murni, I.K.; Dramowski, A.; Sharland, M.; Huebner, J.; Zingg, W. Role of antimicrobial stewardship programmes in children: A systematic review. *J. Hosp. Infect.* **2018**, *99*, 117–123. [[CrossRef](#)] [[PubMed](#)]
111. Huebner, C.; Flessa, S.; Huebner, N.O. The economic impact of antimicrobial stewardship programmes in hospitals: A systematic literature review. *J. Hosp. Infect.* **2019**, *102*, 369–376. [[CrossRef](#)] [[PubMed](#)]
112. Karanika, S.; Paudel, S.; Grigoras, C.; Kalbasi, A.; Mylonakis, E. Systematic Review and Meta-analysis of Clinical and Economic Outcomes from the Implementation of Hospital-Based Antimicrobial Stewardship Programs. *Antimicrob. Agents Chemother.* **2016**, *60*, 4840–4852. [[CrossRef](#)] [[PubMed](#)]
113. Holloway, K.A.; Rosella, L.; Henry, D. The Impact of WHO Essential Medicines Policies on Inappropriate Use of Antibiotics. *PLoS ONE* **2016**, *11*, e0152020. [[CrossRef](#)] [[PubMed](#)]

114. Md Rezal, R.S.; Hassali, M.A.; Alrasheedy, A.A.; Saleem, F.; Md Yusof, F.A.; Godman, B. Physicians' knowledge, perceptions and behaviour towards antibiotic prescribing: A systematic review of the literature. *Expert Rev. Anti-Infect. Ther.* **2015**, *13*, 665–680. [[CrossRef](#)]
115. Dar, O.A.; Hasan, R.; Schlundt, J.; Harbarth, S.; Caleo, G.; Dar, F.K.; Littmann, J.; Rweyemamu, M.; Buckley, E.J.; Shahid, M.; et al. Exploring the evidence base for national and regional policy interventions to combat resistance. *Lancet* **2016**, *387*, 285–295. [[CrossRef](#)]
116. McDonagh, M.S.; Peterson, K.; Winthrop, K.; Cantor, A.; Lazur, B.H.; Buckley, D.I. Interventions to reduce inappropriate prescribing of antibiotics for acute respiratory tract infections: Summary and update of a systematic review. *J. Int. Med. Res.* **2018**, *46*, 3337–3357. [[CrossRef](#)]
117. Dyar, O.J.; Beovic, B.; Vlahovic-Palcevski, V.; Verheij, T.; Pulcini, C. How can we improve antibiotic prescribing in primary care? *Expert Rev. Anti-Infect. Ther.* **2016**, *14*, 403–413. [[CrossRef](#)]
118. Auta, A.; Hadi, M.A.; Oga, E.; Adewuyi, E.O.; Abdu-Aguye, S.N.; Adeloye, D.; Strickland-Hodge, B.; Morgan, D.J. Global access to antibiotics without prescription in community pharmacies: A systematic review and meta-analysis. *J. Infect.* **2019**, *78*, 8–18. [[CrossRef](#)]
119. Köchling, A.; Löffler, C.; Reinsch, S.; Hornung, A.; Böhmer, F.; Altiner, A.; Chenot, J.F. Reduction of antibiotic prescriptions for acute respiratory tract infections in primary care: A systematic review. *Implement. Sci.* **2018**, *13*, 47. [[CrossRef](#)]
120. McKay, R.; Mah, A.; Law, M.R.; McGrail, K.; Patrick, D.M. Systematic Review of Factors Associated with Antibiotic Prescribing for Respiratory Tract Infections. *Antimicrob. Agents Chemother.* **2016**, *60*, 4106–4118. [[CrossRef](#)]
121. Roque, F.; Herdeiro, M.T.; Soares, S.; Teixeira Rodrigues, A.; Breitenfeld, L.; Figueiras, A. Educational interventions to improve prescription and dispensing of antibiotics: A systematic review. *BMC Public Health* **2014**, *14*, 1276. [[CrossRef](#)]
122. Teixeira Rodrigues, A.; Roque, F.; Falcao, A.; Figueiras, A.; Herdeiro, M.T. Understanding physician antibiotic prescribing behaviour: A systematic review of qualitative studies. *Int. J. Antimicrob. Agents* **2013**, *41*, 203–212. [[CrossRef](#)]
123. Sakeena, M.H.F.; Bennett, A.A.; McLachlan, A.J. Non-prescription sales of antimicrobial agents at community pharmacies in developing countries: A systematic review. *Int. J. Antimicrob. Agents* **2018**, *52*, 771–782. [[CrossRef](#)]
124. Nepal, G.; Bhatta, S. Self-medication with Antibiotics in WHO Southeast Asian Region: A Systematic Review. *Cureus* **2018**, *10*, e2428. [[CrossRef](#)]
125. Zanichelli, V.; Tebano, G.; Gyssens, I.C.; Vlahović-Palčevski, V.; Monnier, A.A.; Benic, M.S.; Harbarth, S.; Hulscher, M.; Pulcini, C.; Huttner, B. Patient-related determinants of antibiotic use: A systematic review. *Clin. Microbiol. Infect.* **2019**, *25*, 48–53. [[CrossRef](#)] [[PubMed](#)]
126. Servia-Dopazo, M.; Figueiras, A. Determinants of antibiotic dispensing without prescription: A systematic review. *J. Antimicrob. Chemother.* **2018**, *73*, 3244–3253. [[CrossRef](#)] [[PubMed](#)]
127. Lescure, D.; Paget, J.; Schellevis, F.; Van Dijk, L. Determinants of Self-Medication with Antibiotics in European and Anglo-Saxon Countries: A Systematic Review of the Literature. *Front. Public Health* **2018**, *6*, 370. [[CrossRef](#)]
128. Saharman, Y.R.; Karuniawati, A.; Severin, J.A.; Verbrugh, H.A. Infections and antimicrobial resistance in intensive care units in lower-middle income countries: A scoping review. *Antimicrob. Resist. Infect. Control* **2021**, *10*, 22. [[CrossRef](#)] [[PubMed](#)]
129. Torres, N.F.; Chibi, B.; Middleton, L.E.; Solomon, V.P.; Mashamba-Thompson, T.P. Evidence of factors influencing self-medication with antibiotics in low and middle-income countries: A systematic scoping review. *Public Health* **2019**, *168*, 92–101. [[CrossRef](#)] [[PubMed](#)]
130. Irek, E.O.; Amupitan, A.A.; Obadare, T.O.; Aboderin, A.O. A systematic review of healthcare-associated infections in Africa: An antimicrobial resistance perspective. *Afr. J. Lab. Med.* **2018**, *7*, 9. [[CrossRef](#)]
131. Badia, J.M.; Casey, A.L.; Petrosillo, N.; Hudson, P.M.; Mitchell, S.A.; Crosby, C. Impact of surgical site infection on healthcare costs and patient outcomes: A systematic review in six European countries. *J. Hosp. Infect.* **2017**, *96*, 1–15. [[CrossRef](#)] [[PubMed](#)]
132. Schreiber, P.W.; Sax, H.; Wolfensberger, A.; Clack, L.; Kuster, S.P. Swissnos the preventable proportion of healthcare-associated infections 2005–2016: Systematic review and meta-analysis. *Infect. Control Hosp. Epidemiol.* **2018**, *39*, 1277–1295. [[CrossRef](#)]
133. Alhomoud, F.; Aljamea, Z.; Almahasnah, R.; Alkhalifah, K.; Basalelah, L.; Alhomoud, F.K. Self-medication and self-prescription with antibiotics in the Middle East-do they really happen? A systematic review of the prevalence, possible reasons, and outcomes. *Int. J. Infect. Dis.* **2017**, *57*, 3–12. [[CrossRef](#)] [[PubMed](#)]
134. May, L.S.; Quirós, A.M.; Ten Oever, J.; Hoogerwerf, J.J.; Schoffelen, T.; Schouten, J.A. Antimicrobial stewardship in the emergency department: Characteristics and evidence for effectiveness of interventions. *Clin. Microbiol. Infect.* **2021**, *27*, 204–209. [[CrossRef](#)] [[PubMed](#)]
135. Kalungia, A.; Godman, B. Implications of non-prescription antibiotic sales in China. *Lancet Infect. Dis.* **2019**, *19*, 1272–1273. [[CrossRef](#)]
136. Kalungia, A.C.; Burger, J.; Godman, B.; Costa, J.D.O.; Simuwelu, C. Non-prescription sale and dispensing of antibiotics in community pharmacies in Zambia. *Expert Rev. Anti-Infect. Ther.* **2016**, *14*, 1215–1223. [[CrossRef](#)]
137. Godman, B.; Fadare, J.; Kibuule, D.; Irawati, L.; Mubita, M.; Ogunleye, O.; Oluka, M.; Paramadhas, B.D.A.; Costa, J.D.O.; De Lemos, L.L.P.; et al. Initiatives Across Countries to Reduce Antibiotic Utilisation and Resistance Patterns: Impact and Implications. In *Drug Resistance in Bacteria, Fungi, Malaria, and Cancer*; Springer Science and Business Media: Berlin/Heidelberg, Germany, 2017; Volume 34, pp. 539–576.

138. Godman, B.; McCabe, H.; DLeong, T.; Mueller, D.; Martin, A.P.; Hoxha, I.; Mwita, J.C.; Rwegerera, G.M.; Massele, A.; Costa, J.D.; et al. Fixed dose drug combinations—Are they pharmaco-economically sound? Findings and implications especially for lower- and middle-income countries. *Expert Rev. Pharm. Outcomes Res.* **2020**, *20*, 1–26.
139. Godman, B.; Malmstrom, R.E.; Diogene, E.; Jayathissa, S.; McTaggart, S.; Cars, T.; Alvarez-Madrado, S.; Baumgärtel, C.; Brzezinska, A.; Bucsecs, A.; et al. Dabigatran—A continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. *Front. Pharmacol.* **2014**, *5*, 109. [[CrossRef](#)] [[PubMed](#)]
140. Godman, B.; Hill, A.; Simoons, S.; Selke, G.; Selke Krulichová, I.; Zampirolli Dias, C.; Martin, A.P.; Oortwijn, W.; Timoney, A.; Gustafsson, L.L.; et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. *Expert Rev. Pharm. Outcomes Res.* **2021**, 1–14. [[CrossRef](#)]
141. Dias, C.Z.; Godman, B.; Gargano, L.P.; Azevedo, P.S.; Garcia, M.M.; Cazarim, M.S.; Pantuzza, L.L.; Ribeiro-Junior, N.G.; Pereira, A.L.; Borin, M.C.; et al. Integrative Review of Managed Entry Agreements: Chances and Limitations. *PharmacoEconomics* **2020**, *38*, 1165–1185. [[CrossRef](#)]
142. Godman, B.; Bucsecs, A.; Vella Bonanno, P.; Oortwijn, W.; Rothe, C.C.; Ferrario, A.; Bosselli, S.; Hill, A.; Martin, A.; Simoons, S.; et al. Barriers for Access to New Medicines: Searching for the Balance between Rising Costs and Limited Budgets. *Front. Public Health* **2018**, *6*, 328. [[CrossRef](#)]
143. Moorkens, E.; Vulto, A.G.; Huys, I.; Dylst, P.; Godman, B.; Keuerleber, S.; Claus, B.; Dimitrova, M.; Petrova, G.; Sović-Brkičić, L.; et al. Policies for biosimilar uptake in Europe: An overview. *PLoS ONE* **2017**, *12*, e0190147. [[CrossRef](#)]
144. Ermisch, M.; Bucsecs, A.; Vella Bonanno, P.; Arickx, F.; Bybau, A.; Bochenek, T.; Van de Casteele, M.; Diogene, E.; Fürst, J.; Garuolienė, K.; et al. Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. *Front. Pharm.* **2016**, *7*. [[CrossRef](#)]
145. Bochenek, T.; Abilova, V.; Alkan, A.; Asanin, B.; de Miguel Beriain, I.; Besovic, Z.; Bonanno, P.V.; Bucsecs, A.; Davidescu, M.; De Weerd, E.; et al. Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. *Front. Pharm.* **2018**, *8*, 942. [[CrossRef](#)] [[PubMed](#)]
146. Godman, B.; Grobler, C.; Van-De-Lisle, M.; Wale, J.; Barbosa, W.B.; Massele, A.; Opondo, P.; Petrova, G.; Tachkov, K.; Sefah, I.; et al. Pharmacotherapeutic interventions for bipolar disorder type II: Addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. *Expert Opin. Pharmacother.* **2019**, *20*, 2237–2255. [[CrossRef](#)] [[PubMed](#)]
147. Godman, B.; Wettermark, B.; Van Woerkom, M.; Fraeyman, J.; Alvarez-Madrado, S.; Berg, C.; Bishop, I.; Bucsecs, A.; Campbell, S.; Finlayson, A.E.; et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: Findings and future implications. *Front. Pharm.* **2014**, *5*, 106. [[CrossRef](#)]
148. World Bank. World Bank Country and Lending Groups—Country Classifications. Available online: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups> (accessed on 8 May 2021).
149. Cameron, A.; Ewen, M.; Ross-Degnan, D.; Ball, D.; Laing, R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. *Lancet* **2009**, *373*, 240–249. [[CrossRef](#)]
150. Ofori-Asenso, R.; Agyeman, A.A. Irrational Use of Medicines—A Summary of Key Concepts. *Pharmacy* **2016**, *4*, 35. [[CrossRef](#)]
151. Aregbeshola, B.S.; Khan, S.M. Out-of-Pocket Payments, Catastrophic Health Expenditure and Poverty among Households in Nigeria. *Int. J. Health Policy Manag.* **2018**, *7*, 798–806. [[CrossRef](#)]
152. Khan, J.A.M.; Ahmed, S.; Evans, T.G. Catastrophic healthcare expenditure and poverty related to out-of-pocket payments for healthcare in Bangladesh—An estimation of financial risk protection of universal health coverage. *Health Policy Plan.* **2017**, *32*, 1102–1110. [[CrossRef](#)] [[PubMed](#)]
153. Godman, B.; Haque, M.; Islam, S.; Iqbal, S.; Urmi, U.L.; Kamal, Z.M.; Shuvo, S.A.; Rahman, A.; Kamal, M.; Haque, M.; et al. Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 across Asia: Findings and Public Health Implications for the Future. *Front. Public Health* **2020**, *8*, 585832. [[CrossRef](#)]
154. Murphy, A.; Palafox, B.; Walli-Attaei, M.; Powell-Jackson, T.; Rangarajan, S.; Alhabib, K.F.; Avezum, A.J.; Calik, K.B.T.; Chifamba, J.; Choudhury, T.; et al. The household economic burden of non-communicable diseases in 18 countries. *BMJ Glob. Health* **2020**, *5*, e002040. [[CrossRef](#)] [[PubMed](#)]
155. Rezal, R.S.; Hassali, M.A.; Alrasheedy, A.A.; Saleem, F.; Aryani Md Yusof, F.; Kamal, M.; Din, R.M.; Godman, B. Prescribing patterns for upper respiratory tract infections: A prescription-review of primary care practice in Kedah, Malaysia, and the implications. *Expert Rev. Anti-Infect. Ther.* **2015**, *13*, 1547–1556. [[CrossRef](#)] [[PubMed](#)]
156. Chowdhury, M.; Stewart Williams, J.; Wertheim, H.; Khan, W.A.; Matin, A.; Kinsman, J. Rural community perceptions of antibiotic access and understanding of antimicrobial resistance: Qualitative evidence from the Health and Demographic Surveillance System site in Matlab, Bangladesh. *Glob. Health Action* **2019**, *12* (Suppl. 1), 1824383. [[CrossRef](#)]
157. Markovic-Pekovic, V.; Grubiša, N.; Burger, J.; Bojanić, L.; Godman, B. Initiatives to reduce nonprescription sales and dispensing of antibiotics: Findings and implications. *J. Res. Pharm. Pract.* **2017**, *6*, 120. [[CrossRef](#)] [[PubMed](#)]
158. Nashilongo, M.M.; Singu, B.; Kalemeera, F.; Mubita, M.; Naikaku, E.; Baker, A.; Ferrario, A.; Godman, B.; Achieng, L.; Kibuule, D. Assessing Adherence to Antihypertensive Therapy in Primary Health Care in Namibia: Findings and Implications. *Cardiovasc. Drugs* **2017**, *31*, 565–578. [[CrossRef](#)]

159. Saleem, Z.; Hassali, M.A.; Hashmi, F.K.; Godman, B.; Saleem, F. Antimicrobial dispensing practices and determinants of antimicrobial resistance: A qualitative study among community pharmacists in Pakistan. *Fam. Med. Community Health* **2019**, *7*, e000138. [CrossRef] [PubMed]
160. Chang, J.; Xu, S.; Zhu, S.; Li, Z.; Yu, J.; Zhang, Y.; Zu, J.; Fang, Y.; Ross-Degnan, D. Assessment of non-prescription antibiotic dispensing at community pharmacies in China with simulated clients: A mixed cross-sectional and longitudinal study. *Lancet Infect. Dis.* **2019**, *19*, 1345–1354. [CrossRef]
161. WHO. Community Pharmacists Are Key Players in COVID-19 Response and Must Stay Up-to-Date on Guidance. 2020. Available online: <https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/5/community-pharmacists-are-key-players-in-covid-19-response-and-must-stay-up-to-date-on-guidance> (accessed on 8 May 2020).
162. Hoxha, I.; Malaj, A.; Kraja, B.; Bino, S.; Oluka, M.; Markovic-Pekovic, V.; Godman, B. Are pharmacists' good knowledge and awareness on antibiotics taken for granted? The situation in Albania and future implications across countries. *J. Glob. Antimicrob. Resist.* **2018**, *13*, 240–245. [CrossRef]
163. Darj, E.; Newaz, M.S.; Zaman, M.H. Pharmacists' perception of their challenges at work, focusing on antimicrobial resistance: A qualitative study from Bangladesh. *Glob. Health Action* **2019**, *12* (Suppl. 1), 1735126. [CrossRef]
164. Waseem, H.; Ali, J.; Sarwar, F.; Khan, A.; Rehman, H.S.U.; Choudri, M.; Arif, N.; Subhan, M.; Saleem, A.R.; Jamal, A.; et al. Assessment of knowledge and attitude trends towards antimicrobial resistance (AMR) among the community members, pharmacists/pharmacy owners and physicians in district Sialkot, Pakistan. *Antimicrob. Resist. Infect. Control* **2019**, *8*, 67. [CrossRef]
165. Wettermark, B.; Godman, B.; Jacobsson, B.; Haaijer-Ruskamp, F.M. Soft regulations in pharmaceutical policy making: An overview of current approaches and their consequences. *Appl. Health Econ. Health Policy* **2009**, *7*, 137–147. [CrossRef]
166. Godman, B. Health authority activities to enhance the quality and efficiency of medicine use and their impact. *Adv. Hum. Biol.* **2021**, *11*, 11–16.
167. Niaz, Q.; Godman, B.; Massele, A.; Campbell, S.; Kurdi, A.; Kagoya, H.R.; Kibuule, D. Validity of World Health Organisation prescribing indicators in Namibia's primary healthcare: Findings and implications. *Int. J. Qual. Health Care* **2018**, *31*, 338–345. [CrossRef] [PubMed]
168. Versporten, A.; Zarb, P.; Caniaux, I.; Gros, M.-F.; Drapier, N.; Miller, M.; Jarlier, V.; Nathwani, D.; Goossens, H.; Koraqi, A.; et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: Results of an internet-based global point prevalence survey. *Lancet Glob. Health* **2018**, *6*, e619–e629. [CrossRef]
169. Nakwatumbah, S.; Kibuule, D.; Godman, B.; Haakuria, V.; Kalemeera, F.; Baker, A.; Mubita, M.; Mwangana, M. Compliance to guidelines for the prescribing of antibiotics in acute infections at Namibia's national referral hospital: A pilot study and the implications. *Expert Rev. Anti-Infect. Ther.* **2017**, *15*, 713–721. [CrossRef]
170. Niaz, Q.; Godman, B.; Campbell, S.; Kibuule, D. Compliance to prescribing guidelines among public health care facilities in Namibia; findings and implications. *Int. J. Clin. Pharm.* **2020**, *42*, 1227–1236. [CrossRef] [PubMed]
171. Afriyie, D.K.; Sefah, I.A.; Sneddon, J.; Malcolm, W.; McKinney, R.; Cooper, L.; Kurdi, A.; Godman, B.; Seaton, R.A. Antimicrobial point prevalence surveys in two Ghanaian hospitals: Opportunities for antimicrobial stewardship. *JAC Antimicrob. Resist.* **2020**, *2*, 1–9. [CrossRef]
172. Mashalla, Y.; Setlhare, V.; Massele, A.; Sepako, E.; Tiroyakgosi, C.; Kgatlwane, J.; Chuma, M.; Godman, B. Assessment of prescribing practices at the primary healthcare facilities in Botswana with an emphasis on antibiotics: Findings and implications. *Int. J. Clin. Pract.* **2017**, *71*, e13042. [CrossRef] [PubMed]
173. Sharland, M.; Gandra, S.; Huttner, B.; Moja, L.; Pulcini, C.; Zeng, M.; Mendelson, M.; Cappello, B.; Cooke, G.; Magrini, N.; et al. Encouraging AWaRe-ness and discouraging inappropriate antibiotic use—The new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. *Lancet Infect. Dis.* **2019**, *19*, 1278–1280. [CrossRef]
174. Saleem, Z.; Hassali, M.A.; Godman, B.; Fatima, M.; Ahmad, Z.; Sajid, A.; Rehman, I.U.; Nadeem, M.U.; Javaid, Z.; Malik, M.; et al. Sale of WHO AWaRe groups antibiotics without a prescription in Pakistan: A simulated client study. *J. Pharm. Policy Pract.* **2020**, *13*, 26. [CrossRef] [PubMed]
175. Hsia, Y.; Lee, B.R.; Versporten, A.; Yang, Y.; Bielicki, J.; Jackson, C.; Newland, J.; Goossens, H.; Magrini, N.; Sharland, M.; et al. Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): An analysis of paediatric survey data from 56 countries. *Lancet Glob. Health* **2019**, *7*, e861–e871. [CrossRef]
176. Hoffmann, M. The right drug, but from whose perspective? A framework for analysing the structure and activities of drug and therapeutics committees. *Eur. J. Clin. Pharm.* **2013**, *69* (Suppl. 1), 79–87. [CrossRef]
177. Matlala, M.; Gous, A.G.S.; Meyer, J.C.; Godman, B. Formulary Management Activities and Practice Implications among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province. *Front. Pharm.* **2020**, *11*. [CrossRef] [PubMed]
178. Matlala, M.; Gous, A.G.; Godman, B.; Meyer, J.C. Structure and activities of pharmacy and therapeutics committees among public hospitals in South Africa; findings and implications. *Expert Rev. Clin. Pharm.* **2017**, *10*, 1273–1280. [CrossRef] [PubMed]
179. Lee, M.H.; Lee, G.A.; Lee, S.H.; Park, Y.H. Effectiveness and core components of infection prevention and control programmes in long-term care facilities: A systematic review. *J. Hosp. Infect.* **2019**, *102*, 377–393. [CrossRef] [PubMed]
180. Mbui, J.M.; Oluka, M.N.; Guantai, E.M.; Sinei, K.A.; Achieng, L.; Baker, A.; Jande, M.; Massele, A.; Godman, B. Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications. *Expert Rev. Clin. Pharm.* **2017**, *10*, 1263–1271. [CrossRef]

181. Matsitse, T.B.; Helberg, E.; Meyer, J.C.; Godman, B.; Massele, A.; Schellack, N. Compliance with the primary health care treatment guidelines and the essential medicines list in the management of sexually transmitted infections in correctional centres in South Africa: Findings and implications. *Expert Rev. Anti-Infect. Ther.* **2017**, *15*, 963–972. [[CrossRef](#)]
182. Brooks, J. US Medicare will stop paying for preventable errors. *Can. Med. Assoc. J.* **2007**, *177*, 841–842. [[CrossRef](#)]
183. Alrasheedy, A.A.; Alsalloum, M.A.; Almuqbil, F.A.; Almuzaini, M.A.; Aba Alkhayl, B.S.; Albishri, A.S.; Alharbi, F.F.; Alharbi, S.R.; Alodhayb, A.K.; Alfadl, A.A.; et al. The impact of law enforcement on dispensing antibiotics without prescription: A multi-methods study from Saudi Arabia. *Expert Rev. Anti-Infect. Ther.* **2020**, *18*, 87–97. [[CrossRef](#)]
184. Godman, B.; Basu, D.; Pillay, Y.; Almeida, P.H.; Mwita, J.C.; Rweggerera, G.M.; Paramadhas, B.D.A.; Tiroyakgosi, C.; Patrick, O.; Niba, L.L.; et al. Ongoing and planned activities to improve the management of patients with Type 1 diabetes across Africa; implications for the future. *Hosp. Pract.* **2020**, *48*, 51–67. [[CrossRef](#)]
185. Godman, B.; Basu, D.; Pillay, Y.; Mwita, J.C.; Rweggerera, G.M.; Anand Paramadhas, B.D.; Tiroyakgosi, C.; Okwen, P.M.; Niba, L.L.; Nonvignon, J.; et al. Review of Ongoing Activities and Challenges to Improve the Care of Patients with Type 2 Diabetes across Africa and the Implications for the Future. *Front. Pharm.* **2020**, *11*, 108. [[CrossRef](#)]
186. WHO. Health Care-Associated Infections. FACT SHEET. 2014. Available online: https://www.who.int/gpsc/country_work/gpsc_ccisc_fact_sheet_en.pdf (accessed on 7 May 2021).
187. Mugomeri, E. The efficacy of infection prevention and control committees in Lesotho: A qualitative study. *Am. J. Infect. Control* **2018**, *46*, e13–e17. [[CrossRef](#)]
188. Gilbert, G.L.; Kerridge, I. The politics and ethics of hospital infection prevention and control: A qualitative case study of senior clinicians' perceptions of professional and cultural factors that influence doctors' attitudes and practices in a large Australian hospital. *BMC Health Serv. Res.* **2019**, *19*, 212. [[CrossRef](#)] [[PubMed](#)]
189. Mpinda-Joseph, P.; Anand Paramadhas, B.D.; Reyes, G.; Maruatona, M.B.; Chise, M.; Monokwane-Thupiso, B.B.; Souda, S.; Tiroyakgosi, C.; Godman, B. Healthcare-associated infections including neonatal bloodstream infections in a leading tertiary hospital in Botswana. *Hosp. Pract.* **2019**, *47*, 203–210. [[CrossRef](#)] [[PubMed](#)]
190. WHO. Minimum Requirements for Infection Prevention and Control Programmes. 2019. Available online: <https://www.who.int/publications/i/item/9789241516945> (accessed on 8 May 2021).
191. Li, M.; Wang, X.; Wang, J.; Tan, R.; Sun, J.; Li, L.; Huang, J.; Wu, J.; Gu, Q.; Zhao, Y.; et al. Infection-prevention and control interventions to reduce colonisation and infection of intensive care unit-acquired carbapenem-resistant *Klebsiella pneumoniae*: A 4-year quasi-experimental before-and-after study. *Antimicrob. Resist. Infect. Control* **2019**, *8*, 8. [[CrossRef](#)]
192. Infection Control Africa Network (ICAN). Training Course: Infection Prevention and Control for Healthcare Workers 12–16 April 2021. Available online: <http://www.icanetwork.co.za/training-course-infection-prevention-and-control-for-healthcare-workers-12-16-april-2021/> (accessed on 8 May 2021).
193. Kurdi, A.; Hasan, A.J.; Baker, K.I.; Seaton, R.A.; Ramzi, Z.S.; Sneddon, J.; Godman, B. A multicentre point prevalence survey of hospital antibiotic prescribing and quality indices in the Kurdistan Regional Government of Northern Iraq: The need for urgent action. *Expert Rev. Anti-Infect. Ther.* **2021**, *19*, 805–814. [[CrossRef](#)] [[PubMed](#)]
194. Momanyi, L.; Opanga, S.; Nyamu, D.; Oluka, M.; Kurdi, A.; Godman, B. Antibiotic prescribing patterns at a leading referral hospital in Kenya: A point prevalence survey. *J. Res. Pharm. Pract.* **2019**, *8*, 149–154. [[CrossRef](#)]
195. Allegranzi, B.; Bagheri Nejad, S.; Chraïti, M.; Combescuré, C.; Attar, H.; Pittet, D. *Report on the Burden of Endemic Health Care-Associated Infection Worldwide*; World Health Organization: Geneva, Switzerland, 2011.
196. Prevention, E.C.f.D.; Control Suetens, C.; Hopkins, S.; Kolman, J.; Högberg, L.D. *Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals: 2011–2012*; Publications Office of the European Union: Luxembourg, 2013.
197. Nejad, S.B.; Allegranzi, B.; Syed, S.B.; Ellis, B.; Pittet, D. Health-care-associated infection in Africa: A systematic review. *Bull. WHO* **2011**, *89*, 757–765. [[CrossRef](#)]
198. Rothe, C.; Schlaich, C.; Thompson, S. Healthcare-associated infections in sub-Saharan Africa. *J. Hosp. Infect.* **2013**, *85*, 257–267. [[CrossRef](#)]
199. Umscheid, C.A.; Mitchell, M.D.; Doshi, J.A.; Agarwal, R.; Williams, K.; Brennan, P.J. Estimating the Proportion of Healthcare-Associated Infections That Are Reasonably Preventable and the Related Mortality and Costs. *Infect. Control Hosp. Epidemiol.* **2011**, *32*, 101–114. [[CrossRef](#)] [[PubMed](#)]
200. Manoukian, S.; Stewart, S.; Dancer, S.; Graves, N.; Mason, H.; McFarland, A.; Robertson, C.; Reilly, J. Estimating excess length of stay due to healthcare-associated infections: A systematic review and meta-analysis of statistical methodology. *J. Hosp. Infect.* **2018**, *100*, 222–235. [[CrossRef](#)] [[PubMed](#)]
201. Ataiyero, Y.; Dyson, J.; Graham, M. Barriers to hand hygiene practices among health care workers in sub-Saharan African countries: A narrative review. *Am. J. Infect. Control* **2019**, *47*, 565–573. [[CrossRef](#)] [[PubMed](#)]
202. Afriyie, D.K.; Amponsah, S.K.; Dogbey, J.; Agyekum, K.; Kesse, S.; Truter, I.; Meyer, J.C.; Godman, B. A pilot study evaluating the prescribing of ceftriaxone in hospitals in Ghana: Findings and implications. *Hosp. Pract.* **2017**, *45*, 143–149. [[CrossRef](#)]
203. Dlamini, N.N.; Meyer, J.C.; Kruger, D.; Kurdi, A.; Godman, B.; Schellack, N. Feasibility of using point prevalence surveys to assess antimicrobial utilisation in public hospitals in South Africa: A pilot study and implications. *Hosp. Pract.* **2019**, *47*, 88–95. [[CrossRef](#)]

204. Kruger, D.; Dlamini, N.N.; Meyer, J.C.; Godman, B.; Kurdi, A.; Lennon, M.; Bennie, M.; Schellack, N. Development of a web-based application to improve data collection of antimicrobial utilization in the public health care system in South Africa. *Hosp. Pract.* **2021**, *2021*, 1–10. [CrossRef]
205. Skosana, P.P.; Schellack, N.; Godman, B.; Kurdi, A.; Bennie, M.; Kruger, D.; Meyer, J. A point prevalence survey of antimicrobial utilisation patterns and quality indices amongst hospitals in South Africa; findings and implications. *Expert Rev. Anti-Infect. Ther.* **2021**, *2021*, 1–13. [CrossRef]
206. BSAC. Practical Guide to Antimicrobial Stewardship in Hospitals. 2013. Available online: <http://bsac.org.uk/wp-content/uploads/2013/07/Stewardship-Booklet-Practical-Guide-to-Antimicrobial-Stewardship-in-Hospitals.pdf> (accessed on 7 May 2021).
207. BSAC. Antimicrobial Stewardship from Principles to Practice. 2018. Available online: <http://www.bsac.org.uk/antimicrobialstewardshipbook/BSAC-AntimicrobialStewardship-FromPrinciplestoPractice-eBook.pdf> (accessed on 7 May 2021).
208. Commonwealth Partnerships for Antimicrobial Stewardship. Working Together to Tackle Antimicrobial Resistance in the Commonwealth. 2020. Available online: <https://commonwealthpharmacy.org/commonwealth-partnerships-for-antimicrobial-stewardship/> (accessed on 8 May 2021).
209. World Health Organization. Antimicrobial Stewardship Programmes in Health-Care Facilities in Low- and Mid-Dle-Income Countries. A Who Practical Toolkit. 2019. Available online: <https://apps.who.int/iris/bitstream/handle/10665/329404/9789241515481-eng.pdf> (accessed on 10 May 2021).
210. Pulcini, C.; Binda, F.; Lamkang, A.S.; Trett, A.; Charani, E.; Goff, D.; Harbarth, S.; Hinrichsen, S.; Levy-Hara, G.; Mendelson, M.; et al. Developing core elements and checklist items for global hospital antimicrobial stewardship programmes: A consensus approach. *Clin. Microbiol. Infect.* **2019**, *25*, 20–25. [CrossRef] [PubMed]
211. CDC. The Core Elements of Human Antibiotic Stewardship Programs in Resource-Limited Settings: National and Hospital Levels. Available online: <https://www.cdc.gov/antibiotic-use/healthcare/implementation.html> (accessed on 8 May 2021).
212. Vu, T.L.; Vu, Q.D.; Hoang, B.L.; Nguyen, T.C.; Ta, T.D.; Nadjm, B.; van Doorn, H.R. Factors influencing choices of empirical antibiotic treatment for bacterial infections in a scenario-based survey in Vietnam. *JAC-Antimicrob. Resist.* **2020**, *2*, dlaa087. [CrossRef]
213. Kakkar, A.K.; Shafiq, N.; Singh, G.; Ray, P.; Gautam, V.; Agarwal, R.; Muralidharan, J.; Arora, P. Antimicrobial Stewardship Programs in Resource Constrained Environments: Understanding and Addressing the Need of the Systems. *Front. Public Health* **2020**, *8*, 140. [CrossRef]
214. Fadare, J.O.; Ogunleye, O.; Iliyasu, G.; Adeoti, A.; Schellack, N.; Engler, D.; Massele, A.; Godman, B. Status of antimicrobial stewardship programmes in Nigerian tertiary healthcare facilities: Findings and implications. *J. Glob. Antimicrob. Resist.* **2019**, *17*, 132–136. [CrossRef]
215. Kalungia, A.C.; Mwambula, H.; Munkombwe, D.; Marshall, S.; Schellack, N.; May, C.; Jones, A.S.C.; Godman, B. Antimicrobial stewardship knowledge and perception among physicians and pharmacists at leading tertiary teaching hospitals in Zambia: Implications for future policy and practice. *J. Chemother.* **2019**, *31*, 378–387. [CrossRef]
216. Gebretekle, G.B.; Haile Mariam, D.H.; Abebe, W.; Amogne, W.; Tenna, A.; Fenta, T.G.; Libman, M.; Yansouni, C.P.; Semret, M. Opportunities and barriers to implementing antibiotic stewardship in low and middle-income countries: Lessons from a mixed-methods study in a tertiary care hospital in Ethiopia. *PLoS ONE* **2018**, *13*, e0208447. [CrossRef] [PubMed]
217. Schellack, N.; Bronkhorst, E.; Coetzee, R.; Godman, B.; Gous, A.G.S.; Kolman SCoetzee, R.; Bronkhorst, E. SASOCP position statement on the pharmacist’s role in antibiotic stewardship South African. *J. Infect. Dis.* **2018**, *33*, 28–35.
218. Okoth, C.; Opanga, S.; Okalebo, F.; Oluka, M.; Baker Kurdi, A.; Godman, B. Point prevalence survey of antibiotic use and resistance at a referral hospital in Kenya: Findings and implications. *Hosp. Pract.* **2018**, *46*, 128–136. [CrossRef]
219. Lew, K.Y.; Ng, T.M.; Tan, M.; Tan, S.H.; Lew, E.L.; Ling, L.M.; Ang, B.; Lye, D.; Teng, C.B. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. *J. Antimicrob. Chemother.* **2014**, *70*, 1219–1225. [CrossRef]
220. Stanic Benic, M.; Milanic, R.; Monnier, A.A.; Gyssens, I.C.; Adriaenssens, N.; Versporten, A.; Zanichelli, V.; Le Maréchal, M.; Huttner, B.; Tebano, G.; et al. Metrics for quantifying antibiotic use in the hospital setting: Results from a systematic review and international multidisciplinary consensus procedure. *J. Antimicrob. Chemother.* **2018**, *73* (Suppl. 6), vi50–vi58. [CrossRef] [PubMed]
221. Mauger, B.; Marbella, A.; Pines, E.; Chopra, R.; Black, E.R.; Aronson, N. Implementing quality improvement strategies to reduce healthcare-associated infections: A systematic review. *Am. J. Infect. Control* **2014**, *42*, S274–S283. [CrossRef]
222. Luangasanatip, N.; Hongsuwan, M.; Limmathurotsakul, D.; Lubell, Y.; Lee, A.S.; Harbarth, S.; Day, N.P.; Graves, N.; Cooper, B.S. Comparative efficacy of inter-ventions to promote hand hygiene in hospital: Systematic review and network meta-analysis. *BMJ* **2015**, *351*, h3728. [CrossRef]
223. Loftus, M.J.; Guitart, C.; Tartari, E.; Stewardson, A.J.; Amer, F.; Bellissimo-Rodrigues, F.; Lee, Y.F.; Mehtar, S.; Sithole, B.L.; Pittet, D. Hand hygiene in low- and middle-income countries. *Int. J. Infect. Dis.* **2019**, *86*, 25–30. [CrossRef]
224. WHO. *Hand Hygiene Self-Assessment Framework*. Available online: https://www.who.int/gpsc/country_work/hhsa_framework_October_2010.pdf?ua=1 (accessed on 8 May 2021).
225. Malhotra, N.R.; Piazza, M.; Demoor, R.; McClintock, S.D.; Hamilton, K.; Sharma, N.; Osiemo, B.; Berger, I.; Hossain, E.; Borovskiy, Y.; et al. Impact of Reduced Preincision Antibiotic Infusion Time on Surgical Site Infection Rates: A Retrospective Cohort Study. *Ann. Surg.* **2020**, *271*, 774–780. [CrossRef]

226. Najjar, P.A.; Smink, D.S. Prophylactic Antibiotics and Prevention of Surgical Site Infections. *Surg. Clin. N. Am.* **2015**, *95*, 269–283. [[CrossRef](#)]
227. de Jonge, S.W.; Gans, S.L.; Ateman, J.J.; Solomkin, J.S.; Dellinger, P.E.; Boermeester, M.A. Timing of preoperative antibiotic prophylaxis in 54,552 patients and the risk of surgical site infection: A systematic review and meta-analysis. *Medicine* **2017**, *96*, e6903. [[CrossRef](#)] [[PubMed](#)]
228. Branch-Elliman, W.; O'Brien, W.; Strymish, J.; Itani, K.; Wyatt, C.; Gupta, K. Association of Duration and Type of Surgical Prophylaxis with Antimicrobial-Associated Adverse Events. *JAMA Surg.* **2019**, *154*, 590–598. [[CrossRef](#)] [[PubMed](#)]
229. Saito, H.; Inoue, K.; Ditai, J.; Weeks, A.D. Pattern of Peri-Operative Antibiotic Use among Surgical Patients in a Regional Referral and Teaching Hospital in Uganda. *Surg. Infect.* **2020**, *21*, 540–546. [[CrossRef](#)] [[PubMed](#)]
230. Harbarth, S.; Samore, M.H.; Lichtenberg, D.; Carmeli, Y. Prolonged Antibiotic Prophylaxis after Cardiovascular Surgery and Its Effect on Surgical Site Infections and Antimicrobial Resistance. *Circulation* **2000**, *101*, 2916–2921. [[CrossRef](#)]
231. Hawn, M.T.; Knowlton, L.M. Balancing the Risks and Benefits of Surgical Prophylaxis: Timing and Duration Do Matter. *JAMA Surg.* **2019**, *154*, 598–599. [[CrossRef](#)]
232. Bull, A.L.; Worth, L.J.; Spelman, T.; Richards, M.J. Antibiotic Prescribing Practices for Prevention of Surgical Site Infections in Australia: Increased Uptake of National Guidelines after Surveillance and Reporting and Impact on Infection Rates. *Surg. Infect.* **2017**, *18*, 834–840. [[CrossRef](#)]
233. Langerman, A.; Thisted, R.; Hohmann, S.; Howell, M. Antibiotic and Duration of Perioperative Prophylaxis Predicts Surgical Site Infection in Head and Neck Surgery. *Otolaryngol. Neck Surg.* **2016**, *154*, 1054–1063. [[CrossRef](#)]
234. Vicentini, C.; Politano, G.; Corcione, S.; Furmenti, M.F.; Quattrocolo, F.; De Rosa, F.G.; Zotti, C.M. Surgical antimicrobial prophylaxis prescribing practices and impact on infection risk: Results from a multicenter surveillance study in Italy (2012–2017). *Am. J. Infect. Control* **2019**, *47*, 1426–1430. [[CrossRef](#)]
235. Nthumba, P.M. Effective Hand Preparation for Surgical Procedures in Low- and Middle-Income Countries. *Surg. Infect.* **2020**, *21*, 495–500. [[CrossRef](#)]
236. Davey, P.; Peden, C.; Brown, E.; Charani, E.; Michie, S.; Ramsay, C.R.; Marwick, C.A. Interventions to improve antibiotic prescribing practices for hospital inpatients (updated protocol). *Cochrane Database Syst. Rev.* **2014**, *2*, Cd003543. [[CrossRef](#)]
237. McLeod, M.; Ahmad, R.; Shebl, N.A.; Micallef, C.; Sim, F.; Holmes, A. A whole-health–economy approach to antimicrobial stewardship: Analysis of current models and future direction. *PLoS Med.* **2019**, *16*, e1002774. [[CrossRef](#)]
238. Curtis, C.E.; Al Bahar, F.; Marriott, J.F. The effectiveness of computerised decision support on antibiotic use in hospitals: A systematic review. *PLoS ONE* **2017**, *12*, e0183062. [[CrossRef](#)]
239. Tahoon, M.A.; Khalil, M.M.; Hammad, E.; Morad, W.S.; Awad, S.M.; Ezzat, S. The effect of educational intervention on healthcare providers' knowledge, attitude, & practice towards antimicrobial stewardship program at, National Liver Institute, Egypt. *Egypt. Liver J.* **2020**, *10*, 5.
240. Majumder, M.A.A.; Singh, K.; Hilaire, M.G.; Rahman, S.; Sa, B.; Haque, M. Tackling Antimicrobial Resistance by promoting Anti-microbial stewardship in Medical and Allied Health Professional Curricula. *Expert Rev. Anti-Infect. Ther.* **2020**, *18*, 1245–1258. [[CrossRef](#)] [[PubMed](#)]
241. Bozkurt, F.; Kaya, S.; Tekin, R.; Gulsun, S.; Deveci, O.; Dayan, S.; Hosoglu, S. Analysis of antimicrobial consumption and cost in a teaching hospital. *J. Infect. Public Health* **2014**, *7*, 161–169. [[CrossRef](#)]
242. Hou, D.; Wang, Q.; Jiang, C.; Tian, C.; Li, H.; Ji, B. Evaluation of the Short-Term Effects of Antimicrobial Stewardship in the Intensive Care Unit at a Tertiary Hospital in China. *PLoS ONE* **2014**, *9*, e101447. [[CrossRef](#)]
243. Amdany, H.K.; McMillan, M. Metronidazole intravenous formulation use in in-patients in Kapkatet District Hospital, Kenya: A best practice implementation project. *JBI Database Syst. Rev. Implement. Rep.* **2014**, *12*, 419–432. [[CrossRef](#)]
244. Yang, Z.; Zhao, P.; Wang, J.; Tong, L.; Cao, J.; Tian, Y.; Yao, Z.; Wang, J.; Zhu, Y.; Jia, Y.; et al. DRUGS System Enhancing Adherence of Chinese Surgeons to Antibiotic Use Guidelines during Perioperative Period. *PLoS ONE* **2014**, *9*, e102226. [[CrossRef](#)] [[PubMed](#)]
245. Okumura, L.M.; Da Silva, M.M.G.; Veroneze, I. Effects of a bundled Antimicrobial Stewardship Program on mortality: A cohort study. *Braz. J. Infect. Dis.* **2015**, *19*, 246–252. [[CrossRef](#)]
246. Okumura, L.M.; Riveros, B.S.; Gomes-da-Silva, M.M.; Veroneze, I. A cost-effectiveness analysis of two different antimicrobial stewardship programs. *Braz. J. Infect. Dis. Off. Publ. Braz. Soc. Infect. Dis.* **2016**, *20*, 255–261.
247. Saied, T.; Hafez, S.F.; Kandeel, A.; El-Kholy, A.; Ismail, G.; Aboushady, M.; Attia, E.; Hassaan, A.; Abdel-Atty, O.; Elfekky, E.; et al. Antimicrobial stewardship to optimize the use of antimicrobials for surgical prophylaxis in Egypt: A multicenter pilot intervention study. *Am. J. Infect. Control* **2015**, *43*, e67–e71. [[CrossRef](#)] [[PubMed](#)]
248. Ntumba, P.; Mwangi, C.; Barasa, J.; Aiken, A.M.; Kubilay, Z.; Allegranzi, B. Multimodal approach for surgical site infection prevention—Results from a pilot site in Kenya. *Antimicrob. Resist. Infect. Control* **2015**, *4*, 87. [[CrossRef](#)]
249. Apisarnthanarak, A.; Lapcharoen, P.; Vanichkul, P.; Srisaeng-Ngoen, T.; Mundy, L.M. Design and analysis of a pharmacist-enhanced antimicrobial stewardship program in Thailand. *Am. J. Infect. Control* **2015**, *43*, 956–959. [[CrossRef](#)] [[PubMed](#)]
250. Boyles, T.H.; Naicker, V.; Rawoot, N.; Raubenheimer, P.J.; Eick, B.; Mendelson, M. Sustained reduction in antibiotic consumption in a South African public sector hospital; Four year outcomes from the Groote Schuur Hospital antibiotic stewardship program. *S. Afr. Med. J.* **2017**, *107*, 115–118. [[CrossRef](#)]

251. Brink, A.J.; Messina, A.P.; Feldman, C.; Richards, G.A.; van den Bergh, D. From guidelines to practice: A pharmacist-driven prospective audit and feedback improvement model for perioperative antibiotic prophylaxis in 34 South African hospitals. *J. Antimicrob. Chemother.* **2016**, *72*, 1227–1234. [[CrossRef](#)]
252. Allegranzi, B.; Aiken, A.M.; Zeynep Kubilay, N.; Nthumba, P.; Barasa, J.; Okumu, G.; Mugarura, R.; Elobu, A.; Jombwe, J.; Maimbo, M.; et al. A multimodal infection control and patient safety intervention to reduce surgical site infections in Africa: A multicentre, before–after, cohort study. *Lancet Infect. Dis.* **2018**, *18*, 507–515. [[CrossRef](#)]
253. Khmour, M.R.; Hallak, H.O.; Aldeyab, M.A.; Nasif, M.A.; Khalili, A.M.; Dallashi, A.A.; Khofash, M.B.; Scott, M.G. Impact of antimicrobial stewardship programme on hospitalized patients at the intensive care unit: A prospective audit and feedback study. *Br. J. Clin. Pharmacol.* **2018**, *84*, 708–715. [[CrossRef](#)] [[PubMed](#)]
254. Abubakar, U.; Syed Sulaiman, S.A.; Adesiyun, A.G. Impact of pharmacist-led antibiotic stewardship interventions on compliance with surgical antibiotic prophylaxis in obstetric and gynecologic surgeries in Nigeria. *PLoS ONE* **2019**, *14*, e0213395. [[CrossRef](#)] [[PubMed](#)]
255. Karaali, C.; Emiroglu, M.; Atalay, S.; Sert, I.; Dursun, A.; Kose, S.; Akbulut, G.; Aydın, C. A new antibiotic stewardship program approach is effective on inappropriate surgical prophylaxis and discharge prescription. *J. Infect. Dev. Ctries.* **2019**, *13*, 961–967. [[CrossRef](#)]
256. Mahmouidi, L.; Ghouchani, M.; Mahi-Birjand, M.; Bananzadeh, A.; Akbari, A. Optimizing compliance with surgical antimicrobial prophylaxis guidelines in patients undergoing gastrointestinal surgery at a referral teaching hospital in southern Iran: Clinical and economic impact. *Infect. Drug Resist.* **2019**, *12*, 2437–2444. [[CrossRef](#)]
257. Xiao, Y.; Shen, P.; Zheng, B.; Zhou, K.; Luo, Q.; Li, L. Change in Antibiotic Use in Secondary and Tertiary Hospitals Nationwide after a National Antimicrobial Stewardship Campaign Was Launched in China, 2011–2016: An Observational Study. *J. Infect. Dis.* **2020**, *221*, S148–S155. [[CrossRef](#)]
258. Mardani, M.; Abolghasemi, S.; Shabani, S. Impact of an antimicrobial stewardship program in the antimicrobial-resistant and prevalence of clostridioides difficile infection and amount of antimicrobial consumed in cancer patients. *BMC Res. Notes* **2020**, *13*, 246. [[CrossRef](#)] [[PubMed](#)]
259. van den Bergh, D.; Messina, A.P.; Goff, D.A.; van Jaarsveld, A.; Coetzee, R.; de Wet, Y.; Bronkhorst, E.; Brink, A.; Mendelson, M.; Richards, G.A. A pharmacist-led prospective antibiotic stewardship intervention improves compliance to community-acquired pneumonia guidelines in 39 public and private hospitals across South Africa. *Int. J. Antimicrob. Agents* **2020**, *56*, 106189. [[CrossRef](#)] [[PubMed](#)]
260. Dinh, A.; Duran, C.; Davido, B.; Bouchand, F.; Deconinck, L.; Matt, M.; Sénard, O.; Guyot, C.; Levasseur, A.-S.; Attal, J.; et al. Impact of an antimicrobial stewardship programme to optimize antimicrobial use for outpatients at an emergency department. *J. Hosp. Infect.* **2017**, *97*, 288–293. [[CrossRef](#)]
261. Bishop, B.M. Antimicrobial Stewardship in the Emergency Department: Challenges, Opportunities, and a Call to Action for Pharmacists. *J. Pharm. Pract.* **2015**, *29*, 556–563. [[CrossRef](#)] [[PubMed](#)]
262. Acosta, A.; Vanegas, E.P.; Rovira, J.; Godman, B.; Bochenek, T. Medicine Shortages: Gaps between Countries and Global Perspectives. *Front. Pharm.* **2019**, *10*. [[CrossRef](#)] [[PubMed](#)]
263. Modisakeng, C.; Matlala, M.; Godman, B.; Meyer, J.C. Medicine shortages and challenges with the procurement process among public sector hospitals in South Africa; findings and implications. *BMC Health Serv. Res.* **2020**, *20*, 234. [[CrossRef](#)]
264. Chigome, A.K.; Matlala, M.; Godman, B.; Meyer, J.C. Availability and Use of Therapeutic Interchange Policies in Managing Antimicrobial Shortages among South African Public Sector Hospitals; Findings and Implications. *Antibiotics* **2019**, *9*, 4. [[CrossRef](#)]
265. Gundlapalli, A.V.; Beekmann, S.E.; Graham, D.R.; Polgreen, P.M. Perspectives and concerns regarding antimicrobial agent shortages among infectious disease specialists. *Diagn. Microbiol. Infect. Dis.* **2013**, *75*, 256–259. [[CrossRef](#)]
266. Pulcini, C.; Beovic, B.; Béraud, G.; Carlet, J.; Cars, O.; Howard, P.; Levy-Hara, G.; Li, G.; Nathwani, D.; Roblot, F.; et al. Ensuring universal access to old antibiotics: A critical but neglected priority. *Clin. Microbiol. Infect.* **2017**, *23*, 590–592. [[CrossRef](#)] [[PubMed](#)]
267. Schellack, N.; Coetzee, M.; Schellack, G.; Gijzelaar, M.; Hassim, Z.; Milne, M.; Bronkhorst, E.; Padayachee, N.; Singh, N.; Kolman, S.; et al. COVID-19: Guidelines for pharmacists in South Africa. *S. Afr. J. Infect. Dis.* **2020**, *35*, 10. [[CrossRef](#)]
268. Uzochukwu, B.; Onwujekwe, O.; Eriksson, B. Inequity in the Bamako Initiative programme—Implications for the treatment of malaria in south-east Nigeria. *Int. J. Health Plan. Manag.* **2004**, *19*, S107–S116. [[CrossRef](#)]
269. Omololu, F.O.; Okunola, R.A.; Salami, K.K. Equity and access to health care services: The experience of the Bamako initiative programme in Nigeria. *J. Med. Med. Sci.* **2012**, *3*, 434–442.
270. Ogbonna, B.O.; Nwako, N.N. Essential Drugs Revolving Fund Scheme in Nigeria; from the Edge of a Precipice towards Sustainability. *J. Adv. Med. Pharm. Sci.* **2016**, *8*, 1–8. [[CrossRef](#)]
271. Shaikhan, F.; Rawaf, S.; Majeed, A.; Hassounah, S. Knowledge, attitude, perception and practice regarding antimicrobial use in upper respiratory tract infections in Qatar: A systematic review. *JRSM Open* **2018**, *9*, 2054270418774971. [[CrossRef](#)]
272. Erku, D.A.; Mekuria, A.B.; Belachew, S.A. Inappropriate use of antibiotics among communities of Gondar town, Ethiopia: A threat to the development of antimicrobial resistance. *Antimicrob. Resist. Infect. Control* **2017**, *6*, 112. [[CrossRef](#)]
273. Wei, X.; Zhang, Z.; Hicks, J.P.; Walley, J.D.; King, R.; Newell, J.N.; Yin, J.; Zeng, J.; Guo, Y.; Lin, M.; et al. Long-term outcomes of an educational intervention to reduce antibiotic prescribing for childhood upper respiratory tract infections in rural China: Follow-up of a cluster-randomised controlled trial. *PLoS Med.* **2019**, *16*, e1002733. [[CrossRef](#)] [[PubMed](#)]

274. Holloway, K.A.; Ivanovska, V.; Wagner, A.K.; Vialle-Valentin, C.; Ross-Degnan, D. Prescribing for acute childhood infections in developing and transitional countries, 1990–2009. *Paediatr. Int. Child Health* **2015**, *35*, 5–13. [[CrossRef](#)]
275. Kibuule, D.; Kagoya, H.R.; Godman, B. Antibiotic use in acute respiratory infections in under-fives in Uganda: Findings and implications. *Expert Rev. Anti-Infect. Ther.* **2016**, *14*, 863–872. [[CrossRef](#)]
276. Farley, E.; Stewart, A.; Davies, M.-A.; Govind, M.; Van den Bergh, D.; Boyles, T.H. Antibiotic use and resistance: Knowledge, attitudes and perceptions among primary care prescribers in South Africa. *S. Afr. Med. J.* **2018**, *108*, 763–771. [[CrossRef](#)]
277. Teng, C.L.; Achike, F.I.; Phua, K.L.; Nurjahan, M.I.; Mastura, I.; Asiah, H.N.; Mariam, A.M.; Narayanan, S.; Norsiah, A.; Sabariah, I.; et al. Modifying antibiotic prescribing: The effectiveness of academic detailing plus information leaflet in a Malaysian primary care setting. *Med. J. Malays.* **2006**, *61*, 323–331.
278. Shrestha, N.; Samir, K.C.; Baltussen, R.; Kafle, K.K.; Bishai, D.; Niessen, L. Practical Approach to Lung Health in Nepal: Better prescribing and reduction of cost. *Trop. Med. Int. Health* **2006**, *11*, 765–772. [[CrossRef](#)]
279. Awad, A.I.; Eltayeb, I.B.; Baraka, O.Z. Changing antibiotics prescribing practices in health centers of Khartoum State, Sudan. *Eur. J. Clin. Pharm.* **2006**, *62*, 135–142. [[CrossRef](#)]
280. Kafle, K.K.; Bhujju, G.B.; Karkee, S.B.; Prasad, R.R.; Shrestha, N.; Shrestha, A.D.; Das, P.L.; Chataut, P.D.; Daud, M. An intervention improving prescribing practices and monitoring drugs availability in a district. *Nepal Med. Coll. J.* **2009**, *11*, 217–221. [[PubMed](#)]
281. Yip, W.; Powell-Jackson, T.; Chen, W.; Hu, M.; Fe, E.; Hu, M.; Jian, W.; Lu, M.; Han, W.; Hsiao, W.C. Capitation combined with pay-for-performance improves antibiotic prescribing practices in rural China. *Health Aff.* **2014**, *33*, 502–510. [[CrossRef](#)]
282. Boonyasiri, A.; Thamlikitkul, V. Effectiveness of multifaceted interventions on rational use of antibiotics for patients with upper respiratory tract infections and acute diarrhea. *J. Med. Assoc. Thail. Chotmaihet Thangphaet* **2014**, *97* (Suppl. 3), S13–S19.
283. Tay, K.H.; Ariffin, F.; Sim, B.L.; Chin, S.Y.; Sobry, A.C. Multi-Faceted Intervention to Improve the Antibiotic Prescriptions among Doctors for Acute URI and Acute Diarrhoea Cases: The Green Zone Antibiotic Project. *Malays. J. Med. Sci.* **2019**, *26*, 101–109. [[CrossRef](#)] [[PubMed](#)]
284. Ofori-Asenso, R.; Brhlikova, P.; Pollock, A.M. Prescribing indicators at primary health care centers within the WHO African region: A systematic analysis (1995–2015). *BMC Public Health* **2016**, *16*, 724. [[CrossRef](#)] [[PubMed](#)]
285. Rwegerera, G.M.; Shailemo, D.H.P.; Pina Rivera, Y.; Mokgosi, K.O.; Bale, P.; Oyewo, T.A.; Luis, B.D.; Habte, D.; Godman, B. Metabolic Control and Determinants among HIV-Infected Type 2 Diabetes Mellitus Patients Attending a Tertiary Clinic in Botswana. *Diabetes Metab. Syndr. Obes.* **2021**, *14*, 85–97. [[CrossRef](#)] [[PubMed](#)]
286. Mwita, J.C.; Godman, B.; Esterhuizen, T.M. Statin prescription among patients with type 2 diabetes in Botswana: Findings and implications. *BMC Endocr. Disord.* **2020**, *20*, 36. [[CrossRef](#)]
287. Achwoka, D.; Waruru, A.; Chen, T.-H.; Masamaro, K.; Ngugi, E.; Kimani, M.; Mukui, I.; Oyugi, J.O.; Mutave, R.; Achia, T.; et al. Noncommunicable disease burden among HIV patients in care: A national retrospective longitudinal analysis of HIV-treatment outcomes in Kenya, 2003–2013. *BMC Public Health* **2019**, *19*, 372. [[CrossRef](#)]
288. Appiah, L.T.; Sarfo, F.S.; Huffman, M.D.; Nguah, S.B.; Stiles, J.K. Cardiovascular risk factors among Ghanaian patients with HIV: A cross-sectional study. *Clin. Cardiol.* **2019**, *42*, 1195–1201. [[CrossRef](#)]
289. Chang, A.Y.; Gómez-Olivé, F.X.; Manne-Goehler, J.; Wade, A.N.; Tollman, S.; Gaziano, T.A.; Salomon, J.A. Multimorbidity and care for hypertension, diabetes and HIV among older adults in rural South Africa. *Bull. World Health Organ* **2018**, *97*, 10–23. [[CrossRef](#)] [[PubMed](#)]
290. Fernandez Urrusuno, R.; Flores Dorado, M.; Vilches Arenas, A.; Serrano Martino, C.; Corral Baena, S.; Montero Balosa, M.C. Improving the appropriateness of antimicrobial use in primary care after implementation of a local antimicrobial guide in both levels of care. *Eur. J. Clin. Pharmacol.* **2014**, *70*, 1011–1020. [[CrossRef](#)] [[PubMed](#)]
291. Kibuule, D.; Mubita, M.; Naikaku, E.; Kalemeera, F.; Godman, B.B.; Sagwa, E. An analysis of policies for cotrimoxazole, amoxicillin and azithromycin use in Namibia’s public sector: Findings and therapeutic implications. *Int. J. Clin. Pract.* **2017**, *71*, e12918. [[CrossRef](#)]
292. Mashalla, Y.J.; Sepako, E.; Setlhare, V.; Chuma, M.; Bulang, M.; Massele, A.Y. Availability of guidelines and policy documents for enhancing performance of practitioners at the Primary Health Care (PHC) facilities in Gaborone, Tlokweng and Mogoditshane, Republic of Botswana. *J. Public Health Epidemiol.* **2016**, *8*, 127–135.
293. Meyer, J.C.; Schellack, N.; Stokes, J.; Lancaster, R.; Zeeman, H.; Defty, D.; Godman, B.; Steel, G. Ongoing Initiatives to Improve the Quality and Efficiency of Medicine Use within the Public Healthcare System in South Africa; A Preliminary Study. *Front. Pharmacol.* **2017**, *8*, 751. [[CrossRef](#)] [[PubMed](#)]
294. Rossato, L.; Negrão, F.J.; Simionatto, S. Could the COVID-19 pandemic aggravate antimicrobial resistance? *Am. J. Infect. Control* **2020**, *48*, 1129–1130. [[CrossRef](#)]
295. Ray, K.N.; Shi, Z.; Gidengil, C.A.; Poon, S.J.; Uscher-Pines, L.; Mehrotra, A. Antibiotic Prescribing During Pediatric Direct-to-Consumer Telemedicine Visits. *Pediatrics* **2019**, *143*, e20182491. [[CrossRef](#)]
296. Hayat, K.; Li, P.; Rosenthal, M.; Xu, S.; Chang, J.; Gillani, A.H.; Khan, F.U.; Sarwar, M.R.; Ji, S.; Shi, L.; et al. Perspective of community pharmacists about community-based antimicrobial stewardship programs. A multicenter cross-sectional study from China. *Expert Rev. Anti-Infect. Ther.* **2019**, *17*, 1043–1050. [[CrossRef](#)]
297. Poyongo, B.P.; Sangeda, R.Z. Pharmacists’ Knowledge, Attitude and Practice Regarding the Dispensing of Antibiotics without Prescription in Tanzania: An Explorative Cross-Sectional Study. *Pharmacy* **2020**, *8*, 238. [[CrossRef](#)] [[PubMed](#)]

298. Zawahir, S.; Lekamwasam, S.; Aslani, P. A cross-sectional national survey of community pharmacy staff: Knowledge and anti-biotic provision. *PLoS ONE* **2019**, *14*, e0215484. [[CrossRef](#)] [[PubMed](#)]
299. Haque, M.; Kumar, S.; Charan, J.; Bhatt, R.; Islam, S.; Dutta, S.; Abhayanand, J.P.; Sharma, Y.; Sefah, I.A.; Kurdi, A.; et al. Utilisation, availability and price changes of medicines and protection equipment for COVID-19 in India: Findings and implications Short title: COVID-19 and price changes of treatments in India. *Front. Pharmacol.* **2021**, *11*, 1822. [[CrossRef](#)] [[PubMed](#)]
300. Selvaraj, S.; Farooqui, H.H.; Karan, A. Quantifying the financial burden of households' out-of-pocket payments on medicines in India: A repeated cross-sectional analysis of National Sample Survey data, 1994–2014. *BMJ Open* **2018**, *8*, e018020. [[CrossRef](#)] [[PubMed](#)]
301. Essack, S.; Bell, J.; Shephard, A. Community pharmacists-Leaders for antibiotic stewardship in respiratory tract infection. *J. Clin. Pharm. Ther.* **2018**, *43*, 302–307. [[CrossRef](#)]
302. Wirtz, V.; Herrera-Patino, J.J.; Santa-Ana-Tellez, Y.; Dreser, A.; Elseviers, M.; Vander Stichele, R. Analysing policy interventions to prohibit over-the-counter antibiotic sales in four Latin American countries. *Trop. Med. Int. Health* **2013**, *18*, 665–673. [[CrossRef](#)]
303. Vacca, C.P.; Niño, C.Y.; Reveiz, L. Restriction of antibiotic sales in pharmacies in Bogotá, Colombia: A descriptive study. *Rev. Panam. De Salud Pública* **2011**, *30*, 586–591.
304. Godman, B.; Sakshaug, S.; Berg, C.; Wettermark, B.; Haycox, A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. *Expert Rev. Pharm. Outcomes Res.* **2011**, *11*, 121–129. [[CrossRef](#)] [[PubMed](#)]
305. Voncina, L.; Strizrep, T.; Godman, B.; Bennie, M.; Bishop, I.; Campbell, S.; Vlahović-Palčevski, V.; Gustafsson, L.L. Influence of demand-side measures to enhance ren-in-angiotensin prescribing efficiency in Europe: Implications for the future. *Expert Rev. Pharm. Outcomes Res.* **2011**, *11*, 469–479.
306. Godman, B.; Bishop, I.; Finlayson, A.E.; Campbell, S.; Kwon, H.-Y.; Bennie, M. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. *Expert Rev. Pharm. Outcomes Res.* **2013**, *13*, 469–482. [[CrossRef](#)]
307. Santa-Ana-Tellez, Y.; Mantel-Teeuwisse, A.K.; Dreser, A.; Leufkens, H.G.; Wirtz, V.J. Impact of over-the-counter restrictions on antibiotic consumption in Brazil and Mexico. *PLoS ONE* **2013**, *8*, e75550. [[CrossRef](#)] [[PubMed](#)]
308. Moura, M.L.; Boszczowski, I.; Mortari, N.; Barrozo, L.V.; Chiaravalloti Neto, F.; Lobo, R.D.; de Lima, A.C.; Levin, A.S. The Impact of Restricting Over-the-Counter Sales of Antimicrobial Drugs: Preliminary Analysis of National Data. *Medicine* **2015**, *94*, e1605. [[CrossRef](#)] [[PubMed](#)]
309. Lopes-Júnior, R.; de Sa Del Fiol, F.; Araujo, J.L.O.; De Toledo, M.I.; Barberato-Filho, S. Decrease in Penicillin Sales in Brazil after Over-the-Counter Restrictions. *Antimicrob. Agents Chemother.* **2015**, *59*, 5862–5863. [[CrossRef](#)] [[PubMed](#)]
310. Mattos, K.P.H.; Visacri, M.B.; Quintanilha, J.C.F.; Lloret, G.R.; Cursino, M.A.; Levin, A.S.; Levy, C.E.; Moriel, P. Brazil's resolutions to regulate the sale of antibiotics: Impact on consumption and Escherichia coli resistance rates. *J. Glob. Antimicrob. Resist.* **2017**, *10*, 195–199. [[CrossRef](#)]
311. Arparsrithongsagul, S.; Kulsomboon, V.; Zuckerman, I.H. Multidisciplinary Perspective Intervention with Community Involvement to Decrease Antibiotic Sales in Village Groceries in Thailand. *Asia Pac. J. Public Health* **2013**, *27*, NP2480–NP2488. [[CrossRef](#)]
312. Markovic-Pekovic, V.; Grubisa, N. Self-medication with antibiotics in the Republic of Srpska community pharmacies: Pharmacy staff behavior. *Pharmacoepidemiol. Drug Saf.* **2012**, *21*, 1130–1133. [[CrossRef](#)]
313. Oponga, S.A.; Rizvi, N.; Wamaitha, A.; Sefah, I.A.; Godman, B. Availability of Medicines in Community Pharmacy to Manage Patients with COVID-19 in Kenya: Pilot Study and Implications. *Sch. Acad. J. Pharm.* **2021**, *10*, 36–42.
314. Roque, F.; Soares, S.; Breitenfeld, L.; López-Durán, A.; Figueiras, A.; Herdeiro, M.T. Attitudes of community pharmacists to antibiotic dispensing and microbial resistance: A qualitative study in Portugal. *Int. J. Clin. Pharm.* **2013**, *35*, 417–424. [[CrossRef](#)]
315. Barker, A.K.; Brown, K.; Ahsan, M.; Sengupta, S.; Safdar, N. What drives inappropriate antibiotic dispensing? A mixed-methods study of pharmacy employee perspectives in Haryana, India. *BMJ Open* **2017**, *7*, e013190. [[CrossRef](#)]
316. Hassali, M.A.; Kamil, T.K.T.; Md Yusof, F.A.; Alrasheedy, A.A.; Yusoff, Z.M.; Saleem, F.; Al-Tamimi, S.K.; Wong, Z.Y.; Aljadhey, H.; Godman, B. General practitioners' knowledge, attitude and prescribing of antibiotics for upper respiratory tract infections in Selangor, Malaysia: Findings and implications. *Expert Rev. Anti-Infect. Ther.* **2015**, *13*, 511–520. [[CrossRef](#)]
317. McNulty, C.A.M.; Nichols, T.; French, D.P.; Joshi, P.; Butler, C.C. Expectations for consultations and antibiotics for respiratory tract infection in primary care: The RTI clinical iceberg. *Br. J. Gen. Pract.* **2013**, *63*, e429–e436. [[CrossRef](#)]
318. Cross, E.L.; Tolfree, R.; Kipping, R. Systematic review of public-targeted communication interventions to improve antibiotic use. *J. Antimicrob. Chemother.* **2016**, *72*, 975–987. [[CrossRef](#)]
319. Lim, K.K.; Teh, C.C. A Cross Sectional Study of Public Knowledge and Attitude towards Antibiotics in Putrajaya, Malaysia. *South. Med. Rev.* **2012**, *5*, 26–33. [[PubMed](#)]
320. McCullough, A.R.; Parekh, S.; Rathbone, J.; Del Mar, C.B.; Hoffmann, T.C. A systematic review of the public's knowledge and beliefs about antibiotic resistance. *J. Antimicrob. Chemother.* **2016**, *71*, 27–33. [[CrossRef](#)] [[PubMed](#)]
321. Rather, I.A.; Kim, B.-C.; Bajpai, V.K.; Park, Y.-H. Self-medication and antibiotic resistance: Crisis, current challenges, and prevention. *Saudi J. Biol. Sci.* **2017**, *24*, 808–812. [[CrossRef](#)] [[PubMed](#)]
322. Monnet, D.L.; Safrany, N.; Heine, N.; Price, C. Comment on: A systematic review of the public's knowledge and beliefs about antibiotic resistance. *J. Antimicrob. Chemother.* **2016**, *71*, 2364–2365. [[CrossRef](#)]

323. Barker, A.K.; Brown, K.; Ahsan, M.; Sengupta, S.; Safdar, N. Social determinants of antibiotic misuse: A qualitative study of community members in Haryana, India. *BMC Public Health* **2017**, *17*, 333. [CrossRef]
324. Elong Ekambi, G.-A.; Okalla Ebongue, C.; Penda, I.C.; Nnanga Nga, E.; Mpondo Mpondo, E.; Eboumbou Moukoko, C.E. Knowledge, practices and attitudes on antibiotics use in Cameroon: Self-medication and prescription survey among children, adolescents and adults in private pharmacies. *PLoS ONE* **2019**, *14*, e0212875. [CrossRef]
325. Ashiru-Oredope, D.; Hopkins, S. Antimicrobial resistance: Moving from professional engagement to public action. *J. Antimicrob. Chemother.* **2015**, *70*, 2927–2930. [CrossRef]
326. Shallcross, L.J.; Howard, S.J.; Fowler, T.; Davies, S.C. Tackling the threat of antimicrobial resistance: From policy to sustainable action. *Philos. Trans. R. Soc. B Biol. Sci.* **2015**, *370*, 20140082. [CrossRef]
327. Behaviour Change for Antibiotic Prescribing in Healthcare Settings. Literature Review and Behavioural Analysis. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/405031/Behaviour_Change_for_Antibiotic_Prescribing_-_FINAL.pdf (accessed on 10 May 2021).
328. WHO Collaborating Centre on Patient Safety. The University of Geneva Hospitals and Faculty of Medicine. Evaluation of Antibiotic Awareness Campaigns. Available online: https://www.who.int/selection_medicines/committees/expert/21/applications/s6_antibiotic_awareness_campaigns.pdf (accessed on 10 May 2021).
329. Ivanovska, V.; Angelovska, B.; Van Dijk, L.; Zdravkovska, M.; Leufkens, H.G.; Mantel-Teeuwisse, A.K. Change in parental knowledge, attitudes and practice of antibiotic use after a national intervention programme. *Eur. J. Public Health* **2018**, *28*, 724–729. [CrossRef] [PubMed]
330. Huttner, B.; Goossens, H.; Verheij, T.; Harbarth, S. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. *Lancet Infect. Dis.* **2010**, *10*, 17–31. [CrossRef]
331. Local Campaign on Antibiotics Alliance (LOCAAL) study group. Doctors and local media: A synergy for public health information? A controlled trial to evaluate the effects of a multifaceted campaign on antibiotic prescribing (protocol). *BMC Public Health* **2011**, *11*, 816.
332. Hornik, R.; Kelly, B. Communication and diet: An overview of experience and principles. *J. Nutr. Educ. Behav.* **2007**, *39* (Suppl. 2), S5–S12. [CrossRef]
333. Ali, A.O.A.; Prins, M.H. Disease and treatment-related factors associated with tuberculosis treatment default in Khartoum State, Sudan: A case-control study. *East. Mediterr. Health J.* **2017**, *23*, 408–414. [CrossRef] [PubMed]
334. Ambaw, A.D.; Alemie, G.A.; W/Yohannes, S.M.; Mengesha, Z.B. Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. *BMC Public Health* **2012**, *12*, 282. [CrossRef]
335. Mehra, M.; Cossrow, N.; Kambili, C.; Underwood, R.; Makkar, R.; Potluri, R. Assessment of tuberculosis burden in China using a dynamic disease simulation model. *Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis.* **2013**, *17*, 1186–1194. [CrossRef]
336. National Department of Health Republic of South Africa. Introduction of New Drugs and Drug Regimens for the Management of Drug Resistant Tuberculosis in South Africa: Policy Framework. Available online: <https://www.nicd.ac.za/assets/files/Introduction%20of%20new%20drugs%20and%20drug%20regimens%20for%20the%20management%20of%20drug%20resistant%20TB%20in%20SA%20-%202015.pdf> (accessed on 8 May 2021).
337. Edwards, A.; Oh, H.; Mircheva, I.; Hollander, C.; Joubert, K.; Schellack, N. An Ototoxicity Grading System Within a Mobile App (OtoCalc) for a Resource-Limited Setting to Guide Grading and Management of Drug-Induced Hearing Loss in Patients with Drug-Resistant Tuberculosis: Prospective, Cross-Sectional Case Series. *JMIR Mhealth Uhealth* **2020**, *8*, e14036. [CrossRef]
338. Knight, S.E.; Anyachebelu, E.J.; Geddes, R.; Maharaj, R. Impact of delayed introduction of sulfadoxine-pyrimethamine and artemether-lumefantrine on malaria epidemiology in KwaZulu-Natal, South Africa. *Trop. Med. Int. Health* **2009**, *14*, 1086–1092. [CrossRef]
339. Phillips, A.N.; Stover, J.; Cambiano, V.; Nakagawa, F.; Jordan, M.R.; Pillay, D.; Doherty, M.; Revill, P.; Bertagnolio, S. Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa. *J. Infect. Dis.* **2017**, *215*, 1362–1365. [CrossRef]
340. Banek, K.; Webb, E.L.; Smith, S.J.; Chandramohan, D.; Staedke, S.G. Adherence to treatment with artemether—Lumefantrine or amodiaquine—Artesunate for uncomplicated malaria in children in Sierra Leone: A randomized trial. *Malar. J.* **2018**, *17*, 222. [CrossRef] [PubMed]
341. Alipanah, N.; Jarlsberg, L.; Miller, C.; Linh, N.N.; Falzon, D.; Jaramillo, E.; Nahid, P. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. *PLoS Med.* **2018**, *15*, e1002595. [CrossRef]
342. Becker, N.; Cordeiro, L.S.; Poudel, K.C.; Sibiyi, T.E.; Sayer, A.G.; Sibeko, L.N. Individual, household, and community level barriers to ART adherence among women in rural Eswatini. *PLoS ONE* **2020**, *15*, e0231952. [CrossRef] [PubMed]
343. Marcolino, M.S.; Oliveira, J.A.Q.; D’Agostino, M.; Ribeiro, A.L.; Alkmim, M.B.M.; Novillo-Ortiz, D. The Impact of mHealth Interventions: Systematic Review of Systematic Reviews. *JMIR Mhealth Uhealth* **2018**, *6*, e23. [CrossRef] [PubMed]
344. Stephens, F.; Gandhi, N.R.; Brust, J.C.M.; Mlisana, K.; Moodley, P.; Allana, S.; Campbell, A.; Shah, S. Treatment Adherence among Persons Receiving Concurrent Multidrug-Resistant Tuberculosis and HIV Treatment in KwaZulu-Natal, South Africa. *J. Acquir. Immune Defic. Syndr.* **2019**, *82*, 124–130. [CrossRef]
345. Mekonnen, H.S.; Azagew, A.W. Non-adherence to anti-tuberculosis treatment, reasons and associated factors among TB patients attending at Gondar town health centers, Northwest Ethiopia. *BMC Res. Notes* **2018**, *11*, 691. [CrossRef]

346. Adeoti, A.O.; Dada, M.; Elebiyo, T.; Fadare, J.; Ojo, O. Survey of antiretroviral therapy adherence and predictors of poor adherence among HIV patients in a tertiary institution in Nigeria. *Pan Afr. Med. J.* **2019**, *33*, 277. [CrossRef] [PubMed]
347. Moomba, K.; Van Wyk, B. Social and economic barriers to adherence among patients at Livingstone General Hospital in Zambia. *Afr. J. Prim. Health Care Fam. Med.* **2019**, *11*, e1–e6. [CrossRef]
348. Vagiri, R.V.; Meyer, J.C.; Godman, B.; Gous, A.G.S. Relationship between adherence and health-related quality of life among HIV-patients in South Africa: Findings and implications. *J. AIDS HIV Res.* **2018**, *10*, 121–132.
349. Baxter, C.; Karim, A.S.S. Recent Advances and the Prospect of an HIV Cure. Available online: <https://www.nrf.ac.za/content/recent-advances-and-prospect-hiv-cure> (accessed on 8 May 2021).
350. Reader, J.; van der Watt, M.E.; Taylor, D.; Le Manach, C.; Mittal, N.; Otilie, S.; Theron, A.; Moyo, P.; Erlank, E.; Nardini, L.; et al. Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box. *Nat. Commun.* **2021**, *12*, 269. [CrossRef] [PubMed]
351. Adam, H.J.; Richardson, S.E.; Jamieson, F.B.; Rawte, P.; Low, D.E.; Fisman, D.N. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: Evidence for herd effects and strain replacement due to Hib vaccination. *Vaccine* **2010**, *28*, 4073–4078. [CrossRef]
352. Heilmann, K.P.; Rice, C.L.; Miller, A.L.; Miller, N.J.; Beekmann, S.E.; Pfaller, M.A.; Richter, S.S.; Doern, G.V. Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. *Antimicrob. Agents Chemother.* **2005**, *49*, 2561–2564. [CrossRef] [PubMed]
353. Cohen, R.; Cohen, J.F.; Chalumeau, M.; Levy, C. Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries. *Expert Rev. Vaccines* **2017**, *16*, 625–640. [CrossRef] [PubMed]
354. Tomczyk, S.M.; Lynfield, R.; Schaffner, W.; Reingold, A.; Miller, L.; Petit, S.; Holtzman, C.; Zansky, S.M.; Thomas, A.; Baumbach, J.; et al. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. *Clin. Infect. Dis.* **2016**, *62*, 1119–1125. [CrossRef]
355. Jokinen, J.; Rinta-Kokko, H.; Siira, L.; Palmu, A.A.; Virtanen, M.J.; Nohynek, H.; Virolainen-Julkunen, A.; Toropainen, M.; Nuorti, J.P. Impact of Ten-Valent Pneumococcal Conjugate Vaccination on Invasive Pneumococcal Disease in Finnish Children—A Population-Based Study. *PLoS ONE* **2015**, *10*, e0120290. [CrossRef]
356. Lewnard, J.A.; Lo, N.C.; Arinaminpathy, N.; Frost, I.; Laxminarayan, R. Childhood vaccines and antibiotic use in low- and middle-income countries. *Nature* **2020**, *581*, 94–99. [CrossRef] [PubMed]
357. Czech, M.; Balcerzak, M.; Antczak, A.; Byliniak, M.; Piotrowska-Rutkowska, E.; Drozd, M.; Juszczyk, G.; Religioni, U.; Vaillancourt, R.; Merks, P. Flu Vaccinations in Pharmacies—A Review of Pharmacists Fighting Pandemics and Infectious Diseases. *Int. J. Environ. Res. Public Health* **2020**, *17*, 7945. [CrossRef] [PubMed]
358. WHO. Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: An Action Framework—Annex to Immunization Agenda 2030. 2020. Available online: https://www.who.int/immunization/VACAMR_Action_Framework.pdf?ua=1 (accessed on 10 May 2021).
359. Vekemans, J.; Hasso-Agopsowicz, M.; Kang, G.; Hausdorff, W.P.; Fiore, A.; Tayler, E.; Klemm, E.J.; Laxminarayan, R.; Srikantiah, P.; Friede, M.; et al. Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action Framework. *Clin. Infect. Dis.* **2021**. [CrossRef] [PubMed]
360. Freeman, D.; Loe, B.S.; Chadwick, A.; Vaccari, C.; Waite, F.; Rosebrock, L.; Jenner, L.; Petit, A.; Lewandowsky, S.; Vanderslott, S.; et al. COVID-19 vaccine hesitancy in the UK: The Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. *Psychol. Med.* **2020**, 1–15. [CrossRef]
361. Lewandowsky, S.; Cook, J.; Schmid, P.; Holford, D.L.; Finn, A.; Leask, J.; Thomson, A.; Lombardi, D.; Al-Rawi, A.K.; Amazeen, M.A.; et al. The COVID-19 Vaccine Communication Handbook. A Practical Guide for Improving Vaccine Communication and Fighting Misinformation. 2021. Available online: https://www.richmond.gov.uk/media/20645/the_covid_19_vaccine_communication_handbook.pdf (accessed on 8 May 2021).
362. Wood, T. Twitter to Start Banning Accounts That Spread Covid-19 Vaccine Misinformation. Available online: <https://www.ladbible.com/news/news-twitter-to-ban-people-who-spread-covid-19-vaccine-misinformation-20210307> (accessed on 7 March 2021).
363. WHO. Countering Misinformation about COVID-19. 2020. Available online: <https://www.who.int/news-room/feature-stories/detail/countering-misinformation-about-covid-19> (accessed on 11 May 2021).
364. UK Government. Community Champions to Give COVID-19 Vaccine Advice and Boost Take Up. 2021. Available online: <https://www.gov.uk/government/news/community-champions-to-give-covid-19-vaccine-advice-and-boost-take-up> (accessed on 11 May 2021).
365. Igoe, M. UN Harassment, COVID-19 Misinformation, and Vaccine Efficacy: This Week in Development. Available online: <https://www.devex.com/news/un-harassment-covid-19-misinformation-and-vaccine-efficacy-this-week-in-development-99134> (accessed on 11 March 2021).
366. WHO. Patient Engagement: Technical Series on Safer Primary Care. Geneva, 2016. Available online: <https://apps.who.int/iris/bitstream/handle/10665/252269/9789241511629-eng.pdf> (accessed on 5 May 2021).
367. The British Psychological Society. Delivering Effective Public Health Campaigns during Covid-19. 2020. Available online: <https://www.bps.org.uk/sites/www.bps.org.uk/files/Policy/Policy%20-%20Files/Delivering%20effective%20public%20health%20campaigns%20during%20Covid-19.pdf> (accessed on 4 May 2021).

368. Charan, J.; Kaur, R.J.; Bhardwaj, P.; Haque, M.; Sharma, P.; Misra, S.; Godman, B. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. *Expert Rev. Clin. Pharm.* **2021**, *14*, 95–103. [CrossRef]
369. Dyer, O. Covid-19: Remdesivir has little or no impact on survival, WHO trial shows. *BMJ* **2020**, *371*, m4057. [CrossRef] [PubMed]
370. WHO. WHO Discontinues Hydroxychloroquine and Lopinavir/Ritonavir Treatment Arms for COVID-19. 2020. Available online: <https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19> (accessed on 4 May 2021).
371. Horby, P.; Mafham, M.; Linsell, L.; Bell, J.L.; Staplin, N.; Emberson, J.R.; Wiselka, M.; Ustianowski, A.; Elmahi, E.; Prudon, B.; et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N. Engl. J. Med.* **2020**, *383*, 2030–2040. [PubMed]
372. Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; et al. A Trial of Lopinavir—Ritonavir in Adults Hospitalized with Severe Covid-19. *N. Engl. J. Med.* **2020**, *382*, 1787–1799. [CrossRef] [PubMed]
373. Recovery Trial. Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on Lopinavir-Ritonavir, 29 June 2020. No Clinical Benefit from Use of Lopinavir-Ritonavir in Hospitalised COVID-19 Patients Studied in RECOVERY. Available online: https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement-29062020_final.pdf (accessed on 10 May 2021).
374. Council for International Organizations of Medical Sciences. Medicines Assessment during Public Health Emergencies Needs Good Science, Best Practices and Proper Communication. 2020. Available online: https://cioms.ch/wp-content/uploads/2020/06/CIOMS_WGXII_Statement.pdf (accessed on 8 May 2021).
375. Zahlanie, Y.; Mang, N.S.; Lin, K.; Hynan, L.S.; Prokesch, B.C. Improved Antibiotic Prescribing Practices for Respiratory Infections Through Use of Computerized Order Sets and Educational Sessions in Pediatric Clinics. *Open Forum Infect. Dis.* **2021**, *8*, ofaa601. [CrossRef] [PubMed]
376. Holstiege, J.; Mathes, T.; Pieper, D. Effects of computer-aided clinical decision support systems in improving antibiotic prescribing by primary care providers: A systematic review. *J. Am. Med. Inform. Assoc.* **2015**, *22*, 236–242. [CrossRef]
377. Riaz, H.; Godman, B.; Hussain, S.; Malik, F.; Mahmood, S.; Shami, A.; Bashir, S. Prescribing of bisphosphonates and antibiotics in Pakistan: Challenges and opportunities for the future. *JPHSR* **2015**, *6*, 111–121.
378. Fadare, J.O.; Oshikoya, K.A.; Ogunleye, O.O.; Desalu, O.O.; Ferrario, A.; Enwere, O.O.; Adeoti, A.; Sunmonu, T.A.; Massele, A.; Baker, A.; et al. Determinants of antibiotic prescribing among doctors in a Nigerian urban tertiary hospital. *Hosp. Pract.* **2018**, *47*, 53–58. [CrossRef]
379. Fadare, J.O.; Oshikoya, K.A.; Ogunleye, O.O.; Desalu, O.O.; Ferrario, A.; Enwere, O.O.; Adeoti, A.; Sunmonu, T.A.; Massele, A.; Baker, A.; et al. Drug promotional activities in Nigeria: Impact on the prescribing patterns and practices of medical practitioners and the implications. *Hosp. Pract.* **2018**, *46*, 77–87. [CrossRef]
380. Adepoju, I.-O.O.; Albersen, B.J.A.; De Brouwere, V.; Van Roosmalen, J.; Zweekhorst, M. mHealth for Clinical Decision-Making in Sub-Saharan Africa: A Scoping Review. *JMIR Mhealth Uhealth* **2017**, *5*, e38. [CrossRef]
381. Birjovanu, G.; Lefevre, C.; Hayward, A.; Molnar, A.; Ncube, F.; Wiseman, S.; Kostkova, P.; Wood, C.; Olufemi, O.; Ogunsola, F.; et al. GADSA: Decision Support App for Antibiotics Prescribing in Nigeria. In Proceedings of the 9th International Conference on Digital Public Health, New York, NY, USA, 20–23 November 2019; pp. 9–10.
382. Charani, E.; Smith, I.; Skodvin, B.; Perozziello, A.; Lucet, J.-C.; Lescure, F.-X.; Birgand, G.; Poda, A.; Ahmad, R.; Singh, S.; et al. Investigating the cultural and contextual determinants of antimicrobial stewardship programmes across low-, middle- and high-income countries—A qualitative study. *PLoS ONE* **2019**, *14*, e0209847. [CrossRef]
383. Miljković, N.; Godman, B.; van Overbeeke, E.; Kovačević, M.; Tsiakitzis, K.; Apatsidou, A.; Nikopoulou, A.; Yubero, C.G.; Horcajada, L.P.; Stemer, G.; et al. Risks in Antibiotic Substitution Following Medicine Shortage: A Health-Care Failure Mode and Effect Analysis of Six European Hospitals. *Front. Med.* **2020**, *7*. [CrossRef] [PubMed]
384. Miljković, N.; Godman, B.; Kovačević, M.; Polidori, P.; Tzimis, L.; Hoppe-Tichy, T.; Saar, M.; Antofie, I.; Horvath, L.; De Rijdt, T.; et al. Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications. *Front. Pharm.* **2020**, *11*. [CrossRef] [PubMed]
385. Afriyie, D.K.; Asare, G.A.; Amponsah, S.K.; Godman, B. COVID-19 pandemic in resource-poor countries: Challenges, experiences and opportunities in Ghana. *J. Infect. Dev. Ctries.* **2020**, *14*, 838–843. [CrossRef] [PubMed]
386. Björkhem-Bergman, L.; Andersén-Karlsson, E.; Laing, R.; Diogene, E.; Melien, O.; Jirlow, M.; Malmström, R.E.; Vogler, S.; Godman, B.; Gustafsson, L.L. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. *Eur. J. Clin. Pharm.* **2013**, *69*, 73–78. [CrossRef]
387. Yoon, C.H.; Ritchie, S.R.; Duffy, E.J.; Thomas, M.G.; McBride, S.; Read, K.; Chen, R.; Humphrey, G. Impact of a smartphone app on prescriber adherence to antibiotic guidelines in adult patients with community acquired pneumonia or urinary tract infections. *PLoS ONE* **2019**, *14*, e0211157. [CrossRef]
388. Eriksen, J.; Gustafsson, L.L.; Ateva, K.; Bastholm-Rahmner, P.; Ovesjo, M.L.; Jirlow, M.; Juhasz-Haverinen, M.; Lärfsars, G.; Malmström, R.E.; Wettermark, B.; et al. High adherence to the ‘Wise List’ treatment recommendations in Stockholm: A 15-year retrospective review of a multifaceted approach promoting rational use of medicines. *BMJ Open* **2017**, *7*, e014345.
389. Gustafsson, L.L.; Wettermark, B.; Godman, B.; Andersén-Karlsson, E.; Bergman, U.; Hasselström, J.; Hensjö, L.-O.; Hjemdahl, P.; Jägre, I.; Julander, M.; et al. The ‘Wise List’—A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm. *Basic Clin. Pharm. Toxicol.* **2011**, *108*, 224–233. [CrossRef] [PubMed]

390. Klein, E.Y.; Milkowska-Shibata, M.; Tseng, K.K.; Sharland, M.; Gandra, S.; Pulcini, C.; Laxminarayan, R. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–2015: An analysis of pharmaceutical sales data. *Lancet Infect. Dis.* **2021**, *21*, 107–115. [[CrossRef](#)]
391. Lorencatto, F.; Charani, E.; Sevdalis, N.; Tarrant, C.; Davey, P. Driving sustainable change in antimicrobial prescribing practice: How can social and behavioural sciences help? *J. Antimicrob. Chemother.* **2018**, *73*, 2613–2624. [[CrossRef](#)]
392. Sharland, M.; Pulcini, C.; Harbarth, S.; Zeng, M.; Gandra, S.; Mathur, S.; Magrini, N. Classifying antibiotics in the WHO Essential Medicines List for optimal use—Be AWaRe. *Lancet Infect. Dis.* **2018**, *18*, 18–20. [[CrossRef](#)]
393. Hsia, Y.; Sharland, M.; Jackson, C.; Wong, I.C.K.; Magrini, N.; Bielicki, J.A. Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: An analysis of sales data from 70 middle-income and high-income countries. *Lancet Infect. Dis.* **2019**, *19*, 67–75. [[CrossRef](#)]
394. Mwita, S.J.M.; Marwa, K.; Hamasaki, K.; Katabalo, D.; Burger, J.; Godman, B.; Ferrario, A.; Masele, A.; Ruganuzza, D. Medicines dispensers' knowledge on the implementation of an artemisinin-based combination therapy policy for the treatment of uncomplicated malaria in Tanzania. *J. Pharm. Health Serv. Res.* **2017**, *8*, 227–233. [[CrossRef](#)]